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The ovary is the female reproductive organ responsible for the production of both 
the female gamete, the oocyte, and two major female sex hormones, estradiol and 
progesterone. During embryonic development, oocytes are formed from primordial germ 
cells and eventually become surrounded by squamous granulosa cells in a follicular 
structure, termed primordial. The oocyte numbers encased in primordial follicles are finite 
at birth and remain arrested in the diplotene stage of meiosis until ovulation or they 
degenerate through atresia.  Once the pool of primordial follicles is depleted, ovarian 
senescence occurs.  We hypothesized that the maternal metabolic changes that occur during 
lean gestational diabetes mellitus would impact offspring ovarian function both basally and 
in response to a dietary stressor later in life.  We observed impacts on follicle numbers and 
alterations in the ovarian proteome, suggesting possible impacts on fertility and oocyte 
quality in relation to in utero and metabolic stressors.  Additionally, we hypothesized that 
the ovarian DNA damage response is altered during obesity in adulthood.  An elevated 
response in markers of DNA damage was observed, indicating that the metabolic status of 
the ovary during obesity initiates a low-level DNA damage response.  Intercellular 
communication is also affected by a metabolic syndrome such as obesity or GDM 
exposure, with reduction of the gap junction protein Connexin-43 expression in antral 
follicles from ovaries that experienced obesity.  Finally, to elucidate the molecular 
mechanisms behind the induction of the DNA damage response in the ovary after 
phosphoramide mustard exposure, we hypothesized that the DNA damage response would 
be blunted due to reduced abundance of the ATM protein.  Using an Atm+/- mouse model 
to investigate impacts on folliculogenesis and the ovarian proteome, we determined that 
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Atm haploinsufficiency results in an irregular DNA damage response, alters the ovarian 
proteome, and impacts the rate of follicle loss after phosphoramide mustard exposure.  
Taken together, these findings demonstrate that the DNA damage response is initiated in 
the ovary during times of metabolic stress and in the absence of Atm, unhealthy follicles 

























CHAPTER 1. GENERAL INTRODUCTION 
 
Dissertation Organization 
 This dissertation includes four manuscripts relevant to this doctoral work, which 
have either been published or submitted for publication in peer-reviewed journals.  These 
manuscripts establish the foundation of the dissertation work and are preceded by a general 
introduction describing the significance of the research topic and review of the literature, 
and proceeded by a discussion of general findings, conclusions, and future considerations.  
In addition, portions of the literature review section of the dissertation have been published 
as an invited review and an additional manuscript published outside of the scope of the 




Parts of the literature review are adapted from: 
Clark KL, S Ganesan, AF Keating. 2018. Impact of toxicant exposures on ovarian gap 
junctions. Reprod. Toxicol. 81: 140-146. 
 
Ovarian development, structure, and function  
 Early in mammalian embryonic development, the highly specialized primordial 
germ cells (PGCs), originate from the post implantation epiblast in response to extra-
embryonic signaling from bone morphogenic proteins BMP4, BMP2, and BMP8B [1-3].  
The proteins then bind with receptors that phosphorylate mothers against decapentaplegic 
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homologs SMAD1 and SMAD5, which then dimerize with SMAD4, leading to 
translocation into the nucleus to initiate the transcriptional regulators of the PCGs – PR 
domain zinc finger protein 1 (BLIMP1), PR domain zinc finger protein 14 (PRDM14), and 
transcription factor AP-2 gamma (AP2γ) [4-6].  The PGCs then migrate from the posterior 
primitive streak into the endoderm, through the hindgut, and into the dorsal mesentery 
before arriving at the genital ridge [7, 8].  Once at the genital ridge, cell migration is 
complete and the PGCs associate with the somatic cells of the gonad and eventually acquire 
their respective sex-specific morphologies and functions.  Some of these cells will serve as 
germline stem cells, which undergo meiosis to produce the female or male gametes.  In the 
female, the PGCs divide synchronously with incomplete cytokinesis to form a cluster of 
cells connected by intracellular bridges, forming a multi-nucleated germ cell nest [9, 10].  
Coordinated somatic cell migration and germ cell apoptosis contribute to the packaging of 
individual germ cell nuclei, which become surrounded by flattened pre-granulosa cells to 
form the finite primordial follicle pool [9, 10].   
The early mammalian gonad is bipotential, composed of undifferentiated precursor 
cells that can follow one of two possible fates, male or female.  The Wolffian 
(mesonephric) ducts are the progenitors for the male reproductive tract and the Müllerian 
(paramesonephric) ducts are the precursors of the female reproductive tract [11].  Sex 
determination is triggered by the expression and proper function of the testes determining 
gene sex-determining region Y (Sry) in the presence of the Y chromosome, which signals 
cells to produce testosterone and anti-Müllerian hormone (AMH), resulting in the 
degeneration of the Müllerian ducts and differentiation of the testes [12, 13].  Conversely, 
the lack of Sry expression results in the regression of the Wolffian ducts and the 
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differentiation into the female reproductive tract [14].  The exact mechanisms behind early 
ovarian development are not well understood, though wingless-type MMTV integration 
site family member 4 (Wnt4), nuclear receptor subfamily 0, group B, member 1 (Dax1), 
and forkhead box L2 (FoxL2) have all been implicated as ovary determining factors [11, 
14].  
The ovaries are paired, oval-shaped organs, residing on each side of the uterus 
within the broad ligament below the fallopian tubes (Figure 1).  The surface of the ovary 
is formed by a simple squamous-cuboidal epithelium, encasing the ovarian cortex and 
medulla.  The ovarian cortex is home to thousands of follicles and considered the functional 
zone of the ovary, producing the sex steroids 17β-estradiol (E2) and progesterone (P4) 
within the stromal tissue and in the follicles as they mature.  The inner medulla is also 
composed of supportive stromal tissue, enriched with a neurovascular network which 
enters at the hilum of the ovary.  The structure of the ovary is dynamic, with extensive 
tissue remodeling occurring during folliculogenesis, ovulation, the formation and 
regression of the corpus luteum (CL), and follicular atresia. 
 
Folliculogenesis 
 The follicle is the basic functional unit of the mammalian ovary, with follicle 
development being crucial for the maturation of oocytes and their subsequent release from 
the follicle.  After the formation of the primordial follicle from the PGC, the oocytes remain 
in the first meiotic prophase until they receive intraovarian signals to activate growth before 
eventually becoming gonadotropin dependent.  Ovarian folliculogenesis is the progression 
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of the primordial follicle into a primary, secondary, and antral follicle, in which the oocyte 
is then maintained prior to ovulation (Figure 1).  
 The initial transition from primordial follicle to primary follicle occurs when the 
surrounding granulosa cell morphology transitions from a squamous to cuboidal shape, 
followed by a dramatic increase in cytoplasmic and nuclear volume in the oocyte [15, 16].  
Gap junctions begin to form between the granulosa cells and the granulosa cells and oocyte, 
allowing intercellular communication and the flow of molecules and nutrients [17, 18]. 
These junctions are described in more detail later. Another structural development as the 
follicle matures from primordial to primary is the formation of the zona pellucida.  The 
zona pellucida is a glycoprotein polymer capsule that forms around the growing oocyte, 
providing protection that increases in thickness as oocyte diameter increases and remains 
with the oocyte even after ovulation, regulating the interaction between the oocyte and 
sperm during and after fertilization [19].   
 As the follicle transitions from a primary to secondary stage follicle, the granulosa 
cells surrounding the oocyte continue to proliferate to form more layers as well as 
increasing in size [15].  The oocyte in the secondary follicle now has a larger, sphere-
shaped nucleus that grows concomitantly with the oocyte.  During this time, the oocyte has 
completed its growth and gains the ability to resume meiosis.  Other structural changes 
begin to occur after the transition to secondary follicle, such as the generation of the theca 
cell layer [15].  The theca cells proliferate from a population of unspecialized mesenchymal 
cells in the ovarian stroma to form a layer adjacent to the basal lamina, with the innermost 
layer known as the theca interna and outer layer called the theca externa [20].  The theca 
interna are a layer of highly vascularized steroidogenic cells while the theca externa is a 
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loosely organized layer of non-steroidogenic cells between the theca interna and ovarian 
stroma [20].  This vascularization enables the follicle to now secrete and respond to steroid 
hormones.   
 The first indication of the next stage of follicular development, the antral follicle, 
is the appearance of an internal cavity in the granulosa cells, characterized by the 
accumulation of fluid and establishment of polarity in the follicle [15].  At this point in 
folliculogenesis, there are no more changes in morphologic complexity, just changes in 
follicle size and cellular positions.  The oocyte is surrounded by the granulosa cell layer 
called the corona radiata, the intermediate granulosa cell layer is termed the cumulus 
oophorus, followed by the periantral and membrana granulosa, the inner and outermost 
domains, respectively [15].  Processes that are implicated in the regulation of granulosa 
cell heterogeneity are cAMP regulatory events in response to follicle stimulating hormone 
(FSH) stimulation [21] and secretion of growth differentiation factor 9 (GDF-9) from the 
oocyte [22].  By the end of the antral stage, a dominant follicle, or in the case of multiparous 
species, follicles, emerge, shunting other recruited follicles towards atresia.  The cumulus 
oophorus layer of the follicle will soon rupture, creating an opening for the oocyte and 
cumulus cells to be expelled during ovulation into the fallopian tube [23].   
 After ovulation, the basal lamina that separates the granulosa and theca cell layers 
degenerates, allowing the capillaries from the theca layer to penetrate into the granulosa 
layer to form a highly vascularized structure called the corpus luteum (CL), which is critical 
in providing the endocrine conditions, including the secretion of progesterone, that are 
necessary for the establishment and maintenance of pregnancy [23].  The luteinization of 
granulosa cells occurs via the accumulation of cytoplasmic lipid droplets, causing the cells 
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to enlarge [24].  The vascularization of the CL is driven by vascular endothelial growth 
factor (VEGF), aiding in the proliferation and support of the CL as it grows and develops 
connective tissue between the luteinized cells [25].  In the event of no conception, 
luteolysis occurs and a new cycle can begin.   
 Unlike male germ cells that are continuously produced throughout the male 
lifespan, female germ cell numbers are finite at birth, with oocyte numbers reaching their 
peak even prior to birth.  At approximately five months of embryonic age in a human 
gestation, approximately seven million oocytes are present in the ovary, dropping to around 
two million at birth and by puberty, this number is estimated to be 250,000 to 400,000 
oocytes [15].  When no functional oocytes remain, ovarian senescence (or menopause) 
occurs.  Premature ovarian failure (POF) is defined as ovarian senescence prior to age 40 
and affects approximately 1% of women, with often unknown etiology [26].   During a 
woman’s reproductive lifespan, roughly 500 oocytes actually reach ovulation, leaving 99% 
of all primordial follicles that a woman was initially born with being lost to atresia [15].   
 
Steroidogenesis  
 The precursor for steroid biosynthesis in the ovary is cholesterol.  In the endocrine 
glands, cholesterol can be synthesized de novo from acetate or obtained from circulating 
cholesterol [27].  The first reaction in steroid hormone biosynthesis is the conversion of 
cholesterol to pregnenolone via the stimulation of the steroidogenic pathway by luteinizing 
hormone (LH) in the ovary [28].  This reaction occurs in the mitochondria, after cholesterol 
is shuttled into the inner mitochondrial matrix by steroid acute regulatory protein (STAR), 
then further catalyzed by an enzyme encoded by cytochrome P450 family 11, subfamily 
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A, member1 (CYP11A), C20-22-lyase [28].  The biochemical reactions that lead to the 
formation of estrogens and androgens in the ovary occur through a series of reactions in 
the ∆4 (delta 4) and ∆5 (delta 5) pathways [29].  
The delta 5 pathway utilizes the enzyme 17α-hydroxylase to convert pregnenolone 
to 17-hydroxypregnenolone, which is then converted to dehydroepiandrosterone (DHEA) 
via C17-20-lyase [29].  DHEA is then transformed to androstenediol through reduction by 
17β-hydroxysteroid oxidoreductase (17β-HSD), though this transformation is reversible 
via the oxidation of androstenediol [29].  The delta 5 pathway reactions are complete with 
the generation of androstenediol.   
The delta 4 pathway utilizes 3β-hydroxysteroid dehydrogenase (3β-HSD) and ∆4-5 
isomerase to convert pregnenolone to progesterone via oxidation and unlike the reversible 
transformation of DHEA/androstenediol in the delta 5 pathway, this reaction is irreversible 
[29].  After the formation of progesterone, the delta 4 pathway proceeds with the same 
enzymes in the delta 5 pathway, with 17α-hydroxylase converting progesterone to 17α-
hydroxyprogesterone and C17-20-lyase converting 17α-hydroxyprogesterone to 
androstenedione [29].  The final product of the pathway, testosterone, is converted via 17β-
HSD in a reversible reaction.   
From these series of biochemical reactions, the androgens androstenedione and 
testosterone can be further processed via the aromatization reaction encoded by 
cytochrome P450 family 19, subfamily A, member 1 (CYP19A1) to form the estrogens 
estrone and estradiol [30].  Additionally, the compounds formed in the delta 5 pathway can 
be converted to compounds in the delta 4 pathway in an irreversible reaction with 3β-HSD 
[29].  Deficiencies in the enzymes that catalyze these reactions can result in the 
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feminization or masculinization of genitalia due to the defects in testosterone biosynthesis 
[31].   Deficiency in the type 3 isoenzyme of 17β-HSD leads to the formation of both male 
and female genitalia [31].  Similarly, deficiencies in 17α-hydroxylase and C17-20-lyase 
results in the lack of testosterone production [32].   
Granulosa cells are unable to convert pregnenolone to androstenedione due to lack 
of 3β-HSD, so estradiol conversion takes place in theca cells from pregnenolone that has 
been shuttled through the basal lamina from the granulosa cells [33].  Likewise, lack of 
17β-HSD in the theca cells leads to the conversion and production of testosterone in the 
granulosa cells [33].  These mechanisms occur via a series of cooperative interactions of 
theca and granulosa cells, acting on hormonal signaling from LH and FSH, respectively, 
and along with the lack of CYP19A1 in theca cells, provides the rationale for the two cell, 
two-gonadotropin theory [33].  Gene expression that encodes for production of respective 
enzymes in ovarian cells increase or decreases dependent on hormonal signaling.  After 
ovulation, the synthesis and production of progesterone occurs similar to the production of 
estradiol, though after cholesterol is converted to pregnenolone, 3β-HSD works to convert 
pregnenolone to progesterone in the luteinized granulosa and theca cells [23].     
 
Hypothalamic-pituitary-gonadal axis 
 Endocrine signals regulate the female reproductive cycle mainly via a negative 
feedback system in the ovary and in the hypothalamus and pituitary glands within the brain, 
termed the hypothalamic-pituitary-gonadal (HPG) axis.  The signal that initiates and drives 
the reproductive cycle arises from gonadotropin-releasing hormone (GnRH) neurons in the 
hypothalamus [34, 35].  A pulse of GnRH is released and stimulates the release of LH and 
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FSH from the pituitary gland, which subsequently travel to the ovary via circulation.  These 
hormones induce morphologic changes that occur during folliculogenesis and formation of 
the CL, aid in the production of the ovarian steroid hormones estradiol and progesterone, 
and LH is critical for ovulation to occur.   
 Once released from the pituitary, FSH acts on FSH receptors in the granulosa cells, 
marking the beginning of the follicular phase.  As the follicles grow, they begin to increase 
the production and secretion of estradiol with the conversion of androstenedione from the 
theca cells.  Increased amounts of FSH act as a stimulus for inhibin B secretion, which 
along with estradiol, has a negative feedback effect on FSH release [36, 37].  Luteinizing 
hormone released from the pituitary binds to receptors in the theca cells and induces the 
production of androgens that are aromatized in the granulosa cells to produce estradiol 
[38].  The growing antral follicles compete for FSH, and those who have fewer FSH 
receptors begin to decline in growth and subsequently become atretic, while a dominant 
follicle emerges and continues to grow, with the peak of estradiol secretion occurring when 
this follicle is fully mature and ready for ovulation [37].  At this time, estradiol secretion 
acts as a positive feedback mechanism and triggers the LH surge required for ovulation 
[38].   
 At the end of the follicular phase, the surge of LH initiates ovulation and the 
beginning of the luteal phase.  Prior to the LH surge, a small increase of progesterone 
occurs and after ovulation and the formation of the CL, progesterone secretion gradually 
increases and dominates [39].  Maintenance of pregnancy is dependent on progesterone 
secretion and circulation, utilizing a negative feedback mechanism to decrease the GnRH 
pulse frequency similar to estradiol during the follicular phase.  In humans, if there is an 
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absence of increased levels of human chorionic gonadotropin (hCG) signaling for 
successful fertilization and pregnancy [40], estradiol and progesterone levels decline, the 
CL diminishes, and FSH levels rise to facilitate another menstrual cycle.   
 
Ovarian gap junctions 
Gap junction intercellular communication (GJIC) facilitates the exchange of ions, 
metabolites, Ca2+, inositol phosphates, and/or cyclic nucleotides of up to 1.8 kD in size 
between cells through contact-dependent mechanisms [17, 18]. Oocyte growth, 
development, and survival depends upon the supply of nutrients, amino acids, glucose 
metabolites, and nucleotides transmitted from follicle cells via gap junctions (GJ).  
Interconnection of ovarian cells via GJ is observed between the innermost layer of cumulus 
cells and the oocyte, between adjacent cumulus cells, between granulosa cells and also 
between cumulus and granulosa cells [90].  Gap junctions are made up of six connexin 
(CX) proteins to form a connexon, a hollow ring in the plasma membrane that enables 
communication between the cells when coupled with another connexon in an adjacent cell 
(Figure 2), with the capacity to change function based on protein isoform or post 
translational modification, though this mechanism remains vague [91, 92].     
Localization of CX proteins is used for GJ identification in a variety of tissues [93] 
and the CX family of proteins is very diverse, with 20 proteins in mice and 21 in humans, 
each the product of a distinct gene [94].  A total of 8 CX proteins are known to be expressed 
in the ovary, with expression varying in a species-specific manner.  Porcine ovaries express 
GJB2, GJB4, GJB1, GJA1, and GJA1 [95, 96].  In ovine ovaries, GJB2, GJB1, GJA4, and 
GJA1 have been detected [97-99].  Similar to the sheep, bovine ovaries also express GJB2, 
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GJB1, GJA4, and GJA1[100, 101].  In mouse and rat, GJB1, GJA4, GJA1, GJC1, and 
GJA10 have been detected in the ovary [102].  Pannexin genes have also been implicated 
in GJ channeling, but less is known about their functions [103].  Pannexin1 (Panx1) has 
been identified in human ovary and placenta, but no further work has been performed to 
describe Panx1 function in the female reproductive system [104].   
Gap junction proteins are subject to hormonal regulation in various tissue types.  
Both E2 and P4 regulate GJIC in the reproductive system, heart, brain, and liver via 
complementary or opposing actions dependent on physiological context and tissue 
phenotype [105].  An increase in Gja1 mRNA and GJ formation is stimulated by E2 while, 
in contrast, an inhibitory effect is mediated by P4 in the female reproductive system [106, 
107].  Follicle stimulating hormone (FSH) and luteinizing hormone (LH) also have similar 
effects on GJIC in reproductive tissues, where FSH stimulates upregulation of Gja1 mRNA 
and protein, and Gja1 expression is elevated as follicle size increases in response to FSH 
[108-111].  In contrast, LH stimulates a reduction in Gja1 mRNA and protein [112-115]. 
Alterations of CX expression are also detected throughout the stages of the estrous 
cycle.  In sheep, GJB2 mRNA expression in the corpus luteum (CL) is at its highest at d10 
of the estrous cycle and decreases in PGF-induced luteal regression [98].  In bovine, GJB2 
mRNA is highest during the second half of the estrous cycle and after luteal regression 
[116].  GJB1 mRNA and protein expression remains relatively stable throughout the 
estrous cycle [98, 99].  In contrast, GJA4 mRNA expression is increased after hCG 
treatment in sheep, and expression of GJA4 protein and mRNA is greatest on d5 of the 
estrous cycle with a gradual decrease thereafter [97].  GJA1 mRNA expression in sheep 
decreases in the granulosa and theca cells after hCG treatment and in the luteal tissue but 
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is observed to increase in the CL on d5 of the estrous cycle [98, 99].  The expression of 
bovine GJA1 mRNA decreases after injection of GnRH and after luteal regression, with 
higher GJA1 levels observed in the CL during the early luteal phase [116].  In addition to 
changes during the estrous cycle, high levels of GJB2 and GJA1 mRNA are detected 
throughout pregnancy in cattle [116]. 
Ovarian GJ investigations have primarily focused on defining the function and role 
of ovarian GJA4 and GJA1. The generation of a Gja4-null mouse demonstrated arrest of 
folliculogenesis at the early antral follicular stage and oocytes that do not reach meiotic 
competence [117, 118]. Interestingly, a genetic variant of Gja4 is associated with primary 
ovarian insufficiency in women [119] while another Gja4 gene variant is associated with 
polycystic ovarian syndrome in women [120].   Deficiency of Gja1 is postnatally lethal in 
mice, so Gja1-/- prenatal ovaries have been cultured ex vivo or via transplant, and these 
ovaries also have retarded oocyte growth and arrested folliculogenesis [121, 122].  Further 
supporting the roles of GJA4 and GJA1 in the ovary are chimeric ovary studies which 
paired wild-type (WT) oocytes with Gja1-deficient somatic cells; Gja1-deficient oocytes 
with WT granulosa cells; WT oocyte with Gja4-deficient granulosa cells; or Gja4-deficient 
oocytes with WT granulosa cells [123, 124].  In ovaries containing WT granulosa cells 
with Gja1-/- oocytes or WT oocytes and Gja4-/- granulosa cells, meiosis occurred, and 
fertilization could be achieved.  In contrast, ovaries with WT granulosa cells and Gja4-/- 
oocytes could not proceed with meiosis and did not achieve fertilization.  In ovaries with 
Gja1-/- granulosa cells and WT oocytes, follicles remained in the early preantral stages and 
contained smaller oocytes [124].   
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 In addition to Gja4 and Gja1, knockout of Gjc1 and Gjb2 in mice has been 
accomplished but leads to embryonic death with cardiovascular defects and insufficient 
embryonic development, respectively [125-128].  Gja10 knockout mice have no ovarian 
defects although they do have deficiencies in the visual system and Gjb1 null mice remain 
fertile [129, 130].  Ovarian findings for these genetic mice models lacking Gja4 and Gja1 
support that ovarian CX proteins have important roles in relation to follicle and oocyte 
survivability, quality, and growth.  
 
Obesity 
 Obesity is a preventable metabolic disorder that has become a global health 
epidemic, with worldwide estimates that roughly 13% of the world’s population is 
considered obese and 39% considered overweight [41] .  In the United States these numbers 
are even more staggering, with nearly 40% of the adult population considered obese [42].  
Moreover, the obesity epidemic seems to affect women more than men, with around 42% 
of adult women experiencing obesity and in some ethnic groups, this number is as high as 
50% [42].  Unfortunately, obesity among young girls is also on the rise, with about 18% of 
girls aged 2-19 considered obese [42].  Obesity is associated with several interrelated 
disorders including diabetes [43], cardiovascular disease [44], chronic inflammation [45], 
and cancer [46].  The reproductive phenotypes observed in obese women include early 
puberty onset [47], poor oocyte quality [48], polycystic ovary syndrome (PCOS) [49], 
infertility [50], pregnancy complications [51], gestational diabetes [52], congenital 
abnormalities in offspring [53], and an increased risk of reproductive cancers [54].  
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 The mechanisms in which changes in central metabolism during obesity affect the 
ovary have previously demonstrated by our group and others.  Hyperinsulinemia is 
common during obesity, impacting the upregulation of the insulin responsive PI3K-PTEN-
AKT-FOXO signaling pathway, resulting in increased follicular activation [55, 56].  With 
increased follicle activation, a reduction of primordial and primary follicle numbers is 
observed in a model of progressive obesity [56].  Disturbances in the estrous cycle are also 
observed in the obese rodent model [57].  Changes in cyclicity are attributed to levels of 
estrogen and progesterone and in premenopausal women, a negative correlation is seen 
with estrogen levels and body mass index (BMI) and higher levels of progesterone are 
observed in obese rodent models [58, 59].  Additionally, pathways involved in steroid 
hormone biosynthesis show disparate expression levels during obesity [60].   
Chronic low-grade inflammation is also a systematic response to obesity, having 
impacts on fertility through inflammatory pathways and constant production of reactive 
oxygen species (ROS) potentially contributing to accumulation of DNA damage in the 
ovary [61-63].  Proinflammatory cytokines TNFα, interleukin family members, and NF-
κB inflammatory singling members have been implicated in ovarian pathologies such as 
endometriosis [64], ovarian hyperstimulation [65], and ovarian cancers [66].  Inflammation 
may contribute to the increased amounts of DNA damage that are present in ovaries during 
obesity [67-69].  In addition to the elevated levels of basal DNA damage seen in the ovary 
from obese mice, the ovary is also more susceptible to ovotoxicants, resulting in enhanced 




Gestational diabetes mellitus  
 Gestational diabetes mellitus (GDM), described as glucose intolerance during 
pregnancy, is a common obstetric disorder that may affect up to 1 in 5 pregnancies 
dependent on population demographics and diagnostic criteria [71].  With obesity 
increasing in recent decades, its estimated that GDM prevalence has also increased by 
~122% between the late 1980s and mid-2000s [72].  GDM is typically diagnosed between 
24 and 28 weeks of gestation and poses immediate health concerns for the mother and her 
offspring.  In the first trimester, offspring may experience restricted intrauterine 
development, increased congenital anomalies, and spontaneous abortion [73].  In the 
second and third trimesters, offspring may experience excessive fetal growth, neonatal 
hypoglycemia, respiratory distress, and polycythemia [73].  While GDM normally resolves 
upon delivery, both mother and offspring have higher chances of becoming overweight or 
obese and acquiring type 2 diabetes later in life [74-77].   
Normal pregnancy is characterized by changes in insulin sensitivity to regulate 
glucose control, similar to the non-pregnant state [78].  As pregnancy progresses, insulin 
sensitivity begins to decline and through changes in maternal estrogen, progesterone, and 
placental lactogen, insulin sensitivity is around 50% lower towards the end of pregnancy 
than in the non-pregnant state [79, 80].  Further, pregnant women have a decrease in blood 
glucose to accommodate the energy requirements for the growing fetus [81].  In contrast, 
women who have GDM during pregnancy have higher levels of glucose in circulation due 
to increased insulin resistance, an inadequate insulin response to glucose, and increased 
hepatic glucose production [82-84].  
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Pre-existing diabetes and obesity are major risk factors for GDM, with ~50% of all 
GDM cases occurring in obese women [85] and successful pregnancy outcomes in obese 
women are more affected by GDM than their lean counterparts [85].  Women who have 
pre-existing diabetes comprise ~25% of GDM cases, linking back to cases of pre-
gestational maternal obesity and possibly attributable to effects on oocyte quality and 
development [86].  Additionally, women from Hispanic and Asian backgrounds have 
greater risk of developing GDM than Caucasian and African-American women [87], and 
prior pregnancies with GDM [72] and history of parental diabetes [88] also contribute to a 
women’s risk of acquiring GDM.  Interestingly, around ~30% of GDM cases occur in lean 
women with no prior history of diabetes [89].  Gestational diabetes is a major health 
concern due to complications and risks for mother and child during pregnancy, as well as 
complications that may arise following pregnancy.   
 
 
Chemical-induced ovotoxicity  
 
Exposure to chemicals during development or in adulthood can have serious 
implications for female fertility via disruption of normal ovarian function (Figure 3).  
Ovotoxicants can selectively affect a follicle population in the ovary, resulting in either 
temporary or permanent infertility [131].  Endocrine disrupting chemicals (EDC) are 
exogenous (natural or synthetic) compounds that disrupt normal actions of endogenous 
hormones such as their synthesis, secretion, transport, metabolism, binding, and 
elimination in various organ systems [132].  In the ovary, EDC’s have been shown to affect 
fertility through induction of follicle loss, alteration of ovarian steroidogenesis, mimicry in 
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receptor signaling, and oocyte competence [133, 134].  The potential sources of exposure 
to EDC’s include plasticizers, pesticides, and solvents [135].   
Plasticizers 
Di (2-ethylhexyl) phthalate (DEHP) is a commonly used phthalate in the 
plasticizing process of polyvinyl chloride resin (PVC) products [136].  It is easily released 
into the environment due to weak bonding capabilities, with exposure occurring via oral 
ingestion, skin contact and inhalation, subsequently entering the bloodstream [137] DEHP 
exposure has been associated with testicular, liver, kidney, and ovary tissue disease [137-
140]. Detrimental effects of DEHP exposure are observed throughout ovarian development 
as well as in adult ovaries and include the alteration of germ cell formation and 
development, meiotic initiation and progression, and primordial follicle development and 
activation [141-144].  Bisphenol A (BPA) is another common plastic ingredient that is 
found in polycarbonate food and beverage containers, metal can coatings, pressure printed 
receipts, and dental sealants [145, 146].  Exposure to BPA occurs when it leaches from its 
source and into the body.  BPA has been shown to affect the female reproductive system 
via endocrine disruption, reproductive cycle disturbances, miscarriage, altered oocyte 
maturation, and decreased fertilization [147].  It has also been demonstrated that BPA, via 
biotransformation, may become a DNA alkylating agent, inducing DNA damage and 
evoking a protective response in the ovary [148].   
Pesticides  
Tris(4-chlorophenyl)methanol (TCPM) is a pesticide that has been found in animal tissue 
globally [149].  TCPM is known byproduct of dichlorodiphenyltrichloroethane (o, p’ – 
DDT), which affects the female reproductive system, specifically by altering uterine 
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contractibility as well as by binding to the estrogen receptor [150, 151].  Glyphosate (N-
(phosphonomethyl)glycine) is the main ingredient in one of a commonly used pesticide, 
and several studies are emerging indicating reproductive effects of glyphosate exposure, 
including embryonic loss [152], birth defects [153], impaired uterine development [154], 
placental cell toxicity [155], and premature birth [156].  Impacts of glyphosate exposure 
on the ovary include impaired folliculogenesis and ovary development, decreased estrogen 
secretion, increased amounts of oxidative stress, and changes to ovarian morphology [157].  
Similar effects were observed in the ovaries of pregnant mice, which resulted in reduced 
female to male offspring sex ratio [158]. 
Solvents and industrial  chemicals 
Perfluorooctane sulfonate (PFOS) is a synthetic surfactant used in a variety of 
household products and PFOS degradation resistance has led to a bioaccumulation in 
both humans and animals [159].  PFOS exposure has several negative implications for 
female reproductive health such as increased incidence of fetal reabsorption [160], 
pregnancy loss [161]. The industrial chemical, tributyltin (TBT), is an environmental 
pollutant used frequently as an anti-fouling agent that has shown to bio-
accumulate in aquatic species[ 1 6 2 ] .  TBT exposure occurs in humans through 
the consumption of contaminated food sources as well as via inhalation or dermal 
contact [163]. Female reproductive effects of TBT exposure during pregnancy in rats 
include transplacental transfer of TBT, decreased maternal weight gain, decreased 




Polycyclic aromatic hydrocarbons 
The polycyclic aromatic hydrocarbon (PAH), 7,12-dimethylbenz[a]anthracene 
(DMBA), is present in smoke or fumes from the burning of organic substances such 
as coal, car exhaust, and cigarette smoke.  DMBA exposure damages ovarian follicles 
at all stages of development, leading to premature ovarian failure [166-168].  In 
humans, females who smoke cigarettes (PAH source) experience menopause onset 
earlier than non-smoking women [169], and offspring of female smokers have fewer 
oocytes in their ovarian reserve due to in utero exposure [170].  Additionally, 
DMBA exposure induces DNA damage in the ovary and activates the DNA repair 
response after exposure [171], with the negative effects of DMBA exposure 
heightened by obesity [68, 70]. 
 
Chemotherapeutics  
With increasing cancer survival rates, women of all ages are impacted by 
chemotherapy-induced infertility.  Cyclophosphamide (CPA) is an alkylating agent used 
in the treatment of autoimmune diseases and in anti-cancer chemotherapy in both adults 
and children.  The reproductive effects of CPA exposure include loss of primordial and 
primary follicles in mice [172], antral follicles in rats [173], and amenorrhea, premature 
ovarian failure, and infertility in women and young girls [174].  In addition to fertility 
issues, CPA exposure has been associated with congenital malformations in offspring 
exposed to CPA in utero as well as pre-gestational germ cell exposures [175].   
Phosphoramide mustard (PM) is an ovotoxic metabolite of CPA [176, 177], which 
initiates the DNA damage response (DDR) by targeting rapidly dividing cells and inducing 
 20
DNA double strand breaks (DSB) [178].  Phosphoramide mustard is also an alkylating 
agent, creating DNA adducts through the cross-linking of DNA strands, obstructing DNA 
strand separation during replication [179].  Previous work by our research group and others 
have demonstrated that PM exposure induces ovarian DNA damage, destroying primordial, 
primary, and antral follicles, resulting in premature ovarian failure [60, 69, 172, 173, 180, 
181].  Phosphoramide mustard can further degrade into another volatile metabolite, 
chloroethylaziridine (CEZ), an airborne cytotoxic source that is exhaled after CPA 
administration [182-185].   CEZ potentially contributes to CPA-induced follicle depletion 
[177] and has been shown to reduce primordial follicle numbers and temporarily reduced 
secondary follicle numbers in an ex vivo model [186].   
The exact processes behind chemotherapy-induced follicle loss are unclear, though 
putative mechanisms have been suggested based on previous animal studies.  Direct 
toxicity to the follicle or oocyte may occur via the toxic reagent crossing through the blood-
follicle barrier in the granulosa cells surrounding the oocyte, causing direct damage to the 
follicular pool [187-190].  Another mechanism suggested to induce follicle loss after 
chemotherapy is the accelerated activation and maturation of primordial follicles via the 
phosphoinositide 3-kinase (PI3K) pathway in response to targeted death of larger growing 
follicles, resulting in follicular “burnout” [191-193].  The methods of follicle depletion 
may be species-specific and/or drug-specific, but these conclusions have yet to be 





DNA damage response  
 The integrity of the genome is constantly bombarded with insults from endogenous 
and exogenous sources, with DNA damaging events occurring almost constantly 
throughout the body.  DNA double strand breaks (DSBs) can arise from chromosome 
breakage, dysfunctional replication fork processing, or telomere deprotection, producing 
chromosome rearrangements that may result in the disruption of gene structure and/or 
function [194].   In some instances of tumor progression, this response may hyperactivated, 
resulting in DNA damage repair in cancer cells, opposing chemotherapy treatment [195]. 
These perpetual events require an intrinsic response in order to effectively repair the DNA 
before the cell cycle is allowed to continue.  If the damage is too much for repair, the cells 
are triggered for apoptosis.  Mechanisms of DSB repair can vary depending on cellular 
conditions such as cell cycle phase and chromatin environment.   
In mammalian cells, there are two predominate pathways that facilitate the repair 
of DSBs, homologous recombination (HR) and non-homologous end joining (NHEJ; 
Figure 4) [196-200].  Non-homologous end joining is a rapid mechanism that joins two 
ends of DNA together with little to no reference to a DNA sequence.  The Ku70-Ku80 
heterodimer initiates NHEJ via binding to the broken DNA ends and recruiting factors such 
as DNA-dependent protein kinase catalytic subunit (DNA-PKcs), DNA ligase IV (LIG4), 
and scaffolding factors x-ray repair cross complementing 4 (XRCC4), XRCC4-like factor 
(XLF), and paralogue of XRCC4 and XLF (PAXX) [201-205].  To ensure end 
compatibility, MRE11 homolog, double strand break repair nuclease (MRE11), (RAD50 
double strand break repair protein (RAD50), and nibrin (NBS1) come together to form the 
MRN complex brings the damaged ends together and a synaptic complex is formed, and 
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DNA end processing is completed by Artemis, DNA polymerases λ and µ, polynucleotide 
kinase 3’-phosphotase (PNKP), and tyrosyl-DNA phosphodiesterase 1 (TDP1) [206].  The 
ends are then ligated together, and the repair process is complete.   
Conversely, HR requires sequence homology between the broken DNA and DNA 
donor strand, leading to more direct and precise repair.  Homologous recombination mainly 
occurs during the S or G2 phases of the cell cycle and carries out recombination between 
sister chromatids [207]. The HR repair mechanism begins with the MRN complex initiating 
the resection of DNA ends.  The endonuclease activity of the MRN complex and 
exonuclease 1 (EXO1) and DNA2-Bloom syndrome protein (BLM) heterodimer resect the 
5’ end of the broken strand, creating a 3’ single-strand DNA (ssDNA) overhang [208, 209].  
The exonuclease activity of the MRN complex then displaces KU70-KU80 from the DNA 
ends and the RPA complex consisting of replication protein A1 (RPA1), RPA2, and RPA3 
coat the ssDNA, but is displaced by recombination mediators breast cancer type 2 
susceptibility protein (BRCA2), possibly partnering with partner and localizer of BRCA2 
(PALB2), and BRCA-BRCA1-associated RING domain protein (BARD1) heterodimer 
[198, 210, 211].  Upon displacement of the RPA complex from the ssDNA end, DNA 
repair protein RAD51 homolog 1 (RAD51) binds to form a nucleoprotein filament.  The 
RAD51 filament then finds the DNA template on the undamaged sister chromatid to begin 
the RAD51-mediated strand exchange facilitated by the BRCA1-BARD1 heterodimer 
[212].  A three-stranded DNA helix intermediate supports the formation of heteroduplex 
DNA that contains the invading and complementary strand.  A D-loop is formed on the 
invading strand is elongated by DNA polymerase using the invaded donor DNA as a 
template [199].  This process is then terminated by strand ligation and annealing via 
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synthesis dependent strand annealing, a non-crossover event common to DNA repair and 
the process of DSB correction is completed [199].   
One of the key players in the DNA damage response (DDR) is the ataxia 
telangiectasia mutated (ATM) protein.  ATM is implicated in three critical functions; 
regulation and simulation of DNA repair, activation of cell cycle checkpoints, and 
signaling for apoptosis induction [213].  ATM acts a sensor and transducer of DNA 
damage, phosphorylating several downstream targets after activation including histone 
2AX (H2AX) [214], mediator of DNA damage checkpoint protein 1 (MDC1) [215], and 
BRCA1 [216] for DNA repair; checkpoint kinase 2 (CHK2) for cell cycle arrest [217], p53 
[218] for apoptosis; and protein kinase B (AKT) [219] for cell survival (Figure 5).  DNA 
DSBs are initially sensed by the MRN complex, a process independent of ATM, and is 
required for the activation of ATM [220-223].  ATM autophosphorylates at serine 1981 
[224, 225], resulting in the production of an active monomer which in turn phosphorylates 
histone 2AX (H2AX) at serine 139 (γH2AX) [226].  Accumulation of γH2AX at the DSB 
site recruit’s other DNA repair proteins such as BRCA1 and MDC1 to facilitate DNA 
repair.  The phosphorylation of CHK2 at threonine 68 results in activation of P53, which 
contributes to P21 accumulation, suppressing CDK2 activity and resulting in cell cycle 
arrest at the G1 phase [227].  In addition to P53 aiding in cell cycle arrest, activation of 
P53 by ATM results in the accumulation of proapoptotic genes and subsequent cell death 
when the damage is irreparable [228].  Contrary to P53-mediated cell death, AKT acts as 
a mediator of cell survival.  ATM phosphorylates AKT at serine 473, resulting in the 
inhibition of apoptotic signals and promotion of cell cycle progression [229]. 
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In the ovary, DNA repair processes are critical for maintaining a robust gamete 
genome.  If damaging alterations in DNA remain in developing follicles, the chances of a 
healthy oocyte reduce dramatically.  Mutations in genes within the DDR pathway such as 
Atm [230] and Brca1 [231] predispose individuals to increased tumor susceptibility and 
women carrying these mutations, they may be subject to accelerated ovarian aging or begin 
with a smaller follicle reserve when compared to unaffected women [232, 233].   
 
Follicular apoptosis and atresia  
 As previously discussed in this introduction, approximately 99% of all 
follicles have an atretic fate.  Therefore, apoptosis is an essential mechanism involved in 
ovarian development and folliculogenesis from the early embryonic stage though adult life.  
Ovarian apoptosis mainly occurs in the granulosa cells or the oocyte, leading to the 
destruction of the follicle [234].  Presumably, oocyte cell death is the primary form of 
apoptosis during development and in quiescent follicles, while granulosa cell apoptosis 
contributes to follicle demise during follicle maturation and growth, though both 
mechanisms of apoptosis are not limited to these stages [235-237].  While follicles at all 
stages of development can undergo atresia, the majority of follicles degenerate at the early 
antral follicle stage [15, 238].   
 Apoptotic signals can materialize through either cell intrinsic or cell extrinsic 
pathways.  The cell intrinsic pathway is mitochondrial-associated, operated via the B-cell 
lymphoma 2 (BCL-2) family of cytoplasmic and mitochondrial proteins [239]. The cell 
extrinsic pathways include “death” ligands FAS ligand (FASL), tumor necrosis factor 
alpha (TNFα), and TNF-related apoptosis-inducing ligand (TRAIL) [240].  An additional 
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pathway, the perforin/granzyme pathway, induces apoptosis via the same executioner 
pathway as the extrinsic and intrinsic pathways, which involves caspase-induced DNA 
fragmentation [241].  Specific to granulosa cell apoptosis are growth factor-induced 
elevated levels of cAMP via granzyme B, BCL-2 activation, TNFα, and FASL [242].  
These pathways all have the same outcome, a caspase cascade in the final executioner 
phase of apoptosis, activating the initiators caspase 8 or caspase 9, followed by the 
activation of executioner caspases 3, 6, and 7 [243].  These caspases cleave various 
substrates resulting in the fragmentation of DNA and ultimately nuclear collapse.  While 
caspase dependent apoptosis is frequently observed during prenatal and postnatal 
primordial follicle loss, studies have found the level of caspase-mediated cell death to not 
be commensurate with the expected loss of primordial follicles, suggesting other apoptotic 
mechanisms independent of caspase induced cell death in some ovarian follicular 
populations [244, 245].   
Gonadotropins stimulate granzyme B, which in turn activates the intracellular pro-
caspases [241].  The protein perforin creates pores within the cell membrane, allowing the 
release of granzyme B from granules into the cytoplasm of the target cell [246].  While 
initially found in cytotoxic T lymphocytes and killer cells, granzyme B activity is observed 
in granulosa cells during early apoptosis, preserving steroidogenic activity in the cell, 
bypassing mitochondrial-mediated apoptosis [241].   
The BCL-2 family of proteins contains both anti-apoptotic and pro-apoptotic 
proteins and the balance between these factors determines the induction of apoptosis.  Anti-
apoptotic factors in the BCL-2 family include BCL-2, B-cell lymphoma-extra-large  (BCL-
XL), and induced myeloid leukemia cell differentiation protein Mcl-1 (MCL-1), while pro-
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apoptotic factors include BH3-interacting domain death agonist (BID), apoptosis regulator 
BAX (BAX), Bcl-2-related ovarian killer protein (BOK), and BCL2-associated agonist of 
cell death (BAD) [239, 247].  The mechanism of mitochondrial-initiated apoptosis occurs 
via the formation of pores in the mitochondrial membrane and altering the membrane 
potential by pro-apoptotic factors of the BCL-2 family [234].  The openings in the 
mitochondrial membrane allow the release of cytochrome-c, mitochondria-derived 
activator of caspases (SMAC), and Interleukin-1beta-converting enzyme (ICE) into the 
cytoplasm [234].  After cytochrome-c is released into the cytoplasm, it binds with apoptotic 
protease-activating factor 1 (APAF-1) and pro-caspase 9, forming the apoptosome, 
ultimately resulting in the caspase 9 activation and subsequent DNA fragmentation [248].  
The transmembrane death receptor-mediator interactions that facilitate apoptosis 
include members of the tumor necrosis factor (TNF) receptor superfamily.  Upon binding 
to the FAS receptor, FAS ligand binds to an adaptor proteins FAS-associated protein with 
death domain (FADD), whose amino acid tail send the apoptotic signals to the cell [249, 
250].  Similarly, the binding of the TNF ligand to the TNF receptor results in the binding 
of Tumor necrosis factor type 1-asscoiated death domain (TRADD) adapter protein, whose 
amino acid tail facilitates the transmission of apoptotic signals to the cell [250].  Together, 
this activity induces DNA fragmentation via action on caspase 8 [249].   
 The initiation of apoptosis is a preeminent indicator that a follicle is undergoing 
atresia, but the mechanisms behind the initiation and regulation may vary, with atresia of 
ovarian follicles being classified in three phenotypes, all involving granulosa cell apoptosis 
[251].  The majority of follicles undergo “antral atresia”, affecting the middle prolific 
layers of granulosa cells with apoptosis progressing towards the antrum of the follicle 
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[251].  This process includes the presence of apoptotic bodies and cytoplasmic blebbing, 
with the apoptotic cells in this section of the granulosa membrane being engulfed by 
healthy neighboring granulosa cells and/or infiltrating macrophages [251].  In “basal 
atresia”, the granulosa cells closest to the basal lamina of small antral follicles prematurely 
luteinize and produce progesterone, but do not complete luteinization, followed by cell 
death [251].  The third atresia phenotype is “terminal differentiation apoptosis”, occurring 
in the preovulatory follicle, presenting as granulosa cells that form aggregates and float in 
the antral fluid after sloughing off of the antral surface [252].   
 Alterations in steroidogenesis have also been suggested in the initiation of follicular 
atresia.  In ovine atretic follicles, the levels of estradiol and the ratio of estradiol to 
progesterone were considerably lower than their levels in healthy follicles [253].  
Additionally, atresia in bovine follicles has been associated with low levels of estrogen and 
higher levels of progesterone in follicular fluid [254-256].  Treatment with GnRH and 
androgens and/or withdrawal of estrogen treatment to induce apoptosis in rodents in vivo 
[257, 258].  Growth factors such as insulin-like growth factor (IGF), epidermal growth 
factor (EGF), and fibroblast growth factor (FGF), gonadotropins LH and FSH, and 
estrogens are antiapoptotic, while androgens, interleukin-6 (IL-6), and GnRH have 
atretogenic potential [243], though the precise roles of stage-dependent hormonal 
regulation on follicular atresia needs to be defined further.   
Another mechanism that may influence follicular atresia is autophagy.  Autophagy 
is an intracellular mechanism in which damaged organelles and proteins are degraded, 
recycled, and reused by the cell.  In the prepubertal spiny mouse ovary, during primordial 
and primary follicle degeneration, autophagy is the dominant form of follicular atresia 
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[259], while other studies have demonstrated the presence of autophagy marker LC3 in rat 
granulosa cells [260] or morphological characteristics of autophagy in human granulosa 
cells after exposure to oxidized low-density lipoprotein [261].  More recently, enhanced 
granulosa cell autophagy has been determined to be one of the main orchestrators of 
preantral follicular atresia, while maintaining that granulosa cell apoptosis is responsible 
for antral follicular degeneration [262]. 
 
Summary 
 The information outlined in this literature review demonstrates that proper ovarian 
function is integral for normal reproductive capacity.  Further, impacts of stressors such as 
diet, obesity, metabolic status, and ovotoxicants can alter ovarian function maternally, but 
can also impact offspring through pre-gestational or in utero exposures, though the 
molecular signatures of these events have not been well defined.  The work detailed in this 
dissertation was designed to further elucidate the mechanisms of DNA damage in the ovary 
due to a metabolic stressor or in the absence of a critical regulator in the DDR.  Moreover, 
we aimed to investigate how a metabolic syndrome potentially affects fertility via impacts 
of ovarian gap junctions.  The impact of these stressors on the ovarian proteome was 
evaluated, investigating alterations to proteins due to defined environmental and 
pathological treatment such as GDM, dietary stress, or both, and proteins regulated by 
ATM and/or altered by PM.  Identification of the potential mechanisms governing the 
DDR, follicular atresia, and the relationship with oocyte quality remain valuable to the 
field of ovarian biology and are pivotal in discovering methods to potentially mitigate 
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Figure 1. Stages of ovarian follicular development.  The stages of folliculogenesis are 
depicted with red indicating oocyte, orange indicating granulosa cells, and green indicating 
luteal cells.  The stages of follicle maturation are indicated by roman numerals: I – 
Primordial, II – Primary, III – Secondary, IV – Antral, V – Pre-ovulatory, VI – Ovulated 
oocyte, VII – Early corpus luteum, VIII – Mature and regressing corpus luteum, IX – 































Figure 2.  Gap junction organization.  Each gap junction is formed of two connexons, 
one in each respective cell membrane, comprised of six connexin protein subunits in a ring-
like structure.  Gap junctions facilitate intercellular communication, allowing the flow of 












Figure 3. Impacts of ovotoxicant exposure on female fertility across developmental 
stages.  The effects of an ovotoxic exposure on female reproductive function depends 
primarily on the developmental stage of exposure as well as on the level and duration of 
chemical exposure.  Potential impacts of chemical exposures are summarized at each 




















Figure 4. Mechanisms of DNA double strand break repair.  Non-homologous end 
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Figure 5. ATM-mediated double strand break repair.  Endogenous or exogenous 
sources of DNA damage can result in DNA double strand breaks.  One of the main 
orchestrators of DNA repair is the ATM protein.  The cellular response after a DNA 
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Gestational diabetes mellitus (GDM) is an obstetric disorder affecting 
approximately 10% of pregnancies. The 4HFHS (High Fat High Sucrose) mouse model 
emulates GDM in lean women. Dams are fed a HFHS diet one week prior to mating and 
throughout gestation resulting in inadequate insulin response to glucose in mid-late 
pregnancy. The offspring of HFHS dams have increased adiposity, thus, we hypothesized 
that maternal metabolic alterations during lean GDM would compromise ovarian function 
in offspring both basally and in response to a control or HFHS diet in adulthood.  Briefly, 
 52
DLPL were lean dams and control diet pups; DLPH were lean dams and HFHS pups; DHPL 
were HFHS dams and control diet pups and DHPH were HFHS dams and HFHS pups.  A 
HFHS challenge in the absence of maternal GDM (DLPL vs. DLPH) increased 3 and 
decreased 30 ovarian proteins. Maternal GDM in the absence of a dietary stress (DLPL vs. 
DHPL) increased abundance of 4 proteins and decreased abundance of 85 proteins in the 
offspring ovary. Finally, 87 proteins increased, and 4 proteins decreased in offspring 
ovaries due to dietary challenge and exposure to maternal GDM in utero (DLPL vs. DHPH). 
Canopy FGF signaling regulator 2 (CNPY2), Deleted in azoospermia-associated protein 1 
(DAZAP1), Septin 7 (SEPT7), and Serine/arginine rich splicing factor 2 (SRSF2) were 
altered across multiple offspring groups. Together, these findings suggest a possible impact 
on fertility and oocyte quality in relation to GDM exposure in utero as well as in response 
to a western diet in later life.  
 




The ovary produces the female gamete, the oocyte, and primary sex hormones 17β-
estradiol (E2) and progesterone (P4).  Oocytes arise from primordial germ cells in utero and 
remain encased in primitive follicular structures, arrested at the diplotene stage of meiosis, 
or they degenerate through programmed cell death termed atresia [1].  Through the natural 
progression of time or due to factors that may expedite the process, the pool of ovarian 
oocytes ultimately becomes depleted and ovarian senescence occurs in women [1].  
Ovarian failure preceding age 40 is characterized as primary ovarian insufficiency (POI) 
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[2], which may be attributable to genetics, autoimmune disorders, iatrogenesis, surgical, or 
unknown etiology, and affects approximately 1% of women [3].   
In recent years, globally there has been an expeditious rise in obesity rates in both 
adults and children, predisposing them for health problems including diabetes [4], 
cardiovascular disease [5], cancer [6], and reproductive decline [7].  In the overweight or 
obese female, reproductive complications include POI [8], polycystic ovary syndrome 
(PCOS) [9], poor oocyte quality [10], decreased fecundity [11], gestational diabetes 
mellitus (GDM) [12], and offspring congenital abnormalities [13].  Changes in central 
metabolism negatively affect the ovary, with insulin responsive pathways such as the 
phosphatidylinositol 3-kinase (PI3K) pathway being upregulated during obesity [14], 
reduced follicle number [15], altered steroid hormone biosynthesis [16], and inflammation 
[15].  Additionally, basal ovarian DNA damage and a blunted ovarian response to 
genotoxicants occurs in obese mice [16-19].  Offspring exposed to maternal obesity have 
increased risk of neural tube defects [20], glucose intolerance [21], altered neurobehavior 
[22], intrauterine growth restriction (IUGR) [23], and increased circulating cholesterol and 
body fat [24].  The reproductive outcomes on female offspring exposed to maternal obesity 
in utero include a decrease in the ovarian follicular reserve [25, 26], decreases in ovarian 
vascularity [27], and disturbances in the estrous cycle in a rodent model [28].  
In association to the rise of obesity in reproductive age women, the prevalence of 
GDM is also increasing.  Defined as glucose intolerance during pregnancy, GDM may 
affect up to 20% of pregnancies, dependent on population demographics [29], screening 
and diagnostic criteria [29], and pre-gestational maternal lifestyle factors [30].  Insulin 
sensitivity naturally decreases during pregnancy for all women [31] but overweight and 
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obese women have higher risk of developing GDM than their lean counterparts [12, 32] 
and lean women with GDM have reduced or delayed first-phase insulin response to glucose 
[31]. Immediate health concerns are posed by GDM, and although GDM normally resolves 
postpartum, long-term maternal health effects include a 60% higher risk of acquiring Type 
2 diabetes [33, 34].  Fetal and neonatal complications include macrosomia [35], 
hypoglycemia [36], respiratory distress [36], future obesity [37], and predisposition for 
Type 2 diabetes [38].  
When considering our recent findings that progressive obesity alters a variety of 
ovarian intracellular signaling pathways that could compromise fertility and offspring 
health [14, 15, 17, 19, 39, 40], we hypothesized that similar alterations would result from 
exposure of the developing ovary to metabolic alterations in utero.  A lean GDM model 
has been developed using acute, high-fat feeding one week prior to conception and 
throughout gestation, thereby separating effects of pre-conceptional obesity from maternal 
gestational metabolic alterations on the offspring [41]. We utilized ovaries from offspring 
who experienced GDM in utero and also assessed whether a dietary stress in adulthood 
would affect the ovarian response to such an insult.   
 
Materials and Methods 
Animal procedures and tissue collection 
Ovarian tissue utilized in this study was obtained as part of a larger study [42].  Briefly, 
gestational diabetes was induced in female C57B16/J mice (n = 14) by feeding a high fat, 
high sucrose (HFHS; 45% kcal/fat (lard and soybean oil) and 17% kcal/sucrose) diet 
(D12451, Research Diets, Inc) one week prior to mating and for the duration of gestation, 
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for a total of 4 weeks as described [41, 42].  Control female C57B16/J mice (Jackson 
Laboratories; n = 20) were fed a chow breeder diet (17% kcal/fat (lard) and 2.4% 
kcal/sucrose; LabDiet 5008, Purina) throughout the duration of the study.  Both groups of 
females were mated to C57B16/J sires.  Female offspring from each litter (control – n = 
30; GDM – n = 16) were maintained on the chow breeder diet, until 23 weeks of age, at 
which point 1-2 females from each litter was fed the HFHS diet until 31 weeks of age, at 
which time both groups of offspring were humanely sacrificed.  Mice were not at the same 
stage of the estrous cycle at euthanasia.   Ovaries were collected from adult females and 
one ovary was snap-frozen in liquid nitrogen before storage at -80°C. The contralateral 
ovary was fixed in 4% paraformaldehyde and stored in 70% ethanol prior to histological 
processing.  Ovaries utilized for frozen tissue sections were collected from 10-week-old 
female C57B16/J mice during the pro-estrus stage of the estrous cycle and fixed in 4% 
paraformaldehyde overnight at 4°C.  For cryoprotection, fixed ovaries were passed in 10% 
sucrose/PBS solution for 1-3 hours at room temperature followed by 30% sucrose/PBS 
solution at 4°C overnight prior to embedding in OCT medium (Fisher Healthcare).  All 
animal procedures were approved by the University of Missouri or the Iowa State 
University Institutional Animal Care and Use Committee and handled according to 
National Institutes of Health Guide for Care and Use of Laboratory Animals.   
 
Histology and follicle counting 
Fixed ovaries were paraffin embedded and serially sectioned (n = 4/treatment) at 5 
µm, with every 6th section mounted onto glass slides and stained with hematoxylin and 
eosin.  Healthy follicles containing oocytes with a distinct oocyte nucleus were counted 
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and classified as previously described [43].  Briefly, primordial follicles were identified by 
an oocyte surrounded by a single layer of squamous granulosa cells; primary follicles 
contained the oocyte surrounded by a single layer of cuboidal granulosa cells, and 
secondary follicles contained an oocyte surrounded by multiple layers of granulosa cells.  
Slide identify was blinded to prevent counting bias. Follicle counts performed on a Nikon 
Optiphot using a 5x or 20x objective and bright field images captured on an inverted 
DMI3000B microscope (Leica) and QICAM MicroPublisher 5.0 (MP5.0-RTV-CLR-10, 
QIMAGING) camera using QCapture software at a 5x objective. Total follicles counted 
per ovary were compared between treatments.  
 
Protein isolation, LC-MS/MS, and proteome analysis 
Total ovarian protein was isolated (n = 3/treatment) in lysis buffer (50 mM Tris-
HCL, 1 mM EDTA, pH 8.5), homogenized, and centrifuged at 10,000 rpm at 4°C for 15 
min.  Supernatant was collected, and protein content was quantified using bicinchoninic 
acid assay (BCA; Pierce BCA Protein Assay Kit, Thermofisher). A working protein 
dilution of 50 µg/µl was prepared with lysis buffer.  For LC-MS/MS analysis, total protein 
(50 µg/µl) was digested with trypsin/Lys-C for 16 hours, dried down and reconstituted in 
buffer A (47.5µl; 0.1% formic acid/water) and Peptide Retention Time Calibration (PRTC) 
mixture was utilized as a standard (25 fmol/µl) and was spiked into each sample to serve 
as an internal control.  Protein (10 µg) and PRTC (250 fmol) were injected onto a liquid 
chromatography column (Agilent Zorbax SB-C18, 0.5mm x 150mm, 5 micron) using an 
Agilent 1260 Infinity Capillary Pump.  Peptides were separated by liquid chromatography 
and analyzed using a Q ExactiveTM Hybrid Quadrupole-Orbitrap Mass Spectrometer with 
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a higher energy collisional dissociation (HCD) fragmentation cell. The resulting intact and 
fragmentation pattern was compared to a theoretical fragmentation pattern (from either 
MASCOT or Sequest HT) to identify peptides. The relative abundance of the identified 
proteins was based on the areas of the top three unique peptides for each sample.  The 
arithmetic mean of the PRTC was used as normalization factor.  For each peptide, the signal 
intensity was divided by the arithmetic mean of the PRTC before further analysis.  
Metaboanalyst 3.0 [44, 45] was used for data analysis. Upon finding data integrity 
to be satisfactory (no peptide with more than 50% missing replicates, positive values for 
the area), missing value imputation was performed using a Singular Value Decomposition 
(SVD) method. Filtering, based on interquartile range, was performed to remove values 
unlikely to be of use when modeling the data, followed by generalized log transformation 
(glog 2) before data analysis. The control and treatment samples were compared by the 
Student's t-test. Differences between groups were assessed by the Mann-Whitney rank sum 
test. All p-values were two sided. To adjust for multiple comparisons, Bonferroni 
correction was applied and only p-values less than 0.1 were considered as statistically 
significant. The principal component analysis (PCA) analysis was performed using the 
prcomp package and pairwise score plots providing an overview of the various separation 
patterns among the most significant components were accessed. The partial least squares 
(PLS) regression was then performed using the plsr function provided by R pls package. 
The classification and cross-validation were also performed using the caret package. The 
UniProt protein identifiers that were up/down regulated were used to retrieve the 
corresponding KEGG identifiers using the “Retrieve/ID mapping” tool of UniProt 
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(accessible at tp://www.uniprot.org/uploadlists/). KEGG identifiers were then used to 
retrieve biological pathway association of the proteins. 
 
Gene ontology analysis  
Gene Ontology (GO) analysis was performed using PANTHER version 14.1 
(http://www.pantherdb.org).  Proteins identified in the control and experimental samples 
were compared to the Mus musculus reference list for a statistical overrepresentation test 
to highlight categories in biological process, molecular function, and cellular components 
with significant fold-enrichment in our samples.  The Fisher’s Exact test with False 
Discovery Rate (FDR) correction was used with P < 0.05 considered as a statistically 
significant difference.  
  
Immunofluorescence staining 
Slides were deparaffinized in Citrisolv and rehydrated in subsequent washes of 
ethanol (100%, 95%, 75%), followed by one wash in ddH2O.  Heat mediated antigen 
retrieval was performed using citrate buffer (10 mM citric acid, 0.5% Tween20, pH 6.0) in 
a microwave for 22 min.  Tissue sections on histology slides were encircled with a 
histology pap pen to keep liquid concentrated on the tissue during processing, followed by 
the application of blocking solution (0.1M PBS/0.4% BSA/0.2% Tween20/2.5% goat 
serum) to the slides for 1 hour at room temperature.  In addition, frozen tissue from 10-
week-old female C57B16/J mice was utilized to determine localization of canopy FGF 
signaling regulator 2 (CNPY2), deleted in azoospermia-associated protein 1 (DAZAP1), 
pre-mRNA serine/arginine rich splicing factor 2 (SRSF2), and septin 7 (SEPT7).  Briefly, 
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frozen slides were thawed on a 37°C slide warmer for 5 minutes, tissue encircled with a 
histology pap pen, and rehydrated in phosphate buffered saline with 0.1% Tween20 
(PBSTw) for 20 minutes at room temperature before addition of blocking solution 
(described above).  Primary antibodies for CNPY2, DAZAP1, SRSF2, SEPT7, 
phosphorylated histone 2AX (γH2AX), and cleaved caspase-3 (CASP3; dilutions listed in 
Supplementary Table 1) were added into fresh blocking solution, applied to tissue 
sections and allowed to incubate in a humidified box at 4°C overnight.  Slides were washed 
(3 x 10 min) in PBSTw.  Secondary antibodies (Supplementary Table 1) were added into 
fresh blocking solution and incubated at room temperature for 60 min, followed by washes 
(3 x 10 min) in PBSTw.  Slides were allowed to air dry, counterstained and mounted with 
4-6-diamidino-2-phenyllindole (DAPI) and stored at 4°C until image capture.  Negative 
technical controls to confirm specificity were performed using secondary antibodies alone 
(Supplementary Figure 1). Images were captured on a Zeiss LSM700 confocal 
microscope equipped with an AxioCam MRc5 using a 20x objective lens. For γH2AX 
(n=40 sections; 10 sections per treatment) and cleaved CASP3 (n=40 sections; 10 sections 
per treatment), immunopositive cells were manually counted in the granulosa cells and/or 
oocytes of primary, secondary and antral follicles using the cell counter module of ImageJ 
(https://imagej.nih.gov/ij/plugins/cell-counter.html).   
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism 7.0 One-way ANOVA 
function with multiple comparisons.  Each treatment mean value was compared to the 
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control (DLPL) mean value using Dunnett’s correction with significance level set at P ≤ 
0.05.    
Results 
GDM exposure in utero and subsequent dietary challenge decreased healthy follicle 
number 
The impact of GDM exposure in utero and/or dietary stressor later in life on healthy 
follicle numbers was determined (Figure 1).  There was no difference in primordial follicle 
number between treatment groups (DLPH; DHPL; and DHPH) relative to DLPL control (P = 
0.1361; Figure 1.A).  Dietary stress in adulthood in the DLPH mice did not impact 
primordial, primary, or secondary follicle number (Figure 1A-D). GDM exposure in utero 
also did not affect primordial, primary or secondary follicle number (Figure 1A-D). The 
combination of GDM in utero with dietary stress in adulthood in the DHPH mice 
numerically reduced primordial follicle number (Figure 1A) and decreased (P < 0.05) the 
number of primary and secondary follicles (Figure 1 B-D).    
 
Impact of in utero exposure to GDM on DNA damage in the ovary 
To determine if offspring from GDM mothers had increased ovarian DNA damage, 
tissue sections were immunologically stained for γH2AX and positive foci were quantified.  
The number of ovarian cells (granulosa cells and/or oocytes) that contained positive 
γH2AX foci in the primary, secondary, or antral follicles were not different between 
treatment groups (DLPL: 30.1 ± 13.5; DLPH: 5.5 ± 3.6; DHPL: 48.3 ± 20.5; DHPH: 9.8 ± 5.7; 
Figure 2 A-F). 
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Impact of in utero exposure to GDM on apoptosis in the ovary 
In order to assess levels of apoptosis in the ovary, immunofluorescence staining 
was performed to quantify the level of cleaved CASP3.  There was no impact of GDM 
exposure in utero or dietary stress on any treatment group in the level of cleaved CASP3 
that was detected in the granulosa cells or oocytes of primary, secondary, or antral follicles 
(DLPL: 8.8 ± 2.1; DLPH: 12 ± 2.2; DHPL: 10.3 ± 3; DHPH: 13 ± 7.6; Figure 3 A-F).    
 
In utero exposure to lean GDM alters the offspring ovarian proteome  
There were 504 ovarian proteins identified in DHPL offspring who experienced 
GDM in utero but did not receive the high fat diet in adulthood.  Relative to DLPL offspring 
ovaries, 85 proteins were reduced and 4 were increased in abundance in the ovaries of DHPL 
mice (log2foldchange ≥ 1 and P-value ≤ 0.1; Figure 4A; Supplementary Table 2).   
 
A high fat diet affects the ovarian proteome in adult mice 
A total of 470 ovarian proteins were identified in the DLPH mice.  Relative to the 
Relative to DLPL offspring ovaries, 30 proteins were decreased, and 3 proteins were 
increased in the ovaries of DLPH (log2foldchange ≥ 1 and P-value ≤ 0.1; Figure 4B; 
Supplementary Table 3).   
 
Additive effect of dietary stress in later life on the proteome of offspring exposed to 
lean GDM in utero  
In the DHPH ovaries, 481 total proteins were identified.  When compared to the 
DLPL mice, 4 proteins were increased and 87 proteins were decreased, indicating the 
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combined effects of GDM exposure in utero with an HFD stress in adulthood 
(log2foldchange ≥ 1 and P-value ≤ 0.1; Figure 4C; Supplementary Table 4). 
Furthermore, comparison of the ovarian proteome of the DHPH with the DLPH mice revealed 
the additive effects of in utero GDM since both of these groups experienced the dietary 
stressor in adulthood and 5 proteins were increased and 3 proteins were decreased 
(log2foldchange ≥ 1 and P-value ≤ 0.1; Supplementary Table 5). 
Of these differentially expressed proteins, 8, 49, and 52 proteins were identified 
that were unique to DLPH, DHPL, and DHPH, respectively.  In addition, 20 proteins were 
shared between the groups exposed to GDM in utero, 5 proteins are shared between the 
groups exposed to the HFD, and 14 proteins were shared between all the treatment groups 
(Figure 5).   
 
Overrepresented gene ontology (GO) analysis of maternal GDM exposure in the 
absence or presence of dietary stress in adulthood 
Proteins identified as being different from the DLPL mice (log2foldchange ≥ 1 and 
P-value ≤ 0.1) in each treatment group (DLPH – n = 33; DHPL – n = 89; and DHPH – n = 91) 
were assigned to biological process, molecular function, and cellular component using 
PANTHER GO analysis (Fischer’s Exact with FDR multiple test correction; P < 0.05).  
For biological process, several of the GO categories that showed substantial enrichment in 
the DHPH ovaries relative to controls were associated with a catabolic or metabolic process 
(Supplementary Figure 1A).  There was a 43-fold enrichment of proteins in the DHPH 
ovaries involved in the hydrogen peroxide catabolic process, including the proteins catalase 
(CAT), apolipoprotein A-IV (APOA4), and peroxiredoxin-5, mitochondrial (PRDX5).  
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Proteins from DHPL were enriched in categories related to protein complex disassembly, 
depolymerization, and regulation of actin filament activity (Supplementary Figure 1B).  
Actin crosslink formation had the highest fold-enrichment in the GDM only offspring, with 
proteins such as Filamin-A (FLNA) and myristoylated alanine-rich C-kinase substrate 
(MARCKS) included in the cluster.  There were no significant categories assigned in the 
HFHS diet alone offspring.   
Concerning molecular function, proteins from GDM exposed and HFHS fed 
offspring ovaries, GO categories that were enriched mainly involved enzymatic activity or 
binding (Supplementary Figure 2A).  Transaminase activity included protein-glutamine 
gamma glutamyltransferase 2 (TGM2) and aspartate aminotransferase, mitochondrial 
(GOT2).  Ovaries from females exposed to GDM in utero without a HFHS challenge had 
more binding categories assigned, with the protein kinase C binding category having a 20-
fold enrichment (Supplementary Figure 2B).  Proteins identified in this category included 
serine/arginine-rich splicing factor 2 (SRSF2), FLNA, and MARCKS.  Similar to the GDM 
only group, the HFHS only group had all identified GO terms associated with binding 
(Supplementary Figure 2C).  Pre-mRNA binding was enriched 61-fold in this group, with 
SRSF2, polypyrimidine tract-binding protein (PTBP1), and the splicing factor U2AF 65 
kda subunit (U2AF2) protein identified in this cluster. 
GO terms assigned to cellular component included those involved in cell junctions 
and various cell complexes.  Fascia adherens was enriched 56-fold in the DHPH ovaries, 
with proteins such as vinculin (VCL), alpha-actinin-1 (ACTN1), and spectrin alpha chain, 
non-erythrocytic 1 (SPTAN1) identified (Supplementary Figure 3A).  The interchromatin 
granule cluster was enriched greater than 100-fold, including the proteins SRSF2 and 
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cleavage and polyadenylation specificity factor subunit 6 (CPSF6) (Supplementary 
Figure 3B).  There were substantially less categories identified in the DLPH group 
(Supplementary Figure 3C).  The cytoplasm cluster had the highest enrichment only 
being enriched by 1.75-fold, containing proteins such as SRSF2, PTBP1, and tubulin-
specific chaperone A (TBCA). 
 
Ovarian localization of CNPY2, DAZAP1, SRSF2 and SEPT7 
In order to establish the ovarian localization of selected proteins identified to be of 
interest from the LC-MS/MS analysis, but for whom the ovarian location is unknown, 
immunofluorescence staining was performed on ovarian sections from adult C57B16/J 
mice.  From the LC-MS/MS analysis, CNPY2 had a log2fc of -1.65, -1.72, and -2.18 in 
groups DLPH, DHPL, and DHPH, respectively.  Positive immunofluorescence staining for the 
CNPY2 protein was observed in the theca and granulosa cells, and the pericytoplasmic 
region of the oocyte in primary, secondary, and antral follicle stages (Figure 6A).  
DAZAP1 had a -2.43 log2fc and -5.13 log2fc in the DHPL and DHPH groups, respectively, 
in the LC-MS/MS analysis, but was not altered in the DLPH ovaries, suggesting an impact 
of GDM exposure in utero, and further amplification by dietary stress on ovarian DAZAP1 
abundance.  Immunological staining for DAZAP1 demonstrated positive staining in luteal 
cells, oocyte nucleus, and granulosa cells (Figure 6B).  In contrast to the previous proteins 
selected from our data set, SRSF2 was identified by LC-MS/MS analysis as being 
increased in groups DLPH, DHPL, and DHPH with log2fc of 1.70, 1.91, and 1.42, 
respectively, relative to the DLPL ovaries.  SRSF2 protein was determined by 
immunofluorescence staining to be localized to the oocyte peri-cytoplasmic region and 
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nucleus in pre-ovulatory follicles (Figure 6C).  SEPT7 was noted from the LC-MS/MS 
analysis to be decreased in the DLPH, DHPL, and DHPH ovaries by -1.04, -1.43, and -1.07 
log2fc, respectively.  Positive immunofluorescence staining for SEPT7 was observed in 





The reproductive phenotypic impacts of obesity and insulin resistance have been 
well characterized, yet the percentage of the population at risk continues to increase [46].  
In parallel with rising obesity rates, the number of women acquiring GDM is also 
increasing [47].  One of the major risk factors for GDM development is pre-gestational 
obesity and/or insulin resistance, although interestingly around a third of cases occur in 
lean women [48].   
While the underlying etiology of GDM remains unknown, several experimental 
animal models have been developed that effectively mimic the most common GDM 
features.  Partial pancreatectomy in post-pubertal rodents results in a mild type 1 diabetes 
phenotype via the reduction of β-cell numbers, but limitations include the latency for 
diabetic symptoms to appear  [49].  Administration of alloxan and streptozotocin (STZ) 
impairs and destroys pancreatic β-cells, leading to hyperglycemia and insulin insufficiency 
[50-52].  Nicotinamide (NA) injection prior to STZ administration protects the pancreas 
from severe damage and leads to a lower number of fetal malformations [53-55].  Mouse 
models of GDM are also available via gene knockout or transgenic overexpression but 
although effective at emulating GDM, many of these genetic models have more severe 
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phenotypes than typically observed in human cases of GDM and the genetic changes may 
be passed on to offspring.  A commonly used GDM mouse model are females who are 
heterozygous for a mutation in the leptin receptor (ObR; Db-/+), who have reduced glucose 
homeostasis in the non-pregnant state, but spontaneously develop hyperphagic feeding, 
increased adiposity, insulin resistance, and glucose intolerance during pregnancy [56], 
although conflicting results have been noted in other studies [57-59].   
Another approach for inducing GDM is via dietary manipulation.  Dams consuming 
a high-fat diet to induce obesity and insulin resistance pre-pregnancy have a GDM 
phenotype during pregnancy [60-64].  The maternal model utilized in our study is also diet-
induced, and includes a high fat and high sugar diet, which is comparable to the diet of the 
human population, but obesity is absent prior to gestation.  With this method, we are able 
to elucidate the mechanisms behind GDM without the additive effects of obesity.  These 
females exhibit susceptibility to glucose intolerance later in life when challenged with the 
same diet but in the absence of increased body mass [41]. An obvious drawback with using 
this model is that there is a confounding effect of differing dietary composition and the 
HFHS mice in this study received an additional fat source to the controls in the form of 
sunflower oil. Future studies aimed at assessing any additive impacts of differing fat source 
on the ovarian endpoints measured are possible in the future, though it is far more plausible 
that it is the increased adiposity in this model that contributes to the ovarian effects reported 
herein.  
 The ramifications of GDM and the health of the offspring also need consideration.  
In addition to risk of stillbirth, babies born to mothers who experience diabetes during 
pregnancy have higher rates of macrosomia [35], hypoglycemia [36], respiratory distress 
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[36], future obesity [37], and like the mother, a predisposition for type 2 diabetes later in 
life [38].  Offspring that were exposed to our model of GDM in utero and later on 
challenged with the HFHS diet had increased body weight, higher body fat percentage, and 
increased adipose insulin sensitivity [42].  Reproductive effects on the male offspring from 
these dams included reduced sperm counts, reduced germ cell apoptosis, and low 
testosterone [65].  Our results in the female offspring corroborate the reproductive effects 
noted in the males, with reduced numbers of healthy primary and secondary follicle 
numbers, as well as a numerical decrease in primordial follicle numbers in the DHPH mice 
illustrating that in utero environment coupled with a later stressor in adulthood may have 
negative impacts on female fertility.   
Previous work from our group and others has demonstrated how the metabolic 
changes that occur during obesity can alter folliculogenesis and the responsive pathways 
[15, 16, 19, 66-68].  The ovarian PI3K-PTEN-AKT-FOXO3 signaling pathway is involved 
in follicular activation via an insulin-mediated process [69, 70].  Hyperinsulinemia is 
common during obesity, and from this we have previously reported changes in the 
activation of the PI3K pathway, resulting in increased follicular activation [14].  Thus, it is 
possible that the observed lower number of follicles in the GDM offspring, especially those 
challenged with the high fat diet later in life, result from the increased body mass and 
insulin resistance following in utero metabolic exposures.  In this study, the female mice 
had increased adiposity as measured by nuclear magnetic resonance imaging as early as 4 
weeks of age, despite not being introduced to the HFHS diet until 23 weeks of age [42].  A 
subject for future analysis would be to define at what rate the introduction of the HFHS 
diet to GDM offspring diminishes the follicular pool subsequent to GDM exposure alone.   
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Obesity is also associated with ovarian DNA damage [17, 18, 40] and throughout 
the body [71].  Interestingly, we did not observe any consequential changes on GDM and/or 
dietary stress in later life in the abundance of γH2AX, which is considered the gold standard 
for DNA double strand break localization [72].  As with increased DNA damage detected 
in obesity, increased granulosa cell apoptosis has also been reported [73].  We did not, 
however, observe increased granulosa cell apoptosis as detected by cleaved CASP3 protein 
in our offspring ovaries.  The lack of additional DNA damage and cellular apoptosis in our 
model could be interpreted as that while they have increased body weight and insulin 
sensitivity, they have not necessarily amassed a metabolic syndrome severe enough to 
trigger a genotoxic response.  This remains to be determined.   
Proteomic profiling can be highly informative in investigating alterations to 
proteins due to a defined environmental and pathological treatment.  In an unbiased 
proteomic approach, we identified several proteins of interest, including DAZAP1, SEPT7, 
CNPY2, and SRSF2, to be altered by GDM, adult dietary stress, or both.  DAZAP1 was 
substantially decreased in ovaries from female mice exposed to GDM in utero, and further 
impacted by the additional insult of the HFHS diet.  The deleted in azoospermia (DAZ) 
family of proteins are present in male and female germ cells and play a major role in germ 
cell development and fertility [74].  Mutations in DAZAP1 results in perinatal lethality, 
with those surviving experiencing reproductive defects such as sterility as well as growth 
retardation [75].  Fertility defects associated with DAZAP1 have been typically described 
in males [76, 77], so our finding of alterations to DAZAP1 due to in utero GDM and dietary 
stress and localization in granulosa and luteal cells as well as in the oocyte implies that 
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DAZAP1 may have important roles in ovarian physiology and female fertility through 
altering follicle growth and survival, potentially contributing to POI. 
The Septin family of proteins have been well characterized as being involved in the 
spindle positioning and cell division [78-80].  Loss of SEPT7 results in improper spindle 
organization in the oocyte and disruption of chromosome alignment affecting progression 
of meiosis [62].  Poor oocyte quality is attributed with increased body mass [10], and the 
modest decrease in SEPT7 observed in our study suggests that the metabolic stress from a 
HFHS diet, GDM exposure in utero, or both, may affect oocyte quality and/or maturation.  
SEPT7 was also identified in our enriched cellular component GO analysis in both the 
GDM exposed groups as septin complex, septin ring, and septin cytoskeleton.  In 
agreement with this possibility, localization of SEPT7 within the follicle and the oocyte, 
further implicate SEPT7 as an essential player in murine oocyte meiotic maturation, and 
that SEPT7 is vulnerable to alteration due to metabolic alterations.   
CNPY2 is pivotal in the induction of the PERK-CHOP unfolded protein response 
(UPR) response pathway, which is a highly conserved quality control mechanism for cells 
that are under endoplasmic reticulum (ER) stress [81].  The luminal chaperone GRP78 
dissociates from PERK and CNPY2 during ER stress and unfolded protein accumulation, 
facilitating the initiation of the UPR response [81].  Furthermore, Cnpy2 is differentially 
expressed in human placental tissue from GDM pregnancies, though these results revealed 
a positive fold change [82] in contrast with our findings of decreased CNPY2 protein 
abundance.  We also determined the localization of CNPY2, with positive 
immunoreactivity in the theca cells, granulosa cells, and in the peri-cytoplasm of the 
oocyte.     
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Also associated with the cellular stress response is SRSF2, which is increased 
during genotoxic stress [83] and is increased across all treatment groups in our study and 
was also assigned to several of the GO categories that were highly enriched.  SRSF2 is an 
alternative splicing factor involved in the regulation of apoptotic caspases, with the 
mechanism for pro-apoptotic or anti-apoptotic caspases determined by the numerous splice 
variants [84].  Immunohistochemical analysis of SRSF2 revealed expression in the peri-
cytoplasm of the oocyte, though analysis of cleaved CASP3 revealed no differences in the 
levels of apoptotic cells between any of the groups, so increased SRSF2 observed in this 
study may not be substantial enough to generate a pro-apoptotic response via CASP3.  
Conversely, SRSF2 may be functioning in an anti-apoptotic response to the metabolic 
conditions arising from increasing adiposity and/or insulin resistance.    
In conclusion, these study findings indicate the impact of GDM and HFHS diets on 
follicle number and the ovarian proteome and illustrates that GDM sensitizes the offspring 
ovary to a dietary HFHS stress later in life, consequentially impacting the number of 
healthy follicles.  Further, the altered abundance of ovarian proteins in offspring exposed 
to maternal GDM emphasizes the potential long-term effects of metabolic alterations in 
utero on ovarian function in the absence of obesity.  Many of the proteins identified are 
those for which we have little understanding of their ovarian function and lay the 
foundation for future studies to determine their ovarian importance. Taken together, these 
findings illustrate a possible impact on fertility and oocyte quality provided in a two-hit 
stress model relative to GDM exposure in utero and in response to a western diet later in 
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Figure 1: Effect of GDM and/or HFHS diet on ovarian follicle number.  Follicles were 
classified as (A) primordial; (B) primary; (C) secondary and counted. Bars represent mean 
counted follicle number ± SEM.  Significant difference from DLPL control is indicated by 
the * symbol at = P < 0.05. Representative hematoxylin and eosin stained ovarian sections 









   
     



















Figure 2: Effect of GDM and/or dietary stress on ovarian γH2AX. A primary antibody 
directed against γH2AX was used to determine ovarian localization in (A) DLPL; (B) DHPL; 
(C) DLPH; (D) DHPH mice. (E) Secondary antibody only control. Red punctate staining 
indicates γH2AX while cellular DNA is stained in blue; scale bar = 50 µm.  Arrows indicate 
γH2AX positive staining in the granulosa cells of secondary follicles.  (F) The bars 












































Figure 3: Effect of GDM and/or dietary stress on ovarian cleaved CASP3. A primary 
antibody directed against cleaved CASP3 was used to determine ovarian localization in 
(A) DLPL; (B) DHPL; (C) DLPH; (D) DHPH mice.  (E) Secondary antibody only control. 
Green staining indicates cleaved CASP3 while cellular DNA is stained in blue; scale bar = 
50µm. Arrows indicate cleaved CASP3 positive staining in the granulosa cells of 




















































Figure 4: Volcano plots indicating the proteins detected by LC-MS/MS analysis and 





line shows where P = 0.1, with points above the line having P < 0.1 and points below 
having P > 0.1.  The dotted vertical lines indicate a log2fold change of < ± 1.0.  Pink dots 
indicate proteins identified that are increased or decreased relative to DLPL ovaries, gray 

































Figure 5: Proteins that are in common or unique between treatments. The Venn 
diagram presents the number of ovarian proteins identified as being unique to treatment or 
altered in common by treatment, relative to the DLPL group.  The number in grey circle 
indicates the number of proteins identified in the DLPH group as being different from the 
DLPL group; the blue circle indicates the number of proteins identified in the DHPL group 
as being different from the DLPL group; and the pink circle indicates the number of proteins 
in the DHPH group that differ from the DLPL group. Overlapping areas of the circles 
illustrate the number of proteins that were altered relative to the DLPL group by two or more 




































Figure 6: Localization of ovarian proteins by immunofluorescence staining. (A) 
CNPY2 (20x -1x zoom); (B) DAZAP1(20x -1x zoom); (C) SRSF2 (20x -1x zoom); and 
(D) SEPT7 (20x - 0.5x zoom) protein were localized in the adult mouse ovary. Green 
staining indicates the protein of interest while cellular DNA is stained in blue.  Solid arrow 
indicates theca cells; double tailed arrow indicates granulosa cells; dotted tail arrow 










Supplemental Figures and Legends 















Primary Antibody Host  Dilution  Supplier  Code 
DAZAP1 Rabbit 1:100 (F) Thermo Fisher PA5-52083 
CNPY2 Rabbit 1:100 (F) Thermo Fisher PA5-46131 
SEPT7 Rabbit 1:100 (F) Abcam Ab211482 
SRSF2 (SC35) Rabbit 1:100 (F) Thermo Fisher PA5-78164 
γH2AX Rabbit 1:50 (P) Cell Signaling 2577 
Cleaved caspase 3 Rabbit 1:100 (P) Cell Signaling  9661 
Secondary Antibody Host  Dilution  Supplier  Code 
Rabbit IgG 488 










Supplementary Table 2: Ovarian proteins identified by LC-MS/MS to differ in DHPL 
offspring relative to the DLPL mice (log2foldchange ≥ 1 and P-value ≤ 0.1).   
UniProtID Protein names log2(FC) p value 
Q8BTI8 Serine/arginine repetitive matrix protein 2 -3.828 0.054 
P14602 Heat shock protein beta-1 -2.897 0.003 
Q3TW96 
UDP-N-acetylhexosamine pyrophosphorylase-like 
protein 1 -2.822 0.013 
P00920 Carbonic anhydrase 2 -2.437 0.002 
Q9JII5 DAZ-associated protein 1  -2.428 0.086 
Q9JMG7 Hepatoma-derived growth factor-related protein 3  -2.241 0.025 
Q9D1M0 Protein SEC13 homolog -2.029 0.073 
P62889 60S ribosomal protein L30 -1.991 0.095 
Q62188 Dihydropyrimidinase-related protein 3  -1.981 0.009 
P48758 Carbonyl reductase [NADPH] 1 -1.963 0.005 
Q9D0F9 Phosphoglucomutase-1  -1.944 0.008 
P60335 Poly(rC)-binding protein 1  -1.918 0.024 
P62983 Ubiquitin-40S ribosomal protein S27a  -1.904 0.082 
Q9R0P5 Destrin -1.882 0.003 
P26369 Splicing factor U2AF 65 kDa subunit  -1.872 0.004 
P16546 Spectrin alpha chain, non-erythrocytic 1 -1.871 0.019 
Q64727 Vinculin -1.865 0.041 
Q7TPR4 Alpha-actinin-1 -1.859 0.013 
Q8K183 Pyridoxal kinase  -1.823 0.069 
Q61598 Rab GDP dissociation inhibitor beta  -1.778 0.011 
Q8BTM8 Filamin-A  -1.775 0.037 
Q9QXT0 Protein canopy homolog 2  -1.721 0.031 
P63254 Cysteine-rich protein 1 -1.663 0.078 
P47754 F-actin-capping protein subunit alpha-2  -1.639 0.015 
P61922 4-aminobutyrate aminotransferase, mitochondrial  -1.633 0.051 
P31230 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1 -1.631 0.055 
P21614 Vitamin D-binding protein  -1.625 0.055 
Q99L13 
3-hydroxyisobutyrate dehydrogenase, 
mitochondrial  -1.579 0.083 
P04104 Keratin, type II cytoskeletal 1  -1.552 0.076 
Q99JF8 PC4 and SFRS1-interacting protein  -1.541 0.026 
P26443 Glutamate dehydrogenase 1, mitochondrial  -1.541 0.004 
Q8BH97 Reticulocalbin-3 -1.539 0.067 
Q8C1B7 Septin-11 -1.525 0.004 
O35887 Calumenin  -1.522 0.017 
Q91V64 Isochorismatase domain-containing protein 1 -1.478 0.080 
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Q06890 Clusterin  -1.457 0.010 
O55131 Septin-7  -1.432 0.038 
O08756 3-hydroxyacyl-CoA dehydrogenase type-2   -1.423 0.005 
Q9CPY7 Cytosol aminopeptidase  -1.421 0.023 
Q9Z2X1 Heterogeneous nuclear ribonucleoprotein F  -1.418 0.042 
Q9Z1Q5 Chloride intracellular channel protein 1 -1.417 0.002 
Q99MN9 
Propionyl-CoA carboxylase beta chain, 
mitochondrial  -1.410 0.035 
O54724 Caveolae-associated protein 1  -1.389 0.007 
Q60973 Histone-binding protein RBBP7  -1.348 0.058 
P48678 Prelamin-A/C  -1.340 0.014 
Q9QZQ8 Core histone macro-H2A.1  -1.315 0.058 
P13020 Gelsolin -1.293 0.061 
P99027 60S acidic ribosomal protein P2 -1.281 0.069 
P01027 Complement C3   -1.272 0.047 
P27659 60S ribosomal protein L3  -1.263 0.057 
P01867 Ig gamma-2B chain C region -1.263 0.0453 
Q9D2G2 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  -1.251 0.023 
Q9D0J8 Parathymosin -1.249 0.051 
P99024 Tubulin beta-5 chain -1.240 0.074 
O88531 Palmitoyl-protein thioesterase 1  -1.238 0.014 
Q8BG05 Heterogeneous nuclear ribonucleoprotein A3  -1.211 0.053 
P70699 Lysosomal alpha-glucosidase  -1.206 0.021 
P24452 Macrophage-capping protein  -1.184 0.002 
P42208 Septin-2  -1.183 0.073 
P40124 Adenylyl cyclase-associated protein 1  -1.180 0.093 
Q8BIJ6 Isoleucine--tRNA ligase, mitochondrial -1.173 0.083 
P26350 Prothymosin alpha  -1.170 0.034 
Q62261 Spectrin beta chain, non-erythrocytic 1  -1.160 0.080 
P63325 40S ribosomal protein S10 -1.155 0.068 
Q6IRU2 Tropomyosin alpha-4 chain  -1.153 0.075 
P26645 Myristoylated alanine-rich C-kinase substrate  -1.147 0.029 
P08207 Protein S100-A10  -1.141 0.051 
P83917 Chromobox protein homolog 1 -1.141 0.081 
P62960 Nuclease-sensitive element-binding protein 1  -1.139 0.090 
Q9WVA3 Mitotic checkpoint protein BUB3  -1.139 0.047 
Q03265 ATP synthase subunit alpha, mitochondrial -1.136 0.057 
P55264 Adenosine kinase  -1.136 0.023 
Q61545 RNA-binding protein EWS -1.121 0.015 
Q6NVF9 
Cleavage and polyadenylation specificity factor 
subunit 6 -1.090 0.041 
Supplementary Table 2: (continued) 
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P26039 Talin-1 -1.076 0.097 
P09813 Apolipoprotein A-II  -1.071 0.056 
P63168 Dynein light chain 1, cytoplasmic  -1.070 0.026 
Q9WV32 Actin-related protein 2/3 complex subunit 1B  -1.069 0.044 
P56399 Ubiquitin carboxyl-terminal hydrolase 5  -1.037 0.046 
P24270 Catalase  -1.034 0.043 
Q9WVA4 Transgelin-2 -1.015 0.052 
Q05920 Pyruvate carboxylase, mitochondrial  -1.013 0.088 
Q9QYC0 Alpha-adducin  -1.009 0.054 
Q8BFW7 Lipoma-preferred partner homolog -1.006 0.042 
P18760 Cofilin-1  -1.004 0.096 
A2BDX3 Adenylyltransferase and sulfurtransferase MOCS3  1.138 0.076 
O08795 Glucosidase 2 subunit beta  1.145 0.087 
Q64433 10 kDa heat shock protein, mitochondrial  1.209 0.078 
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Supplementary Table 3: Ovarian proteins identified by LC-MS/MS to differ in DLPH 
offspring relative to the DLPL mice (log2foldchange ≥ 1 and P-value ≤ 0.1).   
UniProtID Protein names log2(FC) p value 
O88531 Palmitoyl-protein thioesterase 1 -2.159 0.006 
Q9WUK2 Eukaryotic translation initiation factor 4H -2.023 0.094 
Q9CY58 
Plasminogen activator inhibitor 1 RNA-binding 
protein -1.954 0.058 
P62830 60S ribosomal protein L23 -1.884 0.066 
Q9WV54 Acid ceramidase -1.860 0.067 
P01027 Complement C3  -1.826 0.042 
P40124 Adenylyl cyclase-associated protein 1 -1.677 0.036 
Q99L13 3-hydroxyisobutyrate dehydrogenase, mitochondrial  -1.668 0.041 
P17225 Polypyrimidine tract-binding protein 1 -1.664 0.093 
Q9QXT0 Protein canopy homolog 2  -1.647 0.053 
Q9CPU0 Lactoylglutathione lyase  -1.570 0.050 
Q61545 RNA-binding protein EWS -1.537 0.080 
P62889 60S ribosomal protein L30 -1.520 0.073 
P21614 Vitamin D-binding protein  -1.457 0.023 
P26039 Talin-1 -1.420 0.034 
P02088 Hemoglobin subunit beta-1  -1.393 0.096 
Q8C1B7 Septin-11 -1.369 0.081 
P61922 4-aminobutyrate aminotransferase, mitochondrial       -1.353 
 
0.014 
P26443 Glutamate dehydrogenase 1, mitochondrial  -1.340 0.018 
O08756 3-hydroxyacyl-CoA dehydrogenase type-2  -1.325 0.025 
P0C0S6 Histone H2A.Z  -1.310 0.027 
Q9CQ60 6-phosphogluconolactonase  -1.250 0.061 
P04104 Keratin, type II cytoskeletal 1 -1.248 0.045 
P09671 Superoxide dismutase [Mn], mitochondrial  -1.149 0.014 
Q62188 Dihydropyrimidinase-related protein 3  -1.142 0.043 
P83917 Chromobox protein homolog 1  -1.137 0.036 
P06745 Glucose-6-phosphate isomerase  -1.110 0.066 
P26369 Splicing factor U2AF 65 kDa subunit  -1.044 0.086 
O55131 Septin-7  -1.037 0.050 
Q9CPY7 Cytosol aminopeptidase  -1.003 0.066 
A2BDX3 Adenylyltransferase and sulfurtransferase MOCS3  1.539 0.059 
Q62093 Serine/arginine-rich splicing factor 2  1.704 0.082 




Supplementary Table 4: Ovarian proteins identified by LC-MS/MS to differ in DHPH 
offspring relative to the DLPL mice (log2foldchange ≥ 1 and P-value ≤ 0.1; DHPH).   
UniProtID Protein names log2(FC) p value 
Q9JII5 DAZ-associated protein 1  -5.132 0.004 
P06728 Apolipoprotein A-IV  -3.736 0.007 
Q9WUK2 Eukaryotic translation initiation factor 4H  -2.794 0.002 
P29699 Alpha-2-HS-glycoprotein  -2.734 0.034 
Q9D1Q6 Endoplasmic reticulum resident protein 44  -2.558 0.009 
Q9CQE8 
RNA transcription, translation and transport factor 
protein -2.529 0.022 
P01027 Complement C3  -2.267 0.013 
Q9QXT0 Protein canopy homolog 2  -2.181 0.011 
Q62348 Translin  -2.081 0.008 
P27659 60S ribosomal protein L3  -2.056 0.020 
Q8BMS1 Trifunctional enzyme subunit alpha, mitochondrial  -2.014 0.004 
P70670 
Nascent polypeptide-associated complex subunit 
alpha, muscle-specific form  -1.915 0.026 
P51859 Hepatoma-derived growth factor  -1.776 0.018 
P21981 Protein-glutamine gamma-glutamyltransferase 2  -1.767 0.075 
P10126 Elongation factor 1-alpha 1  -1.759 0.085 
P17225 Polypyrimidine tract-binding protein 1  -1.742 0.040 
Q8CI94 Glycogen phosphorylase, brain form -1.737 0.093 
P40124 Adenylyl cyclase-associated protein 1  -1.691 0.006 
O08638 Myosin-11  -1.661 0.081 
Q8VDD5 Myosin-9  -1.639 0.090 
P61982 14-3-3 protein gamma  -1.628 0.054 
P26369 Splicing factor U2AF 65 kDa subunit  -1.616 0.004 
Q9D0K2 
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, 
mitochondrial  -1.611 0.009 
P01942 Hemoglobin subunit alpha -1.606 0.045 
O35855 
Branched-chain-amino-acid aminotransferase, 
mitochondrial  -1.557 0.056 
Q64727 Vinculin  -1.533 0.027 
Q8C1B7 Septin-11 -1.512 0.010 
P01867 Ig gamma-2B chain C region -1.497 0.035 
P60335 Poly(rC)-binding protein 1  -1.471 0.046 
P62301 40S ribosomal protein S13 -1.467 0.089 
Q9WUU7 Cathepsin Z -1.454 0.035 
Q9CZ13 Cytochrome b-c1 complex subunit 1, mitochondrial  -1.454 0.074 
Q9R1P3 Proteasome subunit beta type-2  -1.434 0.016 
Q9D0F9 Phosphoglucomutase-1  -1.421 0.070 
Q99PU5 Long-chain-fatty-acid--CoA ligase ACSBG1 -1.408 0.049 
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Q91V92 ATP-citrate synthase  -1.388 0.082 
O35887 Calumenin  -1.358 0.044 
P02088 Hemoglobin subunit beta-1  -1.346 0.071 
P28474 Alcohol dehydrogenase class-3  -1.346 0.026 
P31786 Acyl-CoA-binding protein  -1.340 0.019 
Q8K4Z3 NAD(P)H-hydrate epimerase  -1.325 0.048 
P62880 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2  -1.321 0.029 
P20239 Zona pellucida sperm-binding protein 2  -1.316 0.042 
Q9R1T2 SUMO-activating enzyme subunit 1  -1.311 0.069 
O08756 3-hydroxyacyl-CoA dehydrogenase type-2  -1.301 0.017 
P06801 NADP-dependent malic enzyme  -1.299 0.062 
P05202 Aspartate aminotransferase, mitochondrial  -1.261 0.028 
O09131 Glutathione S-transferase omega-1  -1.258 0.034 
P00920 Carbonic anhydrase 2  -1.255 0.077 
Q9CQV8 14-3-3 protein beta/alpha  -1.253 0.070 
O08997 Copper transport protein ATOX1  -1.226 0.061 
Q9DB15 39S ribosomal protein L12, mitochondrial  -1.225 0.055 
Q8BH95 Enoyl-CoA hydratase, mitochondrial  -1.223 0.095 
P61922 4-aminobutyrate aminotransferase, mitochondrial  -1.223 0.013 
Q9CPU0 Lactoylglutathione lyase  -1.218 0.043 
P45591 Cofilin-2  -1.214 0.096 
Q9WVA3 Mitotic checkpoint protein BUB3  -1.211 0.027 
Q60973 Histone-binding protein RBBP7  -1.210 0.044 
P26039 Talin-1 -1.208 0.038 
P99027 60S acidic ribosomal protein P2 -1.201 0.053 
P62889 60S ribosomal protein L30 -1.189 0.081 
P99029 Peroxiredoxin-5, mitochondrial  -1.183 0.014 
Q9R1P0 Proteasome subunit alpha type-4  -1.171 0.078 
P0DP28 Calmodulin-3 -1.162 0.009 
P48678 Prelamin-A/C  -1.154 0.004 
Q04447 Creatine kinase B-type  -1.148 0.064 
P19157 Glutathione S-transferase P 1  -1.142 0.070 
Q9CQF3 
Cleavage and polyadenylation specificity factor 
subunit 5  -1.141 0.057 
P26443 Glutamate dehydrogenase 1, mitochondrial  -1.138 0.046 
P47754 F-actin-capping protein subunit alpha-2  -1.134 0.099 
P50247 Adenosylhomocysteinase  -1.124 0.066 
P48758 Carbonyl reductase  -1.121 0.044 
P58774 Tropomyosin beta chain  -1.121 0.082 
Q8BFW7 Lipoma-preferred partner homolog -1.109 0.044 
Q9D7B6 Isobutyryl-CoA dehydrogenase, mitochondrial  -1.091 0.072 
Supplementary Table 4: (continued) 
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P16546 Spectrin alpha chain, non-erythrocytic 1 -1.087 0.029 
Q7TPR4 Alpha-actinin-1  -1.075 0.041 
O55131 Septin-7  -1.074 0.018 
Q3THE2 Myosin regulatory light chain 12B  -1.069 0.024 
Q61545 RNA-binding protein EWS -1.064 0.019 
P57780 Alpha-actinin-4 -1.058 0.064 
P35979 60S ribosomal protein L12 -1.053 0.092 
Q99MN9 Propionyl-CoA carboxylase beta chain, mitochondrial  -1.043 0.048 
P24270 Catalase  -1.035 0.054 
P63325 40S ribosomal protein S10 -1.025 0.071 
Q9CWJ9 Bifunctional purine biosynthesis protein PURH  -1.023 0.057 
P16045 Galectin-1  -1.015 0.001 
P97315 Cysteine and glycine-rich protein 1  1.256 0.060 
A2BDX3 Adenylyltransferase and sulfurtransferase MOCS3  1.395 0.067 
Q62093 Serine/arginine-rich splicing factor 2  1.421 0.006 















Supplementary Table 4: (continued) 
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Supplementary Table 5: Ovarian proteins identified by LC-MS/MS to differ between 
DLPH and DHPH (log2foldchange ≥ 1 and P-value ≤ 0.1).    
UniProtID Protein names log2(FC) p value 
Q99JI4 26S proteasome non-ATPase regulatory subunit 6 -2.115 0.099 
Q8VED5 Keratin, type II cytoskeletal 79 -1.613 0.066 
P09671 Superoxide dismutase [Mn], mitochondrial -1.428 0.009 
Q00612 Glucose-6-phosphate 1-dehydrogenase X  1.089 0.015 
Q8BH97 Reticulocalbin-3 1.506 0.087 
Q9R1P3 Proteasome subunit beta type-2  1.599 0.052 
Q8VI64 Protein MGARP  1.852 0.088 




























Supplementary Figure 1: Gene Ontology (GO) analysis of proteins identified as over-
represented in each treatment group when compared to the DLPL group (P < 0.05). 





























Supplementary Figure 2: Gene Ontology (GO) analysis of proteins identified as over-
represented in each treatment group when compared to the DLPL group (P < 0.05). 























Supplementary Figure 3: Gene Ontology (GO) analysis of proteins identified as over-
represented in each treatment group when compared to the DLPL group (P < 0.05). 
























Supplementary Figure 4: Technical control for immunofluorescence staining. Ovaries 
from an adult mouse were immunologically stained using only the secondary antibody 
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The prevalence of obesity continues to rise.  In the overweight or obese female, 
reproductive complications include poor oocyte quality, decreased fecundity, gestational 
diabetes, and higher risk of reproductive cancers.  Using lean and hyperphagia-induced 
obese female mice aged 10 weeks, we determined that the ovary from obese female mice 
had increased (P < 0.05) numbers of γH2AX-positive cells as well as elevated (P < 0.05) 
oocyte levels of ataxia telangiectasia mutated (ATM) protein.  Interestingly, total ovarian 
phosphorylation of ATM at serine 1981 was not altered (P > 0.05) by obesity but was 
increased with follicular maturation. Interestingly, there was greater ATMSer1981 abundance 
in small relative to large follicles in the obese ovary.   Breast cancer type 1 susceptibility 
protein (BRCA1) was also not altered (P > 0.05) in the ovary from the obese female, nor 
was there any increase (P > 0.05) in the phosphorylation of BRCA1 at serine 1423 or serine 
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1524 during obesity.  Apoptosis levels were not elevated (P > 0.05) in ovary during obesity 
as measure by cleaved caspase 3 (CASP3), though some increases were observed 
dependent of follicle size in both the lean and obese mouse.  Deleted in azoospermia-
associated protein 1 (DAZAP1) and protein canopy homolog 2 (CNPY2), proteins 
implicated in ovarian physiology, were unaltered (P > 0.05) in the ovary from the obese 
model relative to the lean.  Taken together, these data demonstrate increased markers of 
DNA damage in the ovary of obese mice, with follicular stage-dependent shifts in both 
ATMSer1981 and CASP3 protein abundance due to obesity.     
 




 Obesity is a preventable metabolic syndrome, associated with several interrelated 
disorders such as insulin resistance/diabetes [1], cardiovascular disease [2], dyslipidemia 
[3], chronic inflammation [4], and cancer [5].  The prevalence of obesity in the population 
continues to rise, with an estimated 40% of adults and 19% of youth being 
obese/overweight in the United States, though these rates are higher for some ethic groups 
[6].  A decline in reproductive potential is associated with obesity, and reproductive 
complications include poor oocyte quality [7], polycystic ovary syndrome (PCOS) [8], 
decreased fecundity [9], impaired pregnancy success using assisted reproductive 
technologies [10], gestational diabetes (GDM) [11], and increased risk of offspring health 
problems [12].   
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The ovary is the source of the female germ cell, the oocyte, and hormones necessary 
for female growth and development.  Throughout the female lifespan, a finite pool of 
primordial germ cells will remain in diplotene stage of meiosis until sexual maturity, at 
which time they are primed for ovulation and subsequent fertilization or they undergo the 
natural process of degeneration called atresia [13].  Once this pool of primordial follicles 
is depleted, through the natural progression of time or through factors that expedite the 
process, ovarian senescence occurs [13].  The depletion of follicles occurring prior to age 
40 is considered primary ovarian insufficiency (POI) and often has unknown etiology [14].  
Cessation of or dysfunctional ovarian activity predisposes women toward at heightened 
risk for development of gynecological cancers [15], osteoporosis [16], cardiovascular 
disease [17], and Alzheimer’s disease [18].   
The accumulation of DNA damage is considered as a contributing factor to obesity-
related disorders due to the chronic low-grade inflammation and constant production of 
reactive oxygen species (ROS) that may induce endogenous DNA damage throughout the 
body [19-21].  Obesity is also associated with ovarian DNA damage [22-24] and increased 
granulosa cell apoptosis [25].  The cellular DNA damage response (DDR) exists to prevent 
genomic damage by either repairing the damage or triggering the cell towards apoptosis if 
beyond repair.  Central metabolism disturbances during obesity have adverse impacts on 
the DDR [26, 27]. We have previously demonstrated that progressive obesity alters ovarian 
folliculogenesis and inflammation [28], the insulin responsive phosphatidylinositol 3-
kinase (PI3K) pathway [29], steroid hormone biosynthesis [30],  causes basal DNA damage 
and affects the response to genotoxicant exposures [23, 24, 30, 31].   
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Ataxia telangiectasia mutated (ATM) protein is a key DDR initiator, sensing DNA 
damage and transducing downstream targets including breast cancer type 1 susceptibility 
protein (BRCA1) for DNA repair [32]; serine/threonine-protein kinase Chk2 (CHK2) for 
cell cycle arrest [33]; p53 for apoptosis [34], and RAC-alpha serine/threonine-protein 
kinase (AKT) for cell survival [35]. Interestingly, despite hyperphagia-induced obese mice 
having an increase in ATM protein in response to a genotoxic chemical, there was lack of 
an appropriate response in the proteins downstream of ATM [23, 24].  This finding 
provided the rationale for the hypothesis that the ATM-mediated DDR is altered during 
obesity.  Utilizing a model of hyperphagia-induced obesity, this study examined basal 
obesity-induced impacts on the ovarian DDR.     
 
 
Materials and Methods 
Animal procedure and tissue collection  
All experiments were performed according to regulatory guidelines and approved 
by the Institutional Animal Care and Use Committee (IACUC) at Iowa State University.  
Female wild-type normal non-agouti (a/a; n = 10; designated lean) and agouti lethal yellow  
(KK.Cg-Ay/J mice; n = 10; designated obese) were purchased from Jackson Laboratory 
(Bar Harbor, ME) and maintained in an animal facility at Iowa State University under 
controlled room temperature (21°C-22°C) and lighting (12hr light:12hr dark) with ad 
libitum access to food and water.  At 10 weeks of age, mice were euthanized in the pro-
estrus phase of the estrous cycle and ovaries were fixed in 4% paraformaldehyde overnight 
at 4°C for histological analysis.   
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Estrous cycle monitoring 
The estrous cycle was monitored by performing daily vaginal cytological analysis 
in the morning.  Fresh, wet vaginal smears were collected by pipetting saline into the 
vagina, smearing onto histology slides and examination with a Nikon OPTIPHOT 
microscope using a 10X objective.  Classification of estrous cycle stages was determined 
as previously described [36].  Briefly, pro-estrus was characterized by small, round 
nucleated epithelial cells, some cornified epithelial cells, and little to no leukocytes.  Estrus 
was characterized by several cornified epithelial cells containing pyknotic nuclei. The 
presence of cornified cells and leukocytes indicated metestrus.  In diestrus, nucleated 
epithelial cells reappeared in the vaginal smears in addition to the presence of 
polymorphonuclear leukocytes.  Obese mice who displayed persistent diestrus (n = 4) were 
subsequently excluded from further analysis.  
 
Histology 
After fixation, ovaries were passed through a 10%, 20%/0.1M PBS gradient for 1-
3 h each at room temperature, followed by 30% sucrose/0.1M PBS overnight at 4°C and 
embedded in optimal cutting temperature (OCT; Fisher Healthcare) compound before 
being flash frozen on dry ice.  Ovaries were serially sectioned at 7 µm with a maximum of 
3 sections per slide.    
 
Immunofluorescence staining 
Slides were warmed briefly on a 37°C slide warmer and tissue sections were 
encircled with a histology pap pen (Vector Laboratories) to maintain staining solutions 
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concentrated on the tissue during processing.  Tissue was rehydrated and permeabilized in 
0.1M PBS with 0.1% Tween20 (PBSTw) for 20 min, followed by blocking (0.1M PBS/1% 
BSA/1% DMSO/5% goat serum) for 60 min at room temperature.  Primary antibodies 
(Supplemental Table 1) were diluted in fresh blocking solution, applied to the tissue 
sections and incubated in a humidified box at 4°C overnight.  For antigen retrieval, 1% 
sodium dodecyl sulfate (SDS; Sigma Aldrich) was applied for 5 min after the rehydration 
step, followed by three washes of PBSTw for 5 min each and addition of blocking solution 
as described above.  After primary antibody incubation, slides were washed 3 times in 
PBSTw for 10 min per wash.  The appropriate secondary antibody (Supplemental Table 
1) was added to fresh blocking solution, applied to tissue sections and incubated at room 
temperature for 60 min, followed by 4 washes in PBSTw for 10 min per wash.  Slides were 
air dried, followed by addition of Vectashield with DAPI (H1200, Vector Labs) and stored 
overnight at 4°C.  Negative technical controls to confirm specificity were performed using 
secondary antibodies alone (Supplemental Figure 2).  Images were captured on a Zeiss 
LSM700 confocal microscope equipped with an AxioCam MRc5 using a 5 or 20x 
objective.   
 
Protein isolation and western blot analysis 
Total ovarian protein was isolated by tissue homogenization in lysis buffer (50 mM 
Tris-HCL, 1 mM EDTA, pH 8.5) followed by centrifugation at 10,000 rpm at 4°C for 15 
min.  Supernatant was collected and protein content was quantified using a bicinchoninic 
acid assay (BCA; Pierce BCA Protein Assay Kit, Thermo Fisher).  SDS-PAGE was used 
to separate proteins and then transferred to a nitrocellulose membrane.  Membranes were 
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blocked in 5% milk in 0.2% PBSTw for 60 min at room temperature, followed by 
incubation with appropriate primary antibodies (Supplemental Table 1) in fresh blocking 
solution at 4°C overnight.  Membranes were washed 3 times in PBSTw for 10 min each 
wash, followed by incubation in secondary antibody (Supplemental Table 1) for 60 min 
at room temperature.  Following incubation in secondary antibody, membranes were 
washed for 3 times in PBSTw, incubated in enhanced chemiluminescence detection 
substrate (Cell Signaling Technologies) for 7 min and visualized on the Azure c600 (Azure 
Biosystems).  Densitometry of the appropriately-sized bands was measured using ImageJ 
software [37].  Proteins of interest were normalized to ACTB by dividing protein of 
interest’s densitometric value by the densitometric value obtained from total ACTB.   
 
Quantification of protein abundance  
For quantification of ATM (n = 6 ovaries per treatment; 6 sections per ovary), and 
pATM (n = 6 ovaries per treatment; 6 sections per ovary), the threshold percentage of the 
total image area was limited to the oocyte using ImageJ software [37].  For γH2AX (6 
ovaries per treatment; 6 sections per ovary) and cleaved CASP3 (6 ovaries per treatment; 
6 sections per ovary), immunopositive cells were manually counted in primary, secondary 
and antral follicles using the cell counter module of ImageJ software [37].   
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 7.0 unpaired t-test function.  A 
P-value ≤ 0.05 was considered statistically significant and a trend for a statistical difference  
was considered at P < 0.1.  Values are expressed as mean ± SEM.   
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Results 
Obesity increases basal amounts of DNA damage in the ovary  
To determine if obesity increases the amount of basal DNA double strand breaks 
(DSB) in the ovary, tissue sections were analyzed for localization of γH2AX and positive 
foci were quantified (Figure 1).  The number of ovarian cells (granulosa cells and/or 
oocytes) that contained positive γH2AX foci tended (P < 0.1) to be greater in the obese 
relative to the lean ovary (Figure 1E), as well as in both small (P < 0.05) and large (P < 
0.1) follicles (Figure 1F-G) in the obese relative to lean ovary.  In both the lean and obese 
ovaries, larger follicles had more (P < 0.05) γH2AX positive foci than in smaller follicles 
(Figure 1H-I).   
 
Obesity increases ATM protein level 
 In order to establish the basal level of ovarian DDR proteins due to progressive 
obesity, we examined both basal and phosphorylated levels of ATM protein were 
examined. Basal levels of ATM immunofluorescence were localized in the oocyte of all 
follicular stages with no difference in localization patterns between lean or obese mice 
(Figure 2A-D).  ATM oocyte immunoreactivity was elevated (P < 0.05) in the obese ovary 
(Figure 2I) and in the obese ovary relative to the lean in both small and large follicles (P 
< 0.05; Supplementary Figure 1A-B).  There were no differences in basal ATM 
abundance between small or large follicles in either the lean or obese ovaries (P > 0.05; 
Supplementary Figure 1C-D).    
 Phosphorylation of ATM at serine 1981 was present in the oocyte and granulosa 
cells of all follicular stages (Figure 2E-H), though no difference (P > 0.05) was observed 
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between the lean or obese ovary (Figure 2J).  There was an increase in fluorescence 
intensity in the smaller follicles of the obese ovary relative to the lean (P < 0.05), but no 
changes in larger follicles (P > 0.05) (Supplementary Figure 1E-F).  In the lean ovary, 
there was greater (P < 0.05) pATMSer1981 in larger compared to smaller follicles but no 
difference (P > 0.05) between small and large follicles in the obese ovary (Supplementary 
Figure 1G-H).   
 
Ovarian BRCA1 levels are not impacted by obesity 
BRCA1 protein abundance was detected in oocytes of all follicle stages, as well as 
theca cells, stromal cells, and there was some modest staining in the granulosa cells of 
larger follicles (Figure 3A-D).  Staining intensity visibly increased in the theca cells as 
follicle size increased.  There was no observable effect of obesity on total ovarian BRCA1 
protein (Figure 4A-B).   
Localization of pBRCA1Ser1423 in the ovary was observed in the granulosa cells and 
oocyte nucleus (Figure 3E-H).  Phosphorylation activity of BRCA1Ser1423 was not altered 
(P > 0.05) in the obese relative to the lean ovary (Figure 4C-D).  Similarly, 
phosphorylation of BRCA1Ser1524 did not differ (P > 0.05) between the lean and obese ovary 
(Figure 4E-F), and immunoreactivity was localized to granulosa cells and the cytoplasm 
of the oocyte (Figure 3I-L).  Obesity did not (P > 0.05) alter the phosphorylation of 
pBRCA1Ser1423 or BRCA1Ser1524 relative to total ovarian BRCA1 protein (Figure 4G-H).   
Apoptosis is not elevated in the obese ovary though a shift between follicle sizes occurs 
 To assess levels of apoptosis in the obese ovary, tissue sections were analyzed for 
cleaved CASP3 via immunofluorescence (Figure 5A-D) and positive foci were quantified.  
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The number of total cleaved CASP3 positive granulosa cells were not different (P > 0.05) 
between the lean and obese mice (Figure 5E). However, there were more (P < 0.05) 
CASP3 positive foci in smaller follicles of the lean ovary versus the obese ovary (Figure 
5F) and more (P < 0.05) positive foci in the larger follicles relative to the smaller follicles 
in the obese ovary alone (Figure 5I). There were no differences (P > 0.05) in numbers of 
positive CASP3 cells between the large follicles in lean and obese or between the follicle 
sizes in the lean ovaries alone (Figure 5G-H). 
 
Ovarian expression of CNPY2 and DAZAP1 in obesity   
 We previously identified CNPY2 and DAZAP1 in a proteomic analysis of ovaries 
exposed to GDM in utero, with their abundance being decreased as a result of the metabolic 
effects of GDM and/or subsequent dietary challenge later in life [38].  CNPY2 was 
localized mainly to theca cells, with slight staining observed in some of the granulosa cells 
in larger follicles and the oocyte cytoplasm of some oocytes in all follicle stages except for 
primordial (Figure 6A-D).  DAZAP1 had distinct staining throughout the ovary, with 
localization in the oocyte nucleus, granulosa, and luteal cells (Figure 6E-H).  Obesity did 
not impact (P > 0.05) on level or localization pattern of CNPY2 or DAZAP1 relative to 
their lean counterparts (Figure 6I-L).   
 
Discussion 
 The impacts of obesity on health have been well documented, though the 
percentage of the population, including both adults and children, affected by obesity and 
obesity-related disorders continues to rise.  Reproductive outcomes for obese or overweight 
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women result in impaired fertility due to poor oocyte quality [10], disturbances in the 
menstrual cycle [39], PCOS [40], and heightened risk of developing ovarian cancer [41].  
The impacts of obesity may also not be limited to the mother, as offspring exposed to 
maternal obesity in utero have increased risk for neural tube defects [42], glucose 
intolerance [43], intrauterine growth restriction (IUGR) [44], and increased circulating 
cholesterol and body fat [45].  Female offspring experiencing the metabolic effects of 
obesity in utero also exhibit a diminution of the ovarian follicular reserve [46, 47] and 
decreases in ovarian vascularity [48].   
We have previously demonstrated that hyperphagia-induced obese mice have basal 
levels of DNA damage in the ovary and a blunted DDR after a genotoxicant exposure [23, 
24, 30, 31].  Importantly, those observations were made in mice that were 14 weeks of age 
and older. This study elected to use mice that were slightly younger, in order to avoid the 
confounding effect of reduced primordial follicle number which we previously noted from 
12 weeks of age onwards [28].  In support of our previous findings, there was increased 
abundance of γH2AX positive foci in the ovaries from the obese mouse in both small and 
large follicles.  The presence of γH2AX is considered the gold standard for double strand 
break localization [49], and H2AX is activated upon phosphorylation by ATM at the DNA 
break site [50, 51]. A higher body mass index (BMI) contributes to the development of 
DNA lesions [20], but the origins of the elevated amounts of DNA DSBs remains to be 
elucidated.  It is presumable that these lesions are occurring due to the increased 
inflammation and enhanced ROS production that are present during obesity [52-54]. Thus, 
our findings recapitulate our previous observations [23, 24] and support that basal DNA 
damage is present in the ovary of obese females.    
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ATM is first activated by the MRE11, RAD50, and NBS1 (MRN) complex and is 
further stabilized at the location of the DNA DSBs by autophosphorylation at serine 1981 
[55].  Ablation of this autophosphorylation site results in cessation of ATM’s ability to 
phosphorylate any downstream targets [55].  Further, mutations in the Atm gene elicit an 
inadequate response to DNA damage, increasing both radiosensitivity and cancer 
predisposition as a result of faulty DNA repair [56]. Other characteristics of Atm mutations 
include neurodegeneration [57], immunodeficiency [58] and infertility [59, 60], though the 
exact role of the DDR in these etiologies remains to be determined.  We determined that 
there is more basal ATM in the ovary of an obese female, though no measurable differences 
in the amount of total phosphorylated ATMSer1981 were observed, ATMSer1981 abundance 
was elevated in smaller compared to larger follicles in the obese mice, , suggesting both 
dysfunction in ATM phosphorylation and a follicular-stage influence.  This is consistent 
with our previous findings that ATM acts as a sensor for ovarian DNA damage [23, 24, 61, 
62], and that there is a disconnect between elevated ATM and the subsequent activation of 
ATM downstream proteins [23, 24] in the ovary of an obese female.   
Another critical protein required for efficient DNA repair is BRCA1.  
Phosphorylation of BRCA1 at Ser1423 and Ser1524 is ATM-dependent in the event of DNA 
damage [63].  Women with a mutated allele of the Brca1 gene have increased risk of tumor 
development, specifically breast and ovarian cancers, as a result of defective DNA repair 
[64].  We have previously demonstrated that progressive obesity reduced ovarian BRCA1 
protein in mice aged 18 and 24 weeks [23, 24].  In obese mice aged 10 weeks there were 
no observable differences in basal BRCA1 abundance or in the amount of phosphorylated 
BRCA1Ser1423 or BRCA1Ser1524 relative to lean ovaries. Interestingly, DNA repair gene and 
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protein activity in the ovary decreases with age [65, 66], emphasizing the importance of 
the DDR in ovarian aging and fertility. Thus, the obesity-induced decline in BRCA1 that 
we previously noted may be influenced by either attainment of a certain threshold of 
obesity or by ovarian age.  
If the DNA damage within a cell cannot be repaired, the cell may be shunted 
towards apoptosis.  Apoptosis is coordinated by the activation of caspases, which then 
proteolytically process various cellular targets through the amplification of apoptotic 
signals [67].  Caspase 3 (CASP3) is an apoptotic protease involved in ovarian granulosa 
[68] and luteal [69] cell death, though is not required for oocyte death [68]. Further, 
increased granulosa cell apoptosis has been reported with obesity [25].  We and others have 
shown a dramatic increase in ovarian CASP3 positive cells after a genotoxicant exposure 
[62, 70-72].  There was no increase in total ovarian CASP3 positive foci due to obesity, 
however, an interesting shift occurred in that the obese ovary had less CASP3 in small 
compared to large follicles, compared to the lean ovary in which the pattern was switched. 
Thus, similar to the observations with ATMSer1981, there may be follicle type-specific 
alterations due to obesity that could alter fertility in females. It is also possible that basal 
DNA damage isn’t being repaired adequately, and that the damaged follicles are not being 
shunted towards demise, thus contributing to the poor quality of the oocyte frequently seen 
in obesity, but this remains to be elucidated.   
We had previously identified CNPY2 as being altered in the ovary in females who 
had experienced GDM in utero. Specifically, there was a decrease in the abundance of 
CNPY2 in the ovaries of offspring exposed to GDM in utero, adult dietary stress, or both 
[38].  CNPY2 is implicated in cellular stress response, specifically the induction of the 
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PERK-CHOP unfolded protein response (UPR), a highly conserved quality control 
mechanism for cells undergoing endoplasmic reticulum (ER) stress [73].  While we did not 
observe any changes in the abundance of CNPY2 in the ovaries from the obese mouse in 
comparison to the lean control, the ovarian localization pattern was confirmed [38], with 
CNPY2 protein being localized to theca cells, granulosa cells of larger follicles, and the 
oocyte cytoplasm.  The presence of CNPY2 has also been detected in the human placental 
tissue from GDM pregnancies [74], implicating a role for CNPY2 in the female 
reproductive system in relation to a metabolic syndrome, necessitating further analysis for 
the precise role in reproductive health.   
Another ovarian protein reduced in female mice exposed to GDM in utero and 
further impacted by a HFHS diet during adulthood is DAZAP1 [38].  DAZAP1 is a member 
of the deleted in azoospermia (DAZ) family of proteins, which are present in both female 
and male germ cells [75].  DAZ proteins are critical in germ cell development and fertility, 
with mutations in DAZAP1 resulting in sterility, growth retardation, and sometimes 
perinatal death [76].  Another DAZ family protein, deleted in azoospermia-like 1 (DAZL1), 
results in infertility in both male and female mice when disrupted [77].  Defects associated 
with DAZAP1 have previously been described in males [78, 79].  Similar to CNPY2, no 
alterations in ovarian DAZAP1 abundance due to obesity were observed but the ovarian 
localization pattern recapitulated that previously reported [38]. Localization of DAZAP1 
was observed throughout the ovary, with distinct immunostaining in the oocyte nucleus, 
granulosa cells, and luteal cells.   
Taken together, this study confirmed that there is elevated basal DNA damage in 
the ovaries of obese mice. In addition, the data confirm greater ATM protein abundance in 
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large compared to small follicles (both lean and obese) and that there is dysfunction in 
ATM phosphorylation due to obesity. Further, we discovered a shift in CASP3 protein 
from the small to large follicle types in the obese females. The model used eliminates the 
confounding effects of different diets since the obese mice overeat the same diet as the lean 
mice. We did not note any effect on BRCA1 at this stage of obesity, potentially suggesting 
that there is either a threshold of obesity that must be attained before reduced BRCA1 is 
noted, or that ovarian aging coupled with obesity has an additive effect on BRCA1 
abundance. Estimation of ovarian DNA damage and the resulting alterations in DDR 
during obesity could potentially aid in diagnosis and prevention of obesity-related 
reproductive disorders and consideration of DDR-initiating proteins as markers of ovarian 
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Figure 1. Effect of obesity on ovarian γH2AX abundance.  A primary antibody directed 
against γH2AX was used to determine ovarian localization in (A) small follicles and (B) 
large follicles of lean mice; in (C) small follicles and (D) large follicles of obese mice.  
Green punctate staining indicates γH2AX while cellular DNA is stained in blue; scale bar 
= 50 µm.  Dotted tail arrows indicate γH2AX positive staining in the granulosa cells of 
small or large follicles; asterisk indicates oocyte.  The bars represent mean number of 
positive γH2AX foci ± SEM in (E) all follicles; (F) primordial/primary follicles; (G) 
secondary/antral follicles; (H) lean small/large follicles; (I) obese small/large follicles; * = 





























Figure 2. Impact of obesity on the ATM and pATMser1981.  Primary antibody directed 
against ATM in (A) small follicles of lean mice; (B) large follicles of lean mice; in (C) 
small follicles of obese mice; (D) large follicles of obese mice, and pATMSer1981 in (E) 
small follicles of lean mice; (F) large follicles of lean mice; in (G) small follicles of obese 
mice; (H) large follicles of obese mice.  Green staining indicates ATM and red staining 
indicates pATMSer1981 while cellular DNA is stained in blue; scale bar = 50µm.  Dotted tail 
arrow indicates granulosa cells; asterisk indicates oocyte. The bars represent mean values 
from the quantification of total fluorescence intensity ± SEM in (I) ATM and (J) 


























Figure 3. Effect of obesity on BRCA1 localization.  Primary antibodies directed against 
BRCA1 in (A) small follicles of lean mice; (B) large follicles of lean mice; in (C) small 
follicles of obese mice; (D) large follicles of obese mice;  pBRCA1Ser1423 in (E) small 
follicles of lean mice; (F) large follicles of lean mice; in (G) small follicles of obese mice; 
(H) large follicles of obese mice; pBRCA1Ser1524 in (I) small follicles of lean mice; (J) large 
follicles of lean mice; in (K) small follicles of obese mice; (L) large follicles of obese mice.  
Green staining indicates BRCA1 and red staining indicates pBRCASer1423 or pBRCASer1524 
while cellular DNA is stained in blue; scale bar = 50µm. Dotted tail arrow indicates 



























Figure 4. Influence of obesity on total ovarian BRCA1 protein.  Abundance of (A, B) 
BRCA1 protein; (C, D) pBRCA1Ser1423 protein; and (E, F) pBRCA1Ser1524 in lean and obese 
ovaries. (A, C, E) bar charts represent mean densitometric values ± SEM. (B, D, F) Western 
blots for BRCA1, pBRCA1Ser1423, and pBRCA1Ser1524; “L” indicates lean and “O” indicates 
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Figure 5.  Effect of obesity on ovarian CASP3.  A primary antibody directed against 
cleaved CASP3 was used to determine ovarian localization in (A) small follicles and (B) 
large follicles of lean mice; in (C) small follicles and (D) large follicles of obese mice.  Red 
punctate staining indicates CASP3 while cellular DNA is stained in blue; scale bar = 50 
µm.  Arrows indicate CASP3 positive staining in the granulosa cells of small or large 
follicles; asterisk indicates oocyte.  The bars represent mean number of positive CASP3 
foci ± SEM in (E) all follicles; (F) primordial/primary follicles; (G) secondary/antral 






































Figure 6.  Ovarian abundance of CNPY2 and DAZAP1 and effect of obesity.  Primary 
antibody directed against CNPY2 in (A) small follicles of lean mice; (B) large follicles of 
lean mice; in (C) small follicles of obese mice; (D) large follicles of obese mice, and 
DAZAP1 in (E) small follicles of lean mice; (F) large follicles of lean mice; in (G) small 
follicles of obese mice; (H) large follicles of obese mice.  Green staining indicates protein 
of interest while cellular DNA is stained in blue; scale bar = 50µm. Dotted tail arrow 
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Abundance and western blot, respectively, of (I, J) CNPY2 protein and (K, L) DAZAP1 










































Supplementary Figures and Legends 
 
Supplementary Table 1. Primary and secondary antibodies used in this study 











Primary Antibody Host Dilution (IF/WB) Supplier Code 
ACTB Mouse 1:500 (WB) Santa Cruz sc-47778 
ATM Rabbit 1:100 abcam ab32420 
pATMser1981 Rabbit 1:100  R & D Systems AF1655 
BRCA1 Rabbit 1:100 Santa Cruz sc-642 
pBRCA1ser1423* Rabbit 1:100/1:350 Thermo Fisher PA5-36627 
pBRCA1ser1524* Rabbit 1:100/1:350 Thermo Fisher PA5-36829 
Cleaved CASP3 Rabbit 1:100 Cell Signaling 9661 
CNPY2 Rabbit 1:100/1:500 Thermo Fisher PA5-46131 
DAZAP1 Rabbit 1:100/1:500 Novus Biological NBP1-82741 
γH2AX Rabbit 1:50 Cell Signaling 2577 
Secondary Antibody Host Dilution Supplier Code 
Rabbit IgG 488 Goat 1:500  Thermo Fisher A11008 
Rabbit IgG 568 Goat 1:500 Thermo Fisher A11011 
Rabbit IgG HRP  1:1000 (WB) Cell Signaling 7074 






















Supplementary Figure 1.  Impact of obesity on ATM and pATMSer1981 in different 
follicle stages.  The bars represent mean values from the quantification of fluorescence 
intensity  ± SEM of ATM in (A) primordial/primary follicles; (B) secondary/antral 










in (E) primordial/primary follicles; (F) secondary/antral follicles; (G) lean small/large 























Supplementary Figure 2. Technical controls for immunofluorescence staining. 
Ovaries from a lean adult mouse were immunologically stained using only the secondary 
antibody appropriate for (A) γH2AX; (B) ATM; (C) pATMSer1981; (D) BRCA1; (E) 
pBRCA1Ser1423; (F) pBRCASer1524; (G) CASP3; (H) CNPY2; (I) DAZAP1; cellular DNA 
is stained in blue; scale bar = 50 µm.   
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Ataxia telangiectasia mutated (ATM) protein recognizes and repairs DNA double 
strand breaks (DSB) through activation of cell cycle checkpoints and DNA repair proteins.  
Atm gene mutations increase female reproductive cancer risk.  Phosphoramide mustard 
(PM) induces ovarian DNA damage and destroys primordial follicles, and pharmacological 
ATM inhibition prevents PM-induced follicular depletion.  Wild-type (WT) C57BL/6 or 
Atm+/- mice were dosed once intraperitoneally with sesame oil (95%) or PM (25 mg/kg) in 
the proestrus phase of the estrous cycle and ovaries harvested 3 days thereafter. Atm+/- mice 
spent ~25% more time in diestrus phase than WT.  Liquid chromatography with tandem 
mass spectrometry (LC-MS/MS) on ovarian protein was performed and bioinformatically 
analyzed. Relative to WT, Atm+/- mice had 64 and 243 proteins increased or decreased in 
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abundance, respectively. In WT mice, PM increased 162 and decreased 20 proteins.  In 
Atm+/- mice, 173 and 37 proteins were increased and decreased, respectively, by PM. 
Exportin-2 (XPO2) was localized to granulosa cells of all follicle stages and was 7.2-fold 
greater in Atm+/- than WT mice. Cytoplasmic FMR1-interacting protein 1 (CYFIP1) was 
6.8-fold lower in Atm+/- mice and was located in the surface epithelium with apparent 
translocation to the ovarian medulla post-PM exposure. PM induced γH2AX, but fewer 
γH2AX positive foci were identified in Atm+/- ovaries. Similarly, cleaved caspase-3 was 
lower in the Atm+/- PM-treated, relative to WT mice.  These findings support ATM 
involvement in ovarian DNA repair and suggest that ATM functions to regulate ovarian 
atresia. 
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Introduction 
The integrity of the genome is constantly insulted by endogenous and exogenous 
sources and an intrinsic response is needed to effectively repair any damaged DNA.  Ataxia 
telangiectasia mutated (ATM) protein is a major orchestrator of DNA repair and activated 
ATM precipitates the cellular DNA damage repair response (DDR).  The cell cycle is 
arrested, and the DNA damage is fixed, or the cell is triggered for apoptosis if beyond 
repair [1].  ATM acts as a sensor and transducer of DNA damage, phosphorylating several 
downstream targets after activation including histone 2AX (H2AX) [2], mediator of DNA 
damage checkpoint protein 1 (MDC1) [3], and breast cancer type 1 susceptibility protein 
(BRCA1) [4] for DNA repair; serine/threonine-protein kinase Chk2 (CHK2) for cell cycle 
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arrest [5].  After the repair process, ATM influences cellular fate by targeting p53 [6] for 
apoptosis, and RAC-alpha serine/threonine-protein kinase (AKT) [7] for cell survival.  
Elevated ATM is associated with a poor tumor response to chemotherapy and platinum 
resistance [8].   
 Mutations in Atm cause ataxia-telangiectasia (A-T) syndrome, a rare autosomal 
recessive disease characterized by neurodegeneration, immunodeficiency, increased 
radiosensitivity, cancer predisposition, and infertility [9].  A-T women have hypoplastic 
ovaries devoid of primordial follicles [10] and female Atm-/- mice are infertile and lack 
viable oocytes [11].  Women who are heterozygous carriers of mutated Atm have elevated 
cancer risk, particularly breast and ovarian [12-17], thus, receive anti-cancer therapy; a 
scenario that further increases their infertility risks.  
Cyclophosphamide (CPA) is an alkylating agent used in the treatment of cancers 
[18] and autoimmune disorders [19, 20] in adults and children.  Phosphoramide mustard 
(PM), an ovotoxic metabolite of CPA [21, 22], destroys rapidly dividing cells by inducing 
DNA double strand breaks (DSB) [23].  The reproductive effects of PM exposure have 
been well characterized by our group and others, which include loss of primordial and 
primary follicles in mice [24-27], antral follicles in rats [28], and amenorrhea, premature 
ovarian failure, and infertility in women and young girls [29].  In addition to fertility issues, 
CPA exposure has been associated with congenital malformations in offspring exposed to 
CPA in utero as well as pre-gestational germ cell exposures [30].  Increasing cancer 
survival rates present the need to identify the mechanisms by which cancer therapies or 
other chemical exposures cause ovarian damage.   
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ATM induction is the earliest observed event during PM-induced ovotoxicity and 
our group made the surprising observation that pharmacological inhibition of ATM 
prevents PM-induced follicular depletion ex vivo [31].  Thus, the hypothesis under 
investigation in this study was that the DNA damage response would be blunted in Atm+/- 
deficient mice and unhealthy follicles that normally would be triggered for repair and/or 
apoptosis would remain in the ovary. Our specific objectives were to determine if lowered 
ATM abundance affected PM-induced follicle loss and to investigate abundance and 
localization of ovarian DNA repair and apoptosis proteins after PM exposure in both wild 
type and ATM-deficient mice.   
 
Materials and Methods 
Animal procedure and tissue collection  
All experiments were performed according to regulatory guidelines and approved 
by the Institutional Animal Care and Use Committee (IACUC) and Institutional Biosafety 
Committee at Iowa State University.  Female C57BL/6J (n = 6) and B6.129S6-Atmtm1Awb/J 
mice (referred to as Atm+/- herein; n = 6) were purchased from Jackson Laboratory (Bar 
Harbor, ME) and maintained in an animal facility at Iowa State University under controlled 
room temperature (21°C-22°C) and lighting (12hr light:12hr dark) with ad libitum access 
to food and water.  At 10 weeks of age, mice were intraperitoneally (IP) injected once with 
PM (25 mg/kg) or sesame oil (95%; n = 3 per group) in the pro-estrus phase of the estrous 
cycle.  Mice were euthanized 3 days after dosing at which time body and organ weights 
were recorded.  Organ weights were normalized to body weight. Ovaries were collected 
and one ovary was fixed in 4% paraformaldehyde overnight at 4°C for histological analysis 
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while the contralateral ovary was snap frozen in liquid nitrogen and stored at -80°C until 
processing for protein extraction.     
 
Estrous cycle monitoring 
The estrous cycle was monitored by performing vaginal cytology analysis in the 
morning for 10 days to ensure that mice were at the same stage of the estrous cycle for PM 
dosing. Briefly, fresh, wet vaginal smears were collected by pipetting saline into the vagina 
and collecting the samples. Vaginal smears were placed onto histology slides and examined 
with a Nikon OPTIPHOT microscope using a 10X objective.  Classification of estrous 
cycle stages was determined as previously described [32].  During the follicular phase, pro-
estrus was characterized by small, round nucleated epithelial cells, some cornified 
epithelial cells, and little to no leukocytes.  Estrus was characterized by several cornified 
epithelial cells containing deteriorating nuclei.  The presence of cornified cells and 
leukocytes indicated the metestrus stage.  In diestrus, nucleated epithelial cells reappeared 
in the vaginal smears in addition to the presence of polymorphonuclear leukocytes.   
 
Histology and follicle counting 
After fixation, ovaries were passed through a 10%, 20%/0.1M PBS gradient for 1-
3 hours each at room temperature, followed by 30% sucrose/0.1M PBS overnight at 4°C 
and embedded in optimal cutting temperature (OCT) compound before being flash frozen 
on dry ice.  Serial sections were cut at 7 µm on a cryostat (Leica CM1850) and every 6th 
section was mounted onto glass slides and stained with hematoxylin and eosin for follicle 
counting, while intermittent sections were retained for immunofluorescence staining.  
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Healthy follicles containing oocytes with a distinct oocyte nucleus were counted and 
classified as previously described [33].  Briefly, primordial follicles were identified by an 
oocyte encircled by a single layer of squamous granulosa cells; primary follicles contained 
an oocyte surrounded by a single layer of cuboidal granulosa cells; secondary follicles 
contained an oocyte surrounded by multiple layers of granulosa cells, and antral follicles 
were identified as those containing an oocyte enclosed by several layers of granulosa cells 
in conjunction with presence of a fluid filled antral space.  Follicle counts and bright field 
images were captured on an inverted DMI3000B microscope (Leica) and QICAM 
MicroPublisher 5.0 (MP5.0-RTV-CLR-10, QIMAGING) camera using QCapture software 
at a 5x objective.  Total counted follicle numbers per ovary were compared between 
treatments.  
 
Protein isolation and proteome analysis  
Total ovarian protein was isolated by tissue homogenization in lysis buffer (50 mM 
Tris-HCL, 1 mM EDTA, pH 8.5) followed by centrifugation at 10,000 rpm at 4°C for 15 
min.  Supernatant was collected and protein content was quantified using a bicinchoninic 
acid assay (BCA) and prepared as a working dilution (50 µg/uL) with lysis buffer (Pierce 
BCA Protein Assay Kit, Thermofisher).  Protein (50 µg/µL) was digested with trypsin/Lys-
C for 16 hours, dried down and reconstituted in buffer A (47.5µl; 0.1% formic acid/water). 
Peptide Retention Time Calibration (PRTC) mixture (25 fmol/µl) was spiked into each 
sample as an internal control.  Protein (10 µg) and PRTC (250 fmol) were injected onto a 
liquid chromatography column (Agilent Zorbax SB-C18, 0.5mm x 150mm, 5 micron) 
using an Agilent 1260 Infinity Capillary Pump.  Peptides were separated by liquid 
 134
chromatography and analyzed using a Q ExactiveTM Hybrid Quadrupole-Orbitrap Mass 
Spectrometer with an HCD fragmentation cell. A positive identification was considered 
only if three positive peptides were identified per protein. The resulting intact and 
fragmentation pattern was compared to a theoretical fragmentation pattern (from either 
MASCOT or Sequest HT) to identify peptides. The relative abundance of the identified 
proteins was based on the areas of the top three unique peptides for each sample.   
For each peptide, the signal intensity was divided by the arithmetic mean of the 
PRTC as the normalization factor before further analysis. MetaboAnalyst 4.0 [34] was used 
for data analysis. Upon finding data integrity to be satisfactory (no peptide with more than 
50% missing replicates, positive values for the area), missing value estimation was imputed 
using Singular Value Decomposition (SVD) method. Non-informative values that were 
near-constant throughout the experiment conditions were detected using interquartile range 
(IQR) estimation method and were deleted. Data transformation was performed based on 
generalized logarithm transformation (glog) to make individual features more comparable. 
The control and treatment samples were compared by t-test with the adjusted P-value 
(FDR) cutoff of 0.05. Fold change (FC) analysis with threshold of 2 was performed to 
compare the absolute value of change between control and treatment values. A volcano 
plot was created to combine the FC and the t-test analysis.  The PCA analysis was 
performed using the prcomp package and pairwise score plots were created to provide an 
overview of the various separation patterns among the most significant components. Partial 
least squared (PLS) regression was then performed using the plsr function provided by R 
pls package to predict the continuous and discrete variables. A PLS-DA model was built 
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to classify and cross-validate PLS using the caret package. Finally, a dendrogram and a 
Heatmap were generated to graphically represent the data. 
The UniProt protein IDs that were up/down regulated with P-values less than 0.05 
were used to retrieve the corresponding KEGG IDs using the “Retrieve/ID mapping” tool 
of UniProt (accessible at http://www.uniprot.org/uploadlists/). KEGG IDs were used to 
retrieve biological pathway association of the proteins. Enrichment analysis was performed 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8 
Tools [35]. 
 
Gene Ontology analysis 
Gene Ontology (GO) analysis was performed using PANTHER version 14.0 
(http://www.pantherdb.org).  Proteins identified in the control and experimental samples 
were compared to the Mus musculus reference list and divided into protein class and 
biological process.  The Fisher’s Exact test with False Discovery Rate (FDR) correction 
was used with P < 0.05 considered as a significant difference between samples.  
 
Immunofluorescence staining 
Slides were warmed briefly on a 37°C slide warmer and tissue sections were 
encircled with a histology pap pen (Vector Laboratories) to keep staining solutions 
concentrated on the tissue during processing.  Tissue was rehydrated and permeabilized in 
0.1M PBS with 0.1% Tween20 (PBSTw) for 20 min, followed by serum blocking (0.1M 
PBS/1% BSA/1% DMSO/5% goat serum) for 60 min at room temperature.  Primary 
antibodies (Supplemental Table 1) were diluted in fresh blocking solution and applied to 
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the tissue sections and incubated in a humidified box at 4°C overnight.  For antigen 
retrieval, 1% sodium dodecyl sulfate (SDS) was applied for 5 min after rehydration, 
followed by three washes of PBSTw for 5 min each and addition of blocking solution as 
described above.  After primary antibody incubation, slides were washed 6 times in PBSTw 
for 5 min per wash.  The appropriate secondary antibody (Supplemental Table 1) was 
added to fresh blocking solution, applied to tissue sections and incubated at room 
temperature for 60 min, followed by 6 washes in PBSTw for 5 min per wash.  Slides were 
air dried, followed by addition of Vectashield with 4,6-diamidino-2-phenylindole (DAPI) 
(H1200, Vector Labs) and cured overnight at 4°C.  Negative technical controls to confirm 
specificity were performed using secondary antibodies alone (Supplemental Figure 1).  
Images were captured on a Zeiss LSM700 confocal microscope equipped with an AxioCam 
MRc5 using a 5 or 20x objective.   
 
Quantification of protein abundance  
For quantification of BRCA1, H2AX, and cytochrome c (CYCS) immunoreactivity 
(n = 3 ovaries per treatment; 2 sections per ovary), the threshold percentage of the total 
ovarian image area was analyzed in whole ovarian sections using ImageJ 
(https://imagej.nih.gov).  When quantifying ATM immunoreactivity, the threshold 
percentage of the total image area was limited to the oocyte (3 ovaries per treatment; 17-
35 oocytes per treatment), while XPO2 immunoreactivity was measured in granulosa cells 
of antral follicles (3 ovaries per treatment; 18-45 follicles per treatment).  For γH2AX (3 
ovaries per treatment; 30-39 follicles per treatment) and cleaved CASP3 (3 ovaries per 
treatment; 33-36 follicles per treatment), immunopositive cells were manually counted in 
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primary, secondary and antral follicles using the cell counter module of ImageJ 
(https://imagej.nih.gov/ij/plugins/cell-counter.html).   
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism 7.0 two-way ANOVA 
function with Tukey multiple comparison tests for follicle numbers, organ weights, and 
immunofluorescent staining values.  The unpaired t-test was used in the evaluation of the 
estrous cycle and body weights.  For the estrous cycle data, the statistical analysis was 
performed on the raw data and the data is presented as percentage of time spent at that stage 
of the estrous cycle during the monitoring period. Bars represent mean value ± standard 
error of the mean (SEM).  A P-value ≤ 0.05 was considered statistically significant and a 
trend for a statistical difference was considered at P < 0.1.   
 
Results 
Effect of phosphoramide mustard exposure on body and organ weight  
Body weight was lower in Atm+/- females relative to WT controls (P < 0.05; 
Supplemental Figure 2) at the onset of the experiment.  There was no effect of either PM 
exposure or Atm deficiency on weight of the heart, kidney, liver, spleen, uterus or ovary (P 
> 0.05; Supplemental Figure 2).    
 
Impact of Atm deficiency on estrous cyclicity and follicle number  
There was no impact of Atm deficiency on the length of time spent in the proestrus, 
metestrus, or estrus phases of the estrous cycle; however, Atm+/- mice remained in the 
diestrus phase of the estrous cycle longer than their WT counterparts (P < 0.05; Figure 
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1D).  There were reduced numbers of primordial (P < 0.05), primary (P < 0.1), and total 
(P < 0.05)  number of follicles in ovaries of Atm+/- mice relative to WT controls (Figure 
2E-G) but no impact of Atm deficiency on secondary or antral follicle number (data not 
shown).  
 
Effect of PM exposure on follicle number 
Phosphoramide mustard decreased (P < 0.05) the number of healthy primordial 
follicles in WT ovaries by 77% (Figure 2E).  However, comparison between the Atm+/- 
mice who received vehicle control and the Atm+/- mice  who received PM, revealed no 
effect (P > 0.05) of PM exposure on primordial follicle number in Atm+/- ovaries, though 
the number of primordial follicles was reduced by 52% (Figure 2E).  Phosphoramide 
mustard decreased the number of healthy primary follicles in the WT ovaries by 37%, but 
similar to primordial follicle numbers, relative to Atm+/- mice who received vehicle control, 
PM did not reduce primary follicle number in Atm+/- mice (Figure 2F).  PM exposure also 
did not affect the number of healthy secondary or antral follicles in WT or Atm+/- mice 
(data not shown). Total follicle number was less in both the CT and PM-exposed Atm+/- 
mice and in WT PM-exposed relative to the WT CT mice (Figure 2G).  There was no PM-
induced difference in total follicle number in Atm+/- mice (Figure 2G). Overall, there was 
a reduction in 51% of all follicle types in WT ovaries due to PM treatment, with only a 




Identification of PM-induced DNA damage and protein markers of ATM-mediated 
double strand break repair 
To determine an altered ovarian DDR and/or atresia in Atm+/- ovaries, protein markers of  
DNA damage and the DDR were examined. Positive ATM immunofluorescent staining 
was observed in the oocyte in all follicle stages, with no difference in localization pattern 
between genotypes or treatment (Figure 3A).  ATM immunoreactivity decreased in 
intensity between the PM-treated genotypes (P < 0.05), but no other differences were noted 
(Figure 3A’).   
To determine if Atm+/- mice have increased amounts of DNA damage basally and 
to assess the DDR after a genotoxic exposure, the abundance of ovarian γH2AX was 
investigated and positive γH2AX foci were quantified in all follicular stages (Figure 3B). 
Increased positive γH2AX foci were detected in WT ovaries after PM-treatment (P < 0.05; 
Figure 3B’). In the Atm+/- ovaries, PM exposure did not increase γH2AX (Figure 3B’).  
There was no effect of genotype or PM treatment on the abundance of non-phosphorylated 
H2AX (Supplemental Figure 3A).  
BRCA1 immunofluorescent staining was observed throughout the ovary in the 
oocytes of primary, secondary, and antral follicles, theca cells, stromal cells, with moderate 
staining occurring in the granulosa cells of some antral follicles (Figure 3C and 
Supplemental Figure 3B).  Whole ovary BRCA1 fluorescence intensity was decreased in 
PM-treated WT ovaries, relative to the WT controls (Figure 3C’). There was lower 
BRCA1 protein staining in the vehicle control-treated Atm+/- ovaries compared to the 
corresponding WT controls (P < 0.05; Figure 3C’). PM exposure in Atm+/- mice did not 
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impact BRCA1 protein abundance as detected by immunofluorescent staining (Figure 
3C’).  
Granulosa cells that stained positively for cleaved CASP3 were assessed by 
immunological staining and positive cells quantified in all follicular stages (Figure 4A).  
An increase in CASP3 positive cells in the WT ovaries after PM-treatment (P < 0.05) was 
observed, and this was absent in Atm+/- PM-treated ovaries, relative to the corresponding 
control. Reduced (P < 0.1) numbers of cleaved CASP3 cells were observed in Atm+/- PM-
treated, relative to WT PM exposed ovaries (Figure 4A’).   
CYCS protein abundance was determined by immunofluorescent staining and was 
observed throughout the entire ovary.  Lack of ATM did not impact basal CYCS, nor was 
an impact of PM exposure on ovarian CYCS in WT mice observed (Figure 4B). There was 
a trend (P < 0.1) for reduced CYCS in Atm+/-ovaries exposed to PM (Figure 4B’).  
 
Proteomic alterations due to Atm haploinsufficiency  
 LC-MS/MS was utilized to determine any proteins of interest that are regulated by 
ATM.  There were 2,123 ovarian proteins identified in vehicle control-treated Atm+/- 
mice and 2,145 ovarian proteins identified in the vehicle control WT mice.  Relative to 
the WT vehicle control-treated ovaries, 64 proteins were increased and 243 were 
decreased in abundance in the ovaries of Atm+/- females (P ≤ 0.05; Supplemental Table 
2). 
 
Effect of phosphoramide mustard exposure on the ovarian proteome  
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 In addition to determining proteins regulated by ATM, LC-MS/MS analysis 
determined those altered by PM treatment.  A total of 2,160 proteins were identified in PM-
exposed WT ovaries.  Relative to the WT controls, 162 proteins were increased, and 20 
proteins were reduced in ovaries of WT mice exposed to PM (P ≤ 0.05; Supplemental 
Table 3).  In PM-treated Atm+/- mice, 2,132 proteins were identified, and 173 proteins were 
increased and 37 decreased compared to Atm+/- mice treated with vehicle control (P ≤ 0.05; 
Supplemental Table 4).  In Atm+/- mice exposed to PM, 116 proteins were decreased and 
61 increased (P ≤ 0.05; Supplemental Table 5) compared to WT PM-exposed mice. 
 Of these differentially expressed proteins that were increased in each PM treated 
group, 132, 141, and 31 were determined to be unique in WT, Atm+/-, and in the PM-treated 
genotype comparison, respectively (Figure 5A).  In contrast, 20, 37, and 116 proteins were 
decreased that were exclusive to the PM-treated WT, Atm+/-, and genotype comparisons, 
accordingly (Figure 5B). Within the separate genotypes and in the absence of PM 
treatment, 39 increased proteins were identified as unique (Figure 5A), while 243 proteins 
were identified as decreased (Figure 5B). Additionally, there were 58 shared proteins that 
were increased between all groups and 49 proteins shared that were decreased between all 
groups (Figure 5A-B).  Forty-nine proteins were shared between the genotypes, with 16 
of these proteins being upregulated and 33 downregulated (Figure 5A-B).   
 
Gene ontology (GO) and pathway analysis  
 Differentially abundant proteins between Atm+/- and WT mice were assigned to 
protein class and biological process using PANTHER GO analysis (Fischer’s Exact with 
FDR multiple test correction; P < 0.05).  GO analysis distributed 221 hit genes into 21 
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protein classes for proteins identified as differing in the Atm+/- vehicle control relative to 
the WT vehicle control (Figure 5C-D). In the Atm+/- PM relative to WT PM, 139 hit genes 
were distributed into 22 protein classes (Figure 5C-D).  Most of the proteins identified 
were classified as nucleic acid binding proteins (28% in vehicle control-treated ovaries, 
15% in PM-treated ovaries; Figure 5C-D).  Protein classes with the greatest assignments 
were hydrolases, transferases, enzyme modulators, and cytoskeletal proteins.  Together, 
these protein classes comprise of ~65% of proteins identified between the WT and Atm+/- 
vehicle-treated mice and ~58% of those proteins identified in the WT and Atm+/- PM-
exposed mice.   
 For biological process, 43 proteins from the control exposure groups and 27 
proteins from the PM exposure groups were assigned to the cellular metabolic process 
cluster, representing around 15% of the proteins over-represented in Atm+/- ovaries.  
Protein-containing complex subunit organization, establishment of cellular localization, 
and intracellular transport also had several proteins assigned (Supplemental Figure 4A).   
 KEGG ID’s were identified via the UniProt ID mapping tool and utilized in a 
pathway enrichment analysis via DAVID to determine the representation of molecular 
networks in Atm+/- relative to WT ovaries.  In PM exposed mice, the metabolic pathways 
ID was enriched in approximately ~18% of proteins (Supplemental Figure 4B).  
Interestingly, this was not observed in vehicle control-treated mice of either genotype.  
Other KEGG pathways identified as differing between the genotypes regardless of 
treatment were spliceosome, ribosome, focal adhesion, and proteoglycans in cancer 
(Supplemental Figure 4B). 
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Effect of PM exposure on ovarian localization of CYFIP1 and XPO2 in WT and Atm+/- 
mice.  
To determine the spatio-temporal distribution of proteins of interest identified in 
the LC-MS/MS analysis, immunofluorescence staining was performed on whole ovarian 
sections.  In the LC-MS/MS analysis, Cytoplasmic FMR1-interacting protein 1 (CYFIP1) 
was reduced by 6.83-fold and 5.57-fold in Atm+/- vehicle-control and Atm+/- PM exposed 
ovaries, respectively, relative to their wild-type counterparts.  CYFIP1 positive cells were 
uniformly spaced along the ovarian surface epithelium in all ovary samples (Figure 6A 
and 6A’), however, PM exposure altered this localization and post-PM exposure, CYFIP1 
protein was present in the ovarian cortex including granulosa cells and medulla (Figure 
6A and 6A’). 
 Exportin-2 (XPO2) increased in the Atm+/- vehicle-control compared to the WT 
vehicle-control ovaries by 7.20-fold and by 6.40-fold in Atm+/- PM-exposed ovaries 
relative to the WT PM-exposed ovaries as detected by LC-MS/MS analysis.  XPO2 
immunological staining revealed positive staining in the granulosa cells of all follicular 
stages and the oocyte, as well as in the corpus luteum (Figure 6B).  
 
Discussion 
Cells employ a highly conserved pathway to sense, signal, and repair DNA.  A key 
event in DNA repair is activation of ATM, a member of the phosphatidylinositol 3-kinase 
(PI3K) superfamily, which also includes ataxia telangiectasia and Rad3-related (ATR) and 
DNA-dependent protein kinase (DNA-PK) [1].  ATM is activated by the MRN complex, 
which contains MRE11, RAD50, and NBS1 proteins [36], initiating serine 1981 
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autophosphorylation and homodimer to active monomer dissociation [37, 38].  Over 700 
ATM and ATR protein targets have been identified [39], including BRCA1 [4], CHK2 [5], 
and P53 [6].   
The exact mechanisms underlying chemotherapy-induced follicle loss remain 
unclear. Direct toxicity to the follicle or oocyte may occur [40-43] or accelerated 
hyperactivation of primordial follicles [44] in response to targeted death of larger growing 
follicles, resulting in follicular “burnout” [45-47]. PM induces ovarian DNA damage in the 
oocyte and granulosa cells [22, 24, 25] and our group discovered that ATM inhibition 
prevents PM-induced follicle depletion [31]. To further explore the events post-
genotoxicant induced ovarian damage, both targeted and exploratory approaches were 
utilized to determine mechanisms involved in the ovarian response to PM exposure and 
further, Atm+/- mice were employed to interrogate the role of ATM in mediating the PM-
induced ovarian response.  
In response to PM exposure in WT mice, both primordial and small primary follicle 
numbers were reduced in WT mice, consistent with our previous findings [26, 27].  
Different numbers of growing follicles post-PM treatment were not observed, suggesting 
lack of hyperactivation of the ovarian reserve. This corresponded with our previous 
findings in which inhibition of PI3K did not have any effect on the extent of PM-induced 
follicle loss [48]. The Atm+/- mice had reduced follicle number at all stages of development, 
highlighting the importance of ATM in basal ovarian physiology and recapitulating 
phenotypic observations in A-T female patients [9]. Atm-/- female mice [49] and female A-
T patients [9] are infertile due to reduced or complete absence of gametes in the ovary.  
Primordial germ cell migration to the genital ridge is unaffected in Atm-/- mice, but oocytes 
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undergo apoptotic degeneration prior to birth [11]. Adult Atm-/- mouse ovaries are also 
devoid of oocytes and superovulation is ineffective [49].  
Similar to our findings in which ATM was pharmacologically inhibited ATM in ex 
vivo cultured ovaries [31], PM-induced follicle loss was less robust in Atm+/- mice, relative 
to WT mice. The effect was not complete inhibition of PM-induced follicle loss, 
presumably due to Atm haploinsufficiency, rather than complete ATM reduction as 
observed in the pharmacological approach [31].  The level of basal ATM in Atm+/- ovaries 
did not differ relative to WT, but there was lack of increased ATM after PM exposure, 
supporting lack of ATM responsiveness to PM exposure in these mice.  
Upon DNA damage, ATM phosphorylates H2AX to γH2AX at the DNA DSB site, 
resulting in a positive feedback loop of DNA repair proteins [50-54] and γH2AX presence 
is considered the gold standard for DSB localization [55]. The DDR was irregular, as 
evidenced by fewer γH2AX positive cells, in Atm+/- mice post-PM treatment.  This was in 
stark contrast with WT PM mice in which there was accumulation of γH2AX positive cells.  
This observation was not attributable to reduced total H2AX protein abundance in the 
Atm+/- mice. The numerical lesser abundance of inactive H2AX could be related to reduced 
ATM, as the two proteins are products of their respective genes, Atm and H2ax, which are 
very closely linked in the same cytogenetic region (11q23) in both humans and mice [56]. 
BRCA1 functions in homologous recombination [57, 58] and nonhomologous end 
joining DNA repair [59, 60] and is phosphorylated by ATM.  Similar to carriers of a mutant 
Atm gene, women with Brca1 mutations have defective DNA repair and increased risks of 
breast and ovarian cancers [61].  Relative to ovaries from WT vehicle-control mice, there 
were lower levels of basal BRCA1 protein in Atm+/- vehicle-control ovaries, and in PM-
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exposed mice (both WT and Atm+/-), potentially an indication that BRCA1 is depleted in 
response to PM exposure as a reflection of BRCA1 function though this remains to be 
determined. Taken together, these findings suggest that ovarian BRCA1 is a direct ATM 
target and that PM exposure affects ovarian BRCA1.  
When DNA damage exceeds the capacity of the cell for repair, it is shunted towards 
apoptosis.  Pro-apoptotic CASP3 is implicated in granulosa [62] and luteal [63] cell death, 
though not necessary for oocyte death [62]. Despite a dramatic increase in CASP3 positive 
cells in the WT mice post-PM exposure, fewer cells positively stained for CASP3 in Atm+/- 
female mice after PM exposure.  This finding in the WT mice is consistent with previous 
studies [21, 25, 43, 64].  DNA damage can also activate the mitochondrial apoptosis 
pathway and CYCS release [65].  Altered CYCS abundance was not noted in this study, 
though there was a slight decline in CYCS due to PM exposure in the Atm+/- ovaries which 
was not apparent in the WT ovaries.  An association between Atm deficiency and 
mitochondrial dysfunction has been documented [66-68]. Thus, these findings support 
reduced apoptosis in the Atm+/- ovaries in response to PM induction, potentially indicating 
lack of shunting of damaged follicles towards atresia, as supported by the reduced extent 
of follicle loss that resulted from PM exposure in the Atm+/- mice.  
To complement the targeted approach focused on the ovarian DDR and apoptotic 
proteins, an unbiased proteomic LC-MS/MS approach was employed to determine 
additional proteins of interest regulated by ATM and altered by PM.  The top proteins 
affected in each comparison are described below, though this does not indicate that proteins 
that are significantly altered but with a lowered fold-change have lesser importance in the 
influence of ATM on ovarian function or in the response to PM exposure. KEGG identifiers 
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from our proteome analysis revealed proteins involved in metabolic pathways including 
pyridoxine 5’-phosphate oxidase (PNPO) and phosphomannomutase 2 (PMM2), and 
proteins associated with the spliceosome.  
Identification of proteins that are increased when ATM functionality is reduced 
support that they are proteins regulated by ATM or that experience secondary effects upon 
ATM loss. RPL29 is associated with ovarian cancer malignancy [69]. ME is involved in 
the luteal transition [70]. NID1 functions in ovarian steroidogenesis and bisphenol A 
exposure reduced Nid1 mRNA in Sertoli cells of mice [71, 72].   
Lack of appropriate ATM function resulted in reduced abundance of proteins that 
have been demonstrated to respond to cellular stress. AHSA1 is regulated by p53 and 
though roles in the ovary are not understood, AHSA increases PI3K phosphorylation [73] 
thus suggesting involvement in ovarian processes of importance. PMM2 mutations result 
in a glycosylation disorder in humans and endoplasmic reticulum stress has been reported 
in a zebrafish model of PMM2 deficiency [74, 75].  Nalp14 mRNA transcript is located in 
the oocytes of follicles up until the preovulatory stage [76] and Nalp14 mutation is 
associated with spermatogenic issues in men [77].   Though not well explored, NESP2 was 
found to be highly expressed in the ovary [78] and NESP1 [79] and NESP3 [80] have roles 
in the testes supporting a gonadal role for ovarian NESP2.  
Identification of proteins increased in response to PM exposure support their 
involvement in the ovarian protective response (OPR). These findings identify potential 
targets that could be medicinally induced in the ovary during CPA/PM treatment to 
minimize ovarian damage that occurs as a treatment side effect. BHMT1 is involved in 
metabolism of homocysteine which can be regulated in the oocyte via this enzyme [81]. 
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Though the ovarian role is not clear, in the testes, ALD1 is found in the vas deferens and 
regulated by dihydrotestosterone (DHT) [82].  Idi1 mRNA is present in reproductive tissue 
of Aedes aegypti mosquito [83], though there is little data on function in mammalian 
reproductive systems.  CP51A is a member of the cytochrome P450 enzyme family of 
proteins, which are critical in chemical metabolism processes [84].  In the testis, CP51A 
has an important role in the production of sterols that regulate meiosis [85].  CDN1B or 
p27kip1 regulates ovarian development in mice through suppression of follicle 
endowment, activation, and promoting cell death [86].   
The proteins that are reduced by PM could represent targets that are used as a mode 
of action of PM to induce ovotoxicity or could indicate that the abundance of these proteins 
is reduced due to their being depleted as they are being utilized in the OPR to PM exposure. 
PDS5B regulates the cohesion of sister chromatids during mitosis and meiosis, a function 
integral to DNA replication and repair [87].  In males, PDS5B regulates androgen-induced 
proliferation inactivation [88] and loss of PDS5B has been implicated in prostate cancer 
[89].  A10A9 has been identified in fluid of ovarian carcinomas and in the serum from 
ovarian carcinoma patients [90].  DDX18 is a member of the DEAD-box helicase family 
of proteins [91] and though there is no known specific reproductive tissue roles of DDX18, 
DDX25 is a gonadotropin-regulated testicular helicase and is essential for spermatogenesis 
[92]. Increased TPS1 is observed during follicular atresia in primate ovaries  [93] and 
inhibits VEGF, suggesting a role for TSP1 as a mediator for ovarian angiogenesis and 
follicle development [94].  Little is known about CE162 in reproductive tissues.   
In ovaries with reduced basal ATM, ovarian proteins that are responsive to PM 
exposure were identified, potentially indicating a response that is not solely due to the 
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genotoxic effects of PM. In addition, considering the importance of maintaining gamete 
quality, there are likely ATM-independent mechanisms to respond to genotoxicants, and 
these proteins may be part of that response. KINH maintains chromosomal stability and in 
mouse oocytes is critical for germinal vesicle breakdown and polar body extrusion [95].  
NAL14 is an inflammasome component and Nlrp14 has been detected in mammalian 
oocytes [96, 97]. In ovarian cancer stem cells, SYQ/QARS binds to aggregated P53 protein 
[98]. CNN1 is a tumor suppressor with suppressive effects in ovarian cancer cells  [99] and 
is also observed in  Sertoli cells [100], as a marker for peritubular myoid cells which 
interact with Sertoli cells during seminiferous tubule development [101]. Conversely, ILK 
has been implicated in pro-metastatic epithelial ovarian cancers [102].   
As is the case with the proteins that are increased in response to PM when ATM is 
deficient, the same is true of those proteins that are reduced in abundance. These reductions 
could represent utilization of these proteins in the response to PM, and could also indicate 
that with decreased abundance of ATM, proteins for which no apparent alteration in their 
overall abundance during PM exposure in the WT ovaries could in fact be functional in 
that scenario, but then be reduced in ovarian content in ATM deficiency, and that they are 
depleted at a faster rate or to a greater extent when ATM is insufficient. MGRAP is a 
mitochondrial transmembrane protein in the ovary (previously named ovary specific acidic 
protein) [103, 104] and Mgrap is regulated by estrogen and suppressed by a GnRH 
antagonist [105].  MBD2 has been identified in breast cancer cells [106]. AIF1L was 
identified via microarray as upregulated in ovarian cancer tissue versus normal ovarian 
tissue [107]. Reduced HMGN5 increases chemosensitivity of human bladder cancer cells 
through inhibition of PI3K/AKT signaling [108], but it also has an oncogenic role in several 
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types of cancers including breast [109] and prostate [110]. AFAM has been detected in 
follicular fluid [111], with serum concentrations remaining stable throughout the menstrual 
cycle [112] and elevated in polycystic ovary syndrome patients [113].   
Two proteins chosen for further characterization to decipher the impact of PM 
exposure in the ovaries of the WT and Atm+/- mice were CYFIP and XPO2. CYFIP1 was 
dramatically decreased in ovaries from Atm+/- female mice both basally and in response to 
PM treatment relative to their wild-type counterparts.  Cyfip1 is frequently deleted or 
reduced in human epithelial cancers and during invasion of epithelial tumors, with 
silencing of Cyfip1 resulting in disorganized epithelial morphogenesis in vitro [114].  Our 
finding of alterations to CYFIP1 in the Atm+/- ovary with localization around the ovarian 
surface epithelium and the appearance of CYFIP1 positive cells within the ovarian cortex 
and medulla after PM treatment indicates a possible role of CYFIP1 in ovarian tissue 
architecture, notable considering the increased rates of ovarian cancers in A-T female 
patients as well as carriers of a mutated Atm allele.  
The cellular apoptosis susceptibility protein XPO2 (also known as CSE1L) was 
greatly increased in the Atm+/- female ovary both due to ATM deficiency and post-PM 
exposure in contrast to WT ovaries in which this response was not observed.  In healthy 
cells, the function of XPO2 has been proposed as a breakpoint in regulating which cells 
proliferate and which cells undergo apoptosis [115].  Modifications in abundance of Xpo2 
have been suggested to promote neoplasia in breast cancers [116-119].  Furthermore, 
increased Xpo2, in association with the tumor suppressor gene Bax and pro-apoptotic 
Casp3, coincides with reduced anti-apoptotic Bcl-2 and has been demonstrated in the 
pathogenesis of endometrial carcinomas [120].  Considering that PM induced ovarian 
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apoptosis in WT, but not in Atm+/- mice, these data suggest that XPO2 may be involved in 
ATM-mediated apoptosis. 
In addition to implications for effective DNA repair, Atm haploinsufficiency may 
impact ovarian aging.  BRCA1 mutation carriers undergo earlier menopause, suggestive of 
decreased ovarian reserve [121-124].  Similarly, DNA repair gene and protein activity in 
the ovary decreases with age [124, 125] illustrating the relationship between DNA DSB 
repair and ovarian aging.  The Atm+/- females spent ~25% more time in the diestrus phase 
of the estrous cycle.  Further, the reduced follicle numbers in the absence of PM exposure 
supports our observation of altered estrous cycles in the Atm+/- females, indicative of POF. 
When reproductive aging begins, the disorganization of the estrous cycle is characterized 
by cycles with varying lengths and declining fertility [126].  These results suggest that 
carriers of the Atm mutation may experience earlier menopause onset in addition to 
subfecundity.   
In conclusion, these findings identify proteins involved in the ovarian response to 
the genotoxicant, PM. This study also underscores the importance of ATM protein to the 
ability of the ovary to mount the OPR to a genotoxicant. Further, proteins that may be 
involved in an ATM-independent ovarian response to a DNA damaging insult have been 
identified, which could lead to therapeutic targets to improve fertility in females who 
undergo anti-cancer treatments. In addition, the data herein provides strong support for a 
role of ATM in regulating how follicles that retain DNA damage are shunted towards an 
atretic demise, further highlighting the importance of ATM in multiple roles in 
coordination of the OPR. These findings are of importance to women undergoing cancer 
treatment for whom lessening the ovotoxicity side effects are of paramount importance. 
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The information reported herein also has value for Atm+/- human carriers and women who 
experience idiopathic POF.  Finally, these data add to the basic understanding of the OPR 
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Figure 1. Impact of Atm deficiency on estrous cyclicity.  The percentage time spent in 
proestrus (A), estrus (B), metestrus (C), diestrus (D) phase of the estrous cycle was 
calculated based upon vaginal cytological assessments in wildtype (WT) and Atm+/- mice.  






















Figure 2. Atm deficiency reduces follicle number and alters PM-induced ovotoxicity. 
Representative hematoxylin and eosin stained ovarian sections from (A) WT CT; (B) WT 
PM; (C) Atm
+/-
 CT; or (D) Atm
+/- 
PM are presented; scale bar = 200 µm.  Follicles were 
classified as (E) primordial; (F) primary; (G) total and counted.  Bars represent mean 
follicle number ± SEM.  Difference between treatments is indicated by the # = P < 0.1, * 
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Figure 3. Effect of Atm deficiency and PM exposure on DNA damage proteins.  
Primary antibodies directed against (A) ATM, (B) γH2AX, and (C) BRCA1 were used to 
determine ovarian localization in WT CT; WT PM; Atm
+/-
 CT; and Atm
+/- 
PM mice.  Green 
staining indicates the protein of interest while DNA is stained in blue; scale bar = 50 µm 
(20x magnification (0.5x-1x zoom).  Double tailed arrow indicates theca cells; dotted tail 
arrow indicates granulosa cells; O indicates oocyte.  Quantification of mean fluorescence 
intensity and/or immunopositive foci ± SEM for (A’) ATM; (B’) γH2AX; (C’) BRCA1.  
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Figure 4. Effect of Atm deficiency and PM exposure on cell death proteins.  Primary 
antibodies directed against (A) CASP3, and (B) CYCS were used to determine ovarian 
localization in WT CT; WT PM; Atm
+/-
 CT; and Atm
+/- 
PM.  Green staining indicates the 
protein of interest while DNA is stained in blue; scale bar = 50 µm (20x magnification 
(0.5x-1x zoom).  Dotted tail arrow indicates granulosa cells; O indicates oocyte.  
Quantification of fluorescence intensity and/or immunopositive foci ± SEM for (A’) 






































Figure 5. Global proteomic effects of Atm deficiency and PM exposure.   The Venn 
diagram presents the number of ovarian proteins identified as being unique to 
genotype/treatment or altered in common by genotype/treatment. (A) Proteins identified as 
increased; (B) Proteins identified as decreased.  The number in the orange oval indicates 
the number of proteins identified in the Atm+/- CT as being different from the WT CT 
group; the blue oval indicates the number of proteins identified in the WT PM group as 
being different from the WT CT; the green oval indicates the number of proteins in the 
Atm+/- PM group that differ from the Atm+/- CT; and the red oval indicates the number of 
proteins in the Atm+/- PM group that differ from the WT PM. Overlapping areas of the 



















































Distribution of the proteins identified in (C) Atm+/-/WT CT and (D) Atm+/-/WT PM 





































Figure 6. Ovarian localization of CYFIP1 and XPO2.  The ovarian location of CYFIP1 
and XPO2 proteins were assessed by immunofluorescence staining. (A) CYFIP1 (5x 
magnification); (A’) CYFIP1 (20x magnification); (B) XPO2 protein were localized in the 
ovary of WT CT; WT PM; Atm
+/-
 CT; and Atm
+/- 
PM mice. Green staining indicates the 
protein of interest while DNA is stained in blue; 5x magnification scale bar = 200 µm, 20x 
scale bar = 50 µm.  Dotted tail arrow indicates granulosa cells; solid arrow indicates ovarian 
surface epithelium; white box indicates area imaged for 20x magnification; blue dotted 
circle indicates ovarian medulla.   
 








 - PM 
  









Supplemental Figures and Legends 
Supplemental Table 1: Primary and secondary antibodies used. * denotes antigen 













Primary Antibody Host Dilution Supplier Code 
ATM Rabbit 1:100 abcam ab32420 
BRCA1 Rabbit 1:100 Santa Cruz sc-642 
Cleaved CASP3 Rabbit 1:100 Cell Signaling 9661 
CYFIP1* Rabbit 1:50 abcam ab154045 
CYTC* Rabbit 1:100 Cell Signaling 4280 
γH2AX Rabbit 1:50 Cell Signaling 2577 
H2AX Rabbit 1:100 abcam ab11175 
XPO2 Rabbit 1:100 abcam ab151546 
Secondary Antibody Host Dilution Supplier Code 
Rabbit IgG 488 Goat 1:500 Thermo Fisher A11008 
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Supplemental Table 2: Ovarian proteins identified by LC-MS/MS to differ in Atm+/- mice 
after vehicle-control relative to WT after vehicle-control (log2foldchange ≥ 0.1 and P-
value ≤ 0.05).   
UniProt ID Protein names log2(FC) p value 
Q7TMB8 Cytoplasmic FMR1-interacting protein 1 -6.832 <0.0001 
Q8BK64 
Activator of 90 kDa heat shock protein ATPase 
homolog 1 
-4.096 <0.0001 
Q9Z2M7 Phosphomannomutase 2 -3.617 <0.0001 
Q6B966 
NACHT, LRR and PYD domains-containing 
protein 14 
-3.508 0.001 
Q6ZWQ0 Nesprin-2 -3.484 0.005 
Q60715 Prolyl 4-hydroxylase subunit alpha-1 -3.350 <0.0001 
Q8BFZ3 Beta-actin-like protein 2 -3.334 0.015 
Q9WTI7 Unconventional myosin-Ic -3.243 0.002 
P68372 Tubulin beta-4B chain -3.122 0.001 
Q61205 
Platelet-activating factor acetylhydrolase IB 
subunit gamma 
-3.111 <0.0001 
Q6A068 Cell division cycle 5-like protein -3.020 0.010 
Q62059 Versican core protein -3.015 0.004 
Q9CWU5 KH domain-containing protein 3 -2.867 0.014 
Q9DBR1 5'-3' exoribonuclease 2 -2.825 0.049 
P62737 Actin, aortic smooth muscle -2.773 0.004 
Q62005 Zona pellucida sperm-binding protein 1 -2.681 0.001 
O08810 
116 kDa U5 small nuclear ribonucleoprotein 
component 
-2.660 0.001 
O88974 Histone-lysine N-methyltransferase SETDB1 -2.657 0.029 
P28654 Decorin -2.632 <0.0001 
Q8BML9 Glutamine--tRNA ligase -2.607 0.014 
Q923D5 WW domain-binding protein 11 -2.513 0.037 
Q07076 Annexin A7 -2.505 0.009 
P62331 ADP-ribosylation factor 6 -2.494 0.001 
Q3THE2 Myosin regulatory light chain 12B -2.399 0.001 
Q9DCH4 
Eukaryotic translation initiation factor 3 subunit 
F 
-2.392 0.003 






O35643 AP-1 complex subunit beta-1 -2.364 0.016 
Q99LJ6 Glutathione peroxidase 7 -2.363 <0.0001 
Q9D0I9 Arginine--tRNA ligase, cytoplasmic -2.284 0.003 
Q61768 Kinesin-1 heavy chain -2.254 0.006 
Q9QXS1 Plectin -2.179 0.002 
Q9Z0H3 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily B 
member 1 
-2.130 0.038 
Q8BKC5 Importin-5 -2.128 0.019 
D3Z7P3 Glutaminase kidney isoform, mitochondrial -2.098 0.013 
O88492 Perilipin-4 -2.046 0.041 
Q9CS42 Ribose-phosphate pyrophosphokinase 2 -2.008 0.006 
Q8BGS2 BolA-like protein 2 -1.930 0.012 
Q99JX4 




Cell division cycle and apoptosis regulator 
protein 1 
-1.903 0.005 
Q9JLM9 Growth factor receptor-bound protein 14 -1.902 0.013 
P62245 40S ribosomal protein S15a -1.885 0.021 
P67871 Casein kinase II subunit beta -1.872 0.021 
O08638 Myosin-11 -1.850 0.003 
Q8QZY1 
Eukaryotic translation initiation factor 3 subunit 
L 
-1.793 0.035 
Q9ESZ8 General transcription factor II-I -1.777 0.028 
P82198 
Transforming growth factor-beta-induced 
protein ig-h3 
-1.735 0.038 
Q9QZE7 Translin-associated protein X -1.724 0.001 
P97310 DNA replication licensing factor MCM2 -1.724 0.001 
Q8BIQ5 Cleavage stimulation factor subunit 2 -1.722 0.006 
O35841 Apoptosis inhibitor 5 -1.695 0.004 
P70372 ELAV-like protein 1 -1.686 <0.0001 
Q9WTP7 
GTP:AMP phosphotransferase AK3, 
mitochondrial 
-1.658 0.028 
D3YXK2 Scaffold attachment factor B1 -1.648 0.001 
P35235 
Tyrosine-protein phosphatase non-receptor type 
11 
-1.632 0.014 
Q8K297 Procollagen galactosyltransferase 1 -1.630 0.007 
Q9JJF0 Nucleosome assembly protein 1-like 5 -1.619 0.020 
Q64471 Glutathione S-transferase theta-1 -1.611 0.007 
P31324 
cAMP-dependent protein kinase type II-beta 
regulatory subunit 
-1.599 0.036 
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Q9D8T2 Gasdermin-D -1.579 0.006 
P36536 GTP-binding protein SAR1a -1.570 0.023 
P27612 Phospholipase A-2-activating protein -1.558 0.005 
P13439 Uridine 5'-monophosphate synthase -1.557 0.027 
P60229 
Eukaryotic translation initiation factor 3 subunit 
E 
-1.546 0.028 
Q8VH51 RNA-binding protein 39 -1.497 0.010 
Q08091 Calponin-1 -1.492 0.027 
P97372 Proteasome activator complex subunit 2 -1.460 <0.0001 
P61222 ATP-binding cassette sub-family E member 1 -1.456 0.007 
Q91W50 Cold shock domain-containing protein E1 -1.427 0.014 
O70194 




Basic leucine zipper and W2 domain-containing 
protein 1 
-1.418 0.015 
B2RQC6 CAD protein -1.387 0.023 
O70318 Band 4.1-like protein 2 -1.387 0.048 
Q80UZ0 
FYVE, RhoGEF and PH domain-containing 
protein 5 
-1.382 0.001 
Q62193 Replication protein A 32 kDa subunit -1.356 0.002 
Q99JX3 Golgi reassembly-stacking protein 2 -1.345 0.013 
P61082 NEDD8-conjugating enzyme Ubc12 -1.337 0.017 
Q8K1J6 
CCA tRNA nucleotidyltransferase 1, 
mitochondrial 
-1.324 0.021 
Q921M7 Protein FAM49B -1.316 0.048 
Q8VDP4 Cell cycle and apoptosis regulator protein 2 -1.314 0.026 
Q80VD1 Protein FAM98B -1.311 0.013 
Q01768 Nucleoside diphosphate kinase B -1.308 0.009 
Q8K4Z5 Splicing factor 3A subunit 1 -1.285 0.001 
Q8BWY3 
Eukaryotic peptide chain release factor subunit 
1 
-1.270 0.016 
Q62523 Zyxin -1.250 <0.0001 
Q9DCL9 Multifunctional protein ADE2R synthetase -1.243 0.017 
Q9D358 








U5 small nuclear ribonucleoprotein 200 kDa 
helicase 
-1.229 0.006 
Q9CXW4 60S ribosomal protein L11 -1.227 0.003 
Q9CQN1 Heat shock protein 75 kDa, mitochondrial -1.217 0.006 
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P20918 Plasminogen -1.209 0.004 
Q8K310 Matrin-3 -1.207 0.004 
P54071 Isocitrate dehydrogenase -1.207 0.002 
P48962 ADP/ATP translocase 1 -1.196 0.013 
P14602 Heat shock protein beta-1 -1.185 0.001 
Q3THK7 GMP synthase -1.182 0.026 
Q8BJY1 
26S proteasome non-ATPase regulatory subunit 
5 
-1.182 <0.0001 
Q9Z2I9 Succinate--CoA ligase -1.182 0.049 
Q3UPL0 Protein transport protein Sec31A -1.173 0.041 
Q68FD5 Clathrin heavy chain 1 -1.165 0.005 
Q9R190 Metastasis-associated protein MTA2 -1.156 0.016 
Q5FWK3 Rho GTPase-activating protein 1 -1.151 0.021 
P23116 
Eukaryotic translation initiation factor 3 subunit 
A 
-1.118 0.008 
P63001 Ras-related C3 botulinum toxin substrate 1 -1.116 0.036 
P49718 DNA replication licensing factor MCM5 -1.089 0.010 
Q8BG32 
26S proteasome non-ATPase regulatory subunit 
11 
-1.084 0.004 
Q8BTM8 Filamin-A -1.084 0.004 
P51125 Calpastatin -1.082 0.023 
Q8VCW8 








cAMP-dependent protein kinase catalytic 
subunit beta 
-1.075 0.003 
Q9EQH2 Endoplasmic reticulum aminopeptidase 1 -1.071 0.019 
P47941 Crk-like protein -1.070 0.013 
P97447 Four and a half LIM domains protein 1 -1.055 0.002 
P62334 26S proteasome regulatory subunit 10B -1.053 0.014 
Q6PHZ2 
Calcium/calmodulin-dependent protein kinase 
type II subunit delta 
-1.048 0.018 
P26039 Talin-1 -1.036 0.049 
Q921F4 Heterogeneous nuclear ribonucleoprotein L-like -1.031 0.007 
P56546 C-terminal-binding protein 2 -1.027 0.001 
P62908 40S ribosomal protein S3 -1.027 0.013 
Q80X90 Filamin-B -1.026 0.050 
P70168 Importin subunit beta-1 -1.025 0.010 
P35441 Thrombospondin-1 -1.025 0.049 
Q8C0C7 Phenylalanine--tRNA ligase alpha subunit -1.024 0.045 
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Q9WVJ2 















Q99NB9 Splicing factor 3B subunit 1 -0.995 0.012 
Q8BJW6 Eukaryotic translation initiation factor 2A -0.991 0.026 
O88829 Lactosylceramide alpha-2,3-sialyltransferase -0.983 0.002 
O35295 Transcriptional activator protein Pur-beta -0.980 0.011 
Q8R081 Heterogeneous nuclear ribonucleoprotein L -0.977 0.049 
Q9CY64 Biliverdin reductase A -0.976 0.004 
Q9Z1Q9 Valine--tRNA ligase -0.973 0.013 
P57780 Alpha-actinin-4 -0.969 0.001 
Q8BGQ7 Alanine--tRNA ligase, cytoplasmic -0.969 0.039 
Q8CIB5 Fermitin family homolog 2 -0.968 0.016 
Q9D8W5 
26S proteasome non-ATPase regulatory subunit 
12 
-0.962 0.011 
Q6DFW4 Nucleolar protein 58 -0.958 0.002 
Q99MR6 Serrate RNA effector molecule homolog -0.947 <0.0001 
Q7TPV4 Myb-binding protein 1A -0.936 0.006 
Q6PE01 
U5 small nuclear ribonucleoprotein 40 kDa 
protein 
-0.926 0.004 
P62500 TSC22 domain family protein 1 -0.915 0.029 
Q9DBG3 AP-2 complex subunit beta -0.914 0.047 
Q9D8N0 Elongation factor 1-gamma -0.914 0.030 
O35286 
Pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15 
-0.905 0.048 
Q9CXY6 Interleukin enhancer-binding factor 2 -0.902 0.001 
Q00PI9 
Heterogeneous nuclear ribonucleoprotein U-
like protein 2 
-0.902 0.002 
Q8R1B4 
Eukaryotic translation initiation factor 3 subunit 
C 
-0.896 0.034 
O55023 Inositol monophosphatase 1 -0.894 0.038 
P80313 T-complex protein 1 subunit eta -0.887 0.021 
P14869 60S acidic ribosomal protein P0 -0.885 0.007 
Q61696 Heat shock 70 kDa protein 1A -0.885 0.009 
Q9CSU0 
Regulation of nuclear pre-mRNA domain-
containing protein 1B 
-0.884 0.037 
Q7TPR4 Alpha-actinin-1 -0.882 0.013 
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Q8K0E8 Fibrinogen beta chain -0.880 0.006 
Q60749 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
-0.878 0.004 
Q501J6 
Probable ATP-dependent RNA helicase 
DDX17 
-0.876 0.003 
Q9EQH3 Vacuolar protein sorting-associated protein 35 -0.875 0.001 
Q3TXS7 
26S proteasome non-ATPase regulatory subunit 
1 
-0.864 0.029 
P62242 40S ribosomal protein S8 -0.862 0.003 
P51150 Ras-related protein Rab-7a -0.860 0.031 
Q61656 Probable ATP-dependent RNA helicase DDX5 -0.852 0.002 
Q61584 
Fragile X mental retardation syndrome-related 
protein 1 
-0.837 0.010 
P17225 Polypyrimidine tract-binding protein 1 -0.837 0.008 





Q9D8S4 Oligoribonuclease, mitochondrial -0.832 0.049 
Q3UEB3 Poly(U)-binding-splicing factor PUF60 -0.832 0.046 
Q99PT1 Rho GDP-dissociation inhibitor 1 -0.824 0.012 
Q9JK53 Prolargin -0.823 0.001 
P61089 Ubiquitin-conjugating enzyme E2 N -0.817 0.049 
Q9JKF1 Ras GTPase-activating-like protein IQGAP1 -0.809 0.018 
P31230 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1 
-0.804 0.015 
P97311 DNA replication licensing factor MCM6 -0.802 0.040 
Q9Z1X4 Interleukin enhancer-binding factor 3 -0.778 0.011 
Q6ZWN5 40S ribosomal protein S9 -0.778 0.023 
Q91V41 Ras-related protein Rab-14 -0.778 0.036 
Q8JZQ9 
Eukaryotic translation initiation factor 3 subunit 
B 
-0.761 0.016 
P62911 60S ribosomal protein L32 -0.760 0.041 
Q99KP6 Pre-mRNA-processing factor 19 -0.751 0.003 
P62281 40S ribosomal protein S11 -0.750 0.031 
Q9D554 Splicing factor 3A subunit 3 -0.745 0.020 
Q9QUI0 Transforming protein RhoA -0.742 0.021 
Q9DBR7 Protein phosphatase 1 regulatory subunit 12A -0.735 0.014 
O89079 Coatomer subunit epsilon -0.735 0.025 
P07901 Heat shock protein HSP 90-alpha -0.734 0.006 
Q6P069 Sorcin -0.734 0.039 
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Q8BH04 
Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial 
-0.724 0.012 
Q62318 Transcription intermediary factor 1-beta -0.722 0.015 
Q8VIJ6 Splicing factor, proline- and glutamine-rich -0.721 0.006 
Q8BFR5 Elongation factor Tu, mitochondrial -0.716 0.013 
Q91VR5 ATP-dependent RNA helicase DDX1 -0.708 0.005 
Q64727 Vinculin -0.703 0.031 
Q61881 DNA replication licensing factor MCM7 -0.695 0.021 
Q61233 Plastin-2 -0.685 0.035 
Q9WUU7 Cathepsin Z -0.684 0.039 
P46935 E3 ubiquitin-protein ligase NEDD4 -0.674 0.044 
A6X935 Inter alpha-trypsin inhibitor, heavy chain 4 -0.673 0.016 
P11499 Heat shock protein HSP 90-beta -0.673 0.014 
P14115 60S ribosomal protein L27a -0.661 0.026 
P25206 DNA replication licensing factor MCM3 -0.652 0.020 
P51660 Peroxisomal multifunctional enzyme type 2 -0.635 0.004 
Q62167 ATP-dependent RNA helicase DDX3X -0.632 0.025 
O88712 C-terminal-binding protein 1 -0.631 0.046 
Q8CI94 Glycogen phosphorylase, brain form -0.629 0.039 
P60335 Poly(rC)-binding protein 1 -0.623 0.012 
P62311 U6 snRNA-associated Sm-like protein LSm3 -0.623 0.033 
Q921F2 TAR DNA-binding protein 43 -0.618 0.007 
P80316 T-complex protein 1 subunit epsilon -0.617 0.017 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein U -0.616 0.001 
Q9R0Q7 Prostaglandin E synthase 3 -0.616 0.025 
P61079 Ubiquitin-conjugating enzyme E2 D3 -0.615 0.012 
P25444 40S ribosomal protein S2 -0.606 0.039 
Q923D2 Flavin reductase -0.603 0.042 
Q922R8 Protein disulfide-isomerase A6 -0.602 0.018 
P08113 Endoplasmin -0.599 0.041 
Q9JII6 Alcohol dehydrogenase -0.598 0.036 
O35685 Nuclear migration protein nudC -0.596 0.016 
P53994 Ras-related protein Rab-2A -0.582 0.010 
P97461 40S ribosomal protein S5 -0.582 0.009 
Q8R326 Paraspeckle component 1 -0.581 0.002 
Q91WV0 Protein Dr1 -0.569 0.001 
Q9D0E1 Heterogeneous nuclear ribonucleoprotein M -0.566 0.008 
P51410 60S ribosomal protein L9 -0.559 0.005 
P62821 Ras-related protein Rab-1A -0.552 0.009 
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O08529 Calpain-2 catalytic subunit -0.530 0.011 
Q99JI4 




Cholesterol side-chain cleavage enzyme, 
mitochondrial 
-0.514 0.029 
Q61990 Poly(rC)-binding protein 2 -0.485 0.011 
P35278 Ras-related protein Rab-5C -0.485 0.030 
Q9WUL7 ADP-ribosylation factor-like protein 3 -0.482 0.030 
P62830 60S ribosomal protein L23 -0.452 0.039 
P42669 Transcriptional activator protein Pur-alpha -0.439 0.018 
P58774 Tropomyosin beta chain -0.424 0.028 
Q99J77 Sialic acid synthase -0.416 0.045 
P62702 40S ribosomal protein S4, X isoform -0.415 0.003 
Q9R0P9 
Ubiquitin carboxyl-terminal hydrolase isozyme 
L1 
-0.398 0.023 
Q9R0P5 Destrin -0.355 0.018 
P63280 SUMO-conjugating enzyme UBC9 -0.333 0.039 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa -0.266 0.021 
P26645 Myristoylated alanine-rich C-kinase substrate 0.380 0.032 
Q9JM76 Actin-related protein 2/3 complex subunit 3 0.422 0.048 
Q99PL5 Ribosome-binding protein 1 0.444 0.018 
Q9JMH6 Thioredoxin reductase 1, cytoplasmic 0.492 0.047 
P53996 Cellular nucleic acid-binding protein 0.537 0.024 
Q9CQ45 Neudesin 0.570 0.049 
Q9CRB2 H/ACA ribonucleoprotein complex subunit 2 0.591 0.002 
Q8R050 
Eukaryotic peptide chain release factor GTP-
binding subunit ERF3A 
0.596 0.032 
P21619 Lamin-B2 0.680 0.049 
P26350 Prothymosin alpha 0.681 0.003 
Q62418 Drebrin-like protein 0.711 0.007 
P61957 Small ubiquitin-related modifier 2 0.713 0.013 
O70310 Glycylpeptide N-tetradecanoyltransferase 1 0.727 0.033 
P26041 Moesin 0.773 0.040 
Q9CR98 Protein FAM136A 0.779 0.037 
Q8VE97 Serine/arginine-rich splicing factor 4 0.798 0.020 
Q6P8I4 
PEST proteolytic signal-containing nuclear 
protein 
0.845 0.045 
P62889 60S ribosomal protein L30 0.864 0.003 
Q66JS6 
Eukaryotic translation initiation factor 3 subunit 
J-B 
0.886 0.022 
P08226 Apolipoprotein E 0.926 0.013 
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Q9R013 Cathepsin F 1.100 0.041 
Q9D3D9 ATP synthase subunit delta, mitochondrial 1.179 0.002 
Q9CXS4 Centromere protein V 1.185 0.045 
P11031 
Activated RNA polymerase II transcriptional 
coactivator p15 
1.193 0.015 
Q9EQS3 c-Myc-binding protein 1.248 0.036 
O55013 Trafficking protein particle complex subunit 3 1.310 0.006 
Q920Q6 RNA-binding protein Musashi homolog 2 1.358 0.008 
P99024 Tubulin beta-5 chain 1.377 0.004 
P83917 Chromobox protein homolog 1 1.440 0.010 
Q61009 Scavenger receptor class B member 1 1.448 0.038 
Q9JLQ0 CD2-associated protein 1.448 0.007 
P56391 Cytochrome c oxidase subunit 6B1 1.449 0.036 
Q9D7G0 Ribose-phosphate pyrophosphokinase 1 1.455 0.031 
Q9CYA0 Cysteine-rich with EGF-like domain protein 2 1.523 0.030 
Q91ZW3 
SWI/SNF-related matrix-associated actin-




NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial 
1.712 0.027 
P15532 Nucleoside diphosphate kinase A 1.733 0.010 
P97927 Laminin subunit alpha-4 1.753 0.033 
Q8R2Y2 Cell surface glycoprotein MUC18 1.772 0.008 
P99028 




Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
1.866 0.018 
P51881 ADP/ATP translocase 2 1.963 0.003 
Q99PV0 Pre-mRNA-processing-splicing factor 8 2.019 0.001 
Q9EQX4 Allograft inflammatory factor 1-like 2.034 0.026 
P11276 Fibronectin 2.053 0.020 
Q9Z0J0 NPC intracellular cholesterol transporter 2 2.066 0.005 
Q9DBR0 A-kinase anchor protein 8 2.208 0.008 





Q9JHW2 Omega-amidase NIT2 2.414 0.010 
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Q62219 
Transforming growth factor beta-1-induced 
transcript 1 protein 
2.469 0.001 
Q9D6J6 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
2.480 0.006 
P58044 Isopentenyl-diphosphate Delta-isomerase 1 2.675 0.012 
P17047 Lysosome-associated membrane glycoprotein 2 2.772 0.001 
Q91YT0 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
2.933 0.022 
P46414 Cyclin-dependent kinase inhibitor 1B 3.050 0.018 
Q9CPT4 Myeloid-derived growth factor 3.254 <0.0001 
P47915 60S ribosomal protein L29 3.575 <0.0001 
Q8BMF3 NADP-dependent malic enzyme, mitochondrial 3.632 0.001 
Q8R5J9 PRA1 family protein 3 3.790 0.006 
O88322 Nidogen-2 5.652 <0.0001 
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Supplemental Table 3: Ovarian proteins identified by LC-MS/MS to differ in WT mice 
after PM relative to WT after vehicle-control (log2foldchange ≥ 0.1 and P-value ≤ 0.05).   
UniProtID Protein names log2(FC) p value 
Q4VA53 
Sister chromatid cohesion protein PDS5 homolog 
B 
-1.447 0.037 
P31725 Protein S100-A9  -0.774 0.001 
Q8K363 ATP-dependent RNA helicase DDX18 -0.763 <0.0001 
P35441 Thrombospondin-1 -0.673 0.017 
Q6ZQ06 Centrosomal protein of 162 kDa -0.654 0.035 
P33622 Apolipoprotein C-III -0.651 0.037 
P02088 Hemoglobin subunit beta-1 -0.633 0.010 
Q6W8Q3 Purkinje cell protein 4-like protein 1 -0.612 0.024 
P01942 Hemoglobin subunit alpha -0.547 0.012 
Q9WTU6 Mitogen-activated protein kinase 9 -0.547 0.001 
P02104 Hemoglobin subunit epsilon-Y2 -0.540 0.049 
P28654 Decorin -0.538 0.016 
Q9Z2I9 
Succinate--CoA ligase [ADP-forming] subunit 
beta, mitochondrial 
-0.508 0.047 
Q9JLM9 Growth factor receptor-bound protein 14 -0.466 0.047 
Q08879 Fibulin-1 -0.462 0.019 
Q01339 Beta-2-glycoprotein 1 -0.440 0.037 
P06797 Cathepsin L1 -0.408 0.003 
Q62193 Replication protein A 32 kDa subunit -0.337 0.008 
A2BDX3 
Adenylyltransferase and sulfurtransferase 
MOCS3 
-0.241 0.033 
Q9DCL9 Multifunctional protein ADE2 -0.070 0.022 
Q6ZWX6 Eukaryotic translation initiation factor 2 subunit 1 0.175 0.030 
P62242 40S ribosomal protein S8 0.195 0.044 
P28653 Biglycan 0.207 0.021 
Q9Z0N1 
Eukaryotic translation initiation factor 2 subunit 
3, X-linked 
0.220 0.029 
Q9EQH3 Vacuolar protein sorting-associated protein 35 0.228 0.031 
Q99LF4 tRNA-splicing ligase RtcB homolog 0.228 0.049 
P61979 Heterogeneous nuclear ribonucleoprotein K 0.260 0.032 
Q61656 Probable ATP-dependent RNA helicase DDX5 0.261 0.022 
P62137 




Q9CQI3 Glia maturation factor beta 0.266 0.004 
P14869 60S acidic ribosomal protein P0 0.267 0.044 
P25444 
 
40S ribosomal protein S2 0.273 0.020 
P83882 60S ribosomal protein L36a 0.275 0.027 
P14115 60S ribosomal protein L27a 0.281 0.037 
Q9DB29 Isoamyl acetate-hydrolyzing esterase 1 homolog 0.285 0.027 
Q8BK64 
Activator of 90 kDa heat shock protein ATPase 
homolog 1 
0.300 0.038 
P97371 Proteasome activator complex subunit 1 0.300 0.004 
Q6PDM2 Serine/arginine-rich splicing factor 1 0.308 0.048 
Q9CPR4 60S ribosomal protein L17 0.312 0.027 
P47753 F-actin-capping protein subunit alpha-1 0.318 0.007 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q 0.318 0.016 
Q9Z1Q5 Chloride intracellular channel protein 1 0.326 0.013 
Q9D8E6 60S ribosomal protein L4 0.335 0.019 
P62830 60S ribosomal protein L23 0.337 0.031 
P35550 rRNA 2'-O-methyltransferase fibrillarin 0.340 0.021 
P47911 60S ribosomal protein L6 0.349 0.011 
Q921M3 Splicing factor 3B subunit 3 0.351 0.042 
Q9D8B3 Charged multivesicular body protein 4b 0.354 0.046 
Q9CX86 Heterogeneous nuclear ribonucleoprotein A0 0.359 0.005 
Q9CQV8 14-3-3 protein beta/alpha 0.367 0.010 
P54775 26S proteasome regulatory subunit 6B 0.370 0.044 
Q61035 Histidine--tRNA ligase, cytoplasmic 0.372 0.011 
Q8VI75 Importin-4 0.373 0.013 
P14685 26S proteasome non-ATPase regulatory subunit 3 0.377 0.019 
Q9EQU5 Protein SET 0.378 0.036 
O35326 Serine/arginine-rich splicing factor 5 0.379 0.032 
P62196 26S proteasome regulatory subunit 8 0.381 0.014 
Q64010 Adapter molecule crk 0.388 0.046 
Q99J77 Sialic acid synthase 0.398 0.033 
P62996 Transformer-2 protein homolog beta 0.404 0.021 
Q61699 Heat shock protein 105 kDa 0.405 0.038 
P97461 40S ribosomal protein S5 0.407 0.030 
Q91WV0 Protein Dr1 0.423 0.042 
Q61171 Peroxiredoxin-2 0.424 0.044 
Q9CQ60 6-phosphogluconolactonase 0.427 0.037 
Q8VDP4 Cell cycle and apoptosis regulator protein 2 0.429 0.023 
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Q9CR98 Protein FAM136A 0.435 0.026 
Q8CHH9 Septin-8 0.438 0.006 
Q6PE01 
U5 small nuclear ribonucleoprotein 40 kDa 
protein 
0.441 0.029 
P62821 Ras-related protein Rab-1A 0.444 0.014 
Q08093 Calponin-2 0.447 0.011 
Q62422 Osteoclast-stimulating factor 1 0.449 0.018 
P14131 40S ribosomal protein S16 0.456 0.010 
Q8VH51 RNA-binding protein 39 0.463 0.048 
Q8CCF0 U4/U6 small nuclear ribonucleoprotein Prp31 0.463 0.048 
P97822 
Acidic leucine-rich nuclear phosphoprotein 32 
family member E 
0.476 0.014 
Q8R5C5 Beta-centractin 0.477 0.006 
O88342 WD repeat-containing protein 1 0.488 0.020 
O55029 Coatomer subunit beta 0.488 0.019 
P16254 Signal recognition particle 14 kDa protein 0.492 0.001 
Q64520 Guanylate kinase 0.494 <0.0001 
Q9CWM4 Prefoldin subunit 1 0.495 0.042 
P51410 60S ribosomal protein L9 0.499 0.001 
Q62167 ATP-dependent RNA helicase DDX3X 0.500 0.036 
Q9R1P3 Proteasome subunit beta type-2 0.502 0.025 
Q62432 Mothers against decapentaplegic homolog 2 0.502 0.009 
Q61581 Insulin-like growth factor-binding protein 7 0.505 0.014 
Q7TPV4 Myb-binding protein 1A 0.510 0.037 
Q64261 Cyclin-dependent kinase 6 0.511 0.023 
Q9Z1D1 
Eukaryotic translation initiation factor 3 subunit 
G 
0.511 0.005 
Q60737 Casein kinase II subunit alpha 0.516 0.020 
P61290 Proteasome activator complex subunit 3 0.519 0.025 
Q9JIX0 Transcription and mRNA export factor ENY2 0.519 0.027 
Q99LP6 GrpE protein homolog 1, mitochondrial 0.527 0.039 
Q60972 Histone-binding protein RBBP4 0.531 0.009 
P14824 Annexin A6 0.540 0.015 
Q9JM14 5'(3')-deoxyribonucleotidase, cytosolic type 0.560 0.032 
P07356 Annexin A2 0.562 0.007 
P97821 Dipeptidyl peptidase 1 0.562 <0.0001 
Q91V76 Ester hydrolase C11orf54 homolog 0.572 0.040 
Q9CZ30 Obg-like ATPase 1 0.576 0.050 
Q62418 Drebrin-like protein 0.578 0.004 
Q6NSR8 Probable aminopeptidase NPEPL1 0.584 0.018 
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P12815 Programmed cell death protein 6 0.585 0.005 
Q9R0P3 S-formylglutathione hydrolase 0.588 0.027 
P47811 Mitogen-activated protein kinase 14 0.592 0.047 
Q8CFX1 GDH/6PGL endoplasmic bifunctional protein 0.592 0.024 
Q9JMH6 Thioredoxin reductase 1, cytoplasmic 0.593 0.017 
Q9D0L8 mRNA cap guanine-N7 methyltransferase 0.598 0.030 
Q920Q6 RNA-binding protein Musashi homolog 2 0.600 0.015 
Q99KQ4 Nicotinamide phosphoribosyltransferase 0.609 0.030 
Q64378 Peptidyl-prolyl cis-trans isomerase FKBP5 0.617 0.045 
Q8VBV7 COP9 signalosome complex subunit 8 0.619 0.027 
Q8K0G8 Epithelial splicing regulatory protein 2 0.624 0.039 
Q6IRU2 Tropomyosin alpha-4 chain 0.629 0.013 
Q9WVE8 
Protein kinase C and casein kinase substrate in 
neurons protein 2 
0.631 0.033 
Q3ULJ0 
Glycerol-3-phosphate dehydrogenase 1-like 
protein 
0.645 0.014 
Q61624 Zinc finger protein 148 0.649 0.040 
P61164 Alpha-centractin 0.650 0.032 
Q920A5 Retinoid-inducible serine carboxypeptidase 0.656 0.010 
Q810B6 Rabankyrin-5 0.659 0.029 
Q8VCI0 Phospholipase B-like 1 0.659 0.004 
Q9CQC6 
Basic leucine zipper and W2 domain-containing 
protein 1 
0.678 0.014 
Q91V12 Cytosolic acyl coenzyme A thioester hydrolase 0.679 <0.0001 
O08709 Peroxiredoxin-6 0.694 0.026 
Q9DAR7 m7GpppX diphosphatase 0.695 0.009 
Q9ERR7 Selenoprotein F 0.704 0.035 
P06745 Glucose-6-phosphate isomerase 0.720 0.020 
Q9CRC9 Glucosamine-6-phosphate isomerase 2 0.725 0.037 
O89017 Legumain 0.732 0.024 
P48036 Annexin A5 0.745 0.006 
P06801 NADP-dependent malic enzyme 0.750 0.029 
O09167 60S ribosomal protein L21 0.751 0.048 
Q9QUG2 DNA polymerase kappa 0.752 0.025 
Q3TYX8 RUN and FYVE domain-containing protein 4 0.781 0.006 
P50429 Arylsulfatase B 0.804 0.040 
O08738 Caspase-6 0.806 0.003 
Q9WVA4 Transgelin-2 0.806 0.001 
Q8R0F6 
Integrin-linked kinase-associated serine/threonine 
phosphatase 2C 
0.810 0.021 
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P63280 SUMO-conjugating enzyme UBC9 0.811 0.001 
O88448 Kinesin light chain 2 0.826 0.020 
Q8BGB7 Enolase-phosphatase E1 0.831 0.032 
Q9CXW3 Calcyclin-binding protein 0.833 0.035 
Q9D0I9 Arginine--tRNA ligase, cytoplasmic 0.837 0.034 
Q60767 Lymphocyte antigen 75 0.839 0.029 
Q05793 
Basement membrane-specific heparan sulfate 
proteoglycan core protein 
0.840 0.044 
Q9CZ04 COP9 signalosome complex subunit 7a 0.858 0.031 
P67871 Casein kinase II subunit beta 0.868 0.016 
O88447 Kinesin light chain 1 0.871 0.011 
Q91V92 ATP-citrate synthase 0.882 0.005 





Q62384 Zinc finger protein ZPR1 0.962 0.028 
Q68FL6 Methionine--tRNA ligase, cytoplasmic 0.969 0.009 
P42567 Epidermal growth factor receptor substrate 15 1.024 0.021 
P35235 
Tyrosine-protein phosphatase non-receptor type 
11 
1.048 0.020 
Q920E5 Farnesyl pyrophosphate synthase 1.075 0.007 
O35969 Guanidinoacetate N-methyltransferase 1.095 0.048 
Q6P6M7 O-phosphoseryl-tRNA(Sec) selenium transferase 1.137 0.042 
O88322 Nidogen-2 1.152 0.047 
Q9WUA3 
ATP-dependent 6-phosphofructokinase, platelet 
type 
1.154 0.002 
Q9CPX8 Cytochrome b-c1 complex subunit 10 1.173 0.005 
Q8BIW1 Exopolyphosphatase PRUNE1 1.195 0.036 
Q7TMR0 Lysosomal Pro-X carboxypeptidase 1.225 0.025 
P30412 Peptidyl-prolyl cis-trans isomerase C 1.230 0.010 
O54941 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily E 
member 1 
1.263 0.030 
Q80ZJ6 Protein zer-1 homolog 1.265 0.049 
Q9Z0S1 3'(2'),5'-bisphosphate nucleotidase 1 1.275 0.020 
P22907 Porphobilinogen deaminase 1.364 0.014 





Q60648 Ganglioside GM2 activator 1.476 0.001 
Q8C6G8 WD repeat-containing protein 26 1.545 0.001 
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P70271 PDZ and LIM domain protein 4 1.561 0.024 
Q9WUP7 
Ubiquitin carboxyl-terminal hydrolase isozyme 
L5 
1.583 0.016 
Q8C166 Copine-1 1.825 0.014 
Q3UTJ2 Sorbin and SH3 domain-containing protein 2 1.933 0.019 
P46414 Cyclin-dependent kinase inhibitor 1B 2.178 0.028 
Q8K0C4 Lanosterol 14-alpha demethylase 2.181 0.007 
P58044 Isopentenyl-diphosphate Delta-isomerase 1 2.619 0.001 
P21300 Aldose reductase-related protein 1 3.167 0.015 
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Supplemental Table 4: Ovarian proteins identified by LC-MS/MS to differ in Atm+/- mice 
after PM relative Atm+/- after vehicle-control (log2foldchange ≥ 0.1 and P-value ≤ 0.05).   
UniProtID Protein names log2(FC) p value 
Q8VI64 Protein MGARP  -1.912 0.010 
Q9Z2D6 Methyl-CpG-binding protein 2  -1.814 0.002 
Q9EQX4 Allograft inflammatory factor 1-like  -1.672 0.039 
Q9JL35 
High mobility group nucleosome-binding 
domain-containing protein 5 
-1.487 0.037 
O89020 Afamin  -1.483 0.036 
Q80SZ7 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-5 
-1.446 0.028 
Q6ZPZ3 Zinc finger CCCH domain-containing protein 4 -1.425 0.030 
Q91VD9 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial  
-1.342 0.014 
Q9D0J8 Parathymosin -1.258 0.017 
Q9QZB7 Actin-related protein 10  -1.057 0.016 
Q3TCN2 Putative phospholipase B-like 2  -1.049 0.047 
P08226 Apolipoprotein E  -1.027 0.035 
P10922 Histone H1.0 -0.980 0.036 
Q9CZN7 Serine hydroxymethyltransferase, mitochondrial  -0.970 0.034 
Q9D3D9 ATP synthase subunit delta, mitochondrial  -0.968 0.009 
P70441 
Na(+)/H(+) exchange regulatory cofactor NHE-
RF1 
-0.906 0.036 
P26645 Myristoylated alanine-rich C-kinase substrate -0.895 0.023 
P19536 Cytochrome c oxidase subunit 5B, mitochondrial  -0.873 0.039 
Q9CQA3 
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial 
-0.873 0.020 
P61957 Small ubiquitin-related modifier 2  -0.861 0.016 
Q8CDB0 
MAP kinase-interacting serine/threonine-protein 
kinase 2  
-0.848 0.049 
Q9CZ13 




Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  
-0.815 0.032 
Q62168 Keratin, type I cuticular Ha2  -0.814 0.021 
P48428 Tubulin-specific chaperone A  -0.810 0.014 






Q9CT10 Ran-binding protein 3  -0.772 0.039 
Q91ZX7 
Prolow-density lipoprotein receptor-related 
protein 1  
-0.734 0.041 
O35129 Prohibitin-2  -0.701 0.032 
P10852 4F2 cell-surface antigen heavy chain  -0.646 0.032 
Q9JI75 Ribosyldihydronicotinamide dehydrogenase -0.551 0.029 
Q9CR68 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial  
-0.455 0.022 
P45376 Aldose reductase  -0.367 0.037 
Q08879 Fibulin-1 -0.355 0.038 
Q60931 
Voltage-dependent anion-selective channel 
protein 3  
-0.334 0.025 
Q8R1I1 Cytochrome b-c1 complex subunit 9 -0.195 0.045 
P97447 Four and a half LIM domains protein 1  0.270 0.050 
Q8BWM0 Prostaglandin E synthase 2  0.288 0.032 
Q9CXZ1 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4, mitochondrial  
0.394 0.018 







glycosyltransferase subunit 2  
0.462 0.032 
Q8CG70 Prolyl 3-hydroxylase 3 0.466 0.031 
O54724 Caveolae-associated protein 1  0.543 0.019 
Q923D2 Flavin reductase 0.547 0.034 
Q6PE01 
U5 small nuclear ribonucleoprotein 40 kDa 
protein  
0.578 0.037 
Q9QXE7 F-box-like/WD repeat-containing protein TBL1X  0.606 0.027 
Q8BGC4 Prostaglandin reductase-3 0.640 0.023 
P51150 Ras-related protein Rab-7a 0.647 0.019 
Q9CQ92 Mitochondrial fission 1 protein  0.661 0.009 
O88544 COP9 signalosome complex subunit 4 0.664 0.022 
Q9Z1X4 Interleukin enhancer-binding factor 3 0.677 0.041 
P19096 Fatty acid synthase  0.700 0.043 
Q9EQH3 Vacuolar protein sorting-associated protein 35 0.713 0.030 
Q91VS7 Microsomal glutathione S-transferase 1  0.722 0.036 
Q62261 Spectrin beta chain, non-erythrocytic 1 0.738 0.014 
P63085 Mitogen-activated protein kinase 1 0.743 0.041 
P05784 Keratin, type I cytoskeletal 18  0.760 0.019 
Q9CQ54 
NADH dehydrogenase [ubiquinone] 1 subunit 
C2  
0.767 0.013 
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O55143 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
0.769 0.005 
Q99MR6 Serrate RNA effector molecule homolog  0.792 0.045 
Q91YR1 Twinfilin-1  0.794 0.035 
P48024 Eukaryotic translation initiation factor 1 0.818 0.034 
O70492 Sorting nexin-3  0.824 0.007 
P84084 ADP-ribosylation factor 5 0.842 0.042 
Q62383 Transcription elongation factor SPT6 0.846 0.033 
Q61263 Sterol O-acyltransferase 1 0.847 0.022 
Q9JK53 Prolargin  0.850 0.014 
P24815 
3 beta-hydroxysteroid dehydrogenase/Delta 5--
>4-isomerase type 1  
0.853 0.007 
Q6ZWN5 40S ribosomal protein S9 0.858 0.020 
Q64471 Glutathione S-transferase theta-1  0.862 0.045 
P62281 40S ribosomal protein S11 0.863 0.007 
Q9WVB0 RNA-binding protein with multiple splicing  0.885 0.037 
P37804 Transgelin  0.887 0.014 
Q3TXS7 
26S proteasome non-ATPase regulatory subunit 
1  
0.889 0.043 
Q61074 Protein phosphatase 1G  0.892 0.022 
P28654 Decorin 0.892 0.040 
P61089 Ubiquitin-conjugating enzyme E2 N  0.902 0.033 
Q9CZY3 Ubiquitin-conjugating enzyme E2 variant 1  0.905 0.018 
Q9Z1Q9 Valine--tRNA ligase  0.922 0.045 
P62242 40S ribosomal protein S8 0.953 0.030 
Q9DBC7 
cAMP-dependent protein kinase type I-alpha 




dependent regulator of chromatin subfamily A 
member 5  
0.961 0.041 
Q3UYV9 Nuclear cap-binding protein subunit 1  0.965 0.047 
P84091 AP-2 complex subunit mu   0.972 0.007 
Q9QUI0 Transforming protein RhoA 0.974 0.037 
O55023 Inositol monophosphatase 1 0.987 0.022 
P35585 AP-1 complex subunit mu-1 0.988 0.030 
Q61879 Myosin-10  0.994 0.015 
Q9WVQ5 Methylthioribulose-1-phosphate dehydratase  0.994 0.038 
P61750 ADP-ribosylation factor 4 1.001 0.016 
P62331 ADP-ribosylation factor 6 1.003 0.044 
Q9CQN1 Heat shock protein 75 kDa, mitochondrial  1.004 0.021 
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Q9Z1Z0 General vesicular transport factor p115  1.006 0.045 
P52825 
Carnitine O-palmitoyltransferase 2, 
mitochondrial  
1.011 0.021 
P32020 Non-specific lipid-transfer protein 1.023 0.048 
Q8VCW8 
Acyl-CoA synthetase family member 2, 
mitochondrial  
1.032 0.005 
O35841 Apoptosis inhibitor 5  1.053 0.001 
Q8K310 Matrin-3 1.061 0.045 
P54071 Isocitrate dehydrogenase [NADP], mitochondrial 1.067 0.015 
O70133 ATP-dependent RNA helicase A  1.070 0.036 
Q9DBE0 Cysteine sulfinic acid decarboxylase 1.072 0.026 
Q7TPV4 Myb-binding protein 1A 1.084 0.017 
P70168 Importin subunit beta-1  1.100 0.006 
Q921F4 Heterogeneous nuclear ribonucleoprotein L-like 1.104 0.038 
Q9DBZ5 
Eukaryotic translation initiation factor 3 subunit 
K  
1.108 0.010 
P63280 SUMO-conjugating enzyme UBC9 1.113 0.039 
Q8BN78 Transcriptional regulator Kaiso 1.116 0.049 
Q61656 Probable ATP-dependent RNA helicase DDX5 1.121 0.026 
Q8BTM8 Filamin-A 1.133 0.014 
Q6A4J8 Ubiquitin carboxyl-terminal hydrolase 7  1.136 0.016 
Q61990 Poly(rC)-binding protein 2  1.137 0.019 
Q80UZ0 
FYVE, RhoGEF and PH domain-containing 
protein 5 
1.143 0.009 
Q8BGB7 Enolase-phosphatase E1  1.163 0.031 
P14685 








KH domain-containing, RNA-binding, signal 
transduction-associated protein 1  
1.176 0.045 
Q8CGC7 Bifunctional glutamate/proline--tRNA ligase 1.183 0.045 
O35114 Lysosome membrane protein 2  1.200 0.041 
Q9CZ30 Obg-like ATPase 1 1.212 0.029 
P26039 Talin-1 1.220 0.011 
Q8VDD5 Myosin-9 1.224 0.027 
O89079 Coatomer subunit epsilon  1.233 0.025 
Q6PIP5 NudC domain-containing protein 1 1.235 0.024 
Q9R0X4 Acyl-coenzyme A thioesterase 9, mitochondrial 1.239 0.025 
Q9DBG9 Tax1-binding protein 3 1.243 0.023 
P62908 40S ribosomal protein S3  1.265 0.042 
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Q9CX56 
26S proteasome non-ATPase regulatory subunit 
8 
1.276 <0.0001 
Q6NZC7 SEC23-interacting protein 1.283 0.022 
O70318 Band 4.1-like protein 2 1.299 0.003 
Q8VCR7 Protein ABHD14B 1.299 0.033 
Q00PI9 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 2  
1.305 0.030 
P22682 E3 ubiquitin-protein ligase CBL 1.307 0.032 
Q61584 
Fragile X mental retardation syndrome-related 
protein 1  
1.310 0.009 
P97461 40S ribosomal protein S5 1.310 0.002 
Q8BJY1 
26S proteasome non-ATPase regulatory subunit 
5 
1.333 0.013 
Q5FWK3 Rho GTPase-activating protein 1 1.336 0.034 
O88844 Isocitrate dehydrogenase [NADP] cytoplasmic 1.347 0.041 
Q62167 ATP-dependent RNA helicase DDX3X 1.349 0.035 
Q9WTP7 
GTP:AMP phosphotransferase AK3, 
mitochondrial 
1.355 0.046 
Q91W50 Cold shock domain-containing protein E1 1.357 0.013 
Q9Z0M5 Lysosomal acid lipase/cholesteryl ester hydrolase  1.367 0.043 
Q3UEB3 Poly(U)-binding-splicing factor PUF60  1.384 0.020 
Q8CI51 PDZ and LIM domain protein 5  1.393 0.019 
Q9JHU4 Cytoplasmic dynein 1 heavy chain 1  1.454 0.050 
Q68FD5 Clathrin heavy chain 1 1.458 0.027 
Q6P4T2 
U5 small nuclear ribonucleoprotein 200 kDa 
helicase  
1.459 0.037 
P97823 Acyl-protein thioesterase 1  1.465 0.044 
Q8VH51 RNA-binding protein 39  1.482 0.039 
Q9ESZ8 General transcription factor II-I  1.504 0.007 
P54823 Probable ATP-dependent RNA helicase DDX6 1.538 0.013 
Q8CIE6 Coatomer subunit alpha  1.542 0.034 
P17427 AP-2 complex subunit alpha-2  1.548 0.046 
Q99K48 
Non-POU domain-containing octamer-binding 
protein  
1.552 0.029 
O35969 Guanidinoacetate N-methyltransferase 1.557 0.008 
P10107 Annexin A1  1.562 0.033 
P61082 NEDD8-conjugating enzyme Ubc12  1.564 0.046 
Q9JKF1 Ras GTPase-activating-like protein IQGAP1 1.567 0.025 
O70503 Very-long-chain 3-oxoacyl-CoA reductase 1.569 0.042 
Q8BG32 
26S proteasome non-ATPase regulatory subunit 
11  
1.579 0.010 
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Q91ZJ5 UTP--glucose-1-phosphate uridylyltransferase 1.589 0.020 
Q9D0I9 Arginine--tRNA ligase, cytoplasmic  1.601 0.026 
Q3UKJ7 WD40 repeat-containing protein SMU1 1.609 0.011 
P07214 SPARC 1.613 0.026 
O70194 
Eukaryotic translation initiation factor 3 subunit 
D  
1.615 0.014 
Q921U8 Smoothelin 1.666 0.006 
Q64378 Peptidyl-prolyl cis-trans isomerase FKBP5  1.693 0.033 
Q9DCG9 




Activator of 90 kDa heat shock protein ATPase 
homolog 1  
1.719 0.014 
Q07797 Galectin-3-binding protein  1.722 0.049 
Q9CZ04 COP9 signalosome complex subunit 7a  1.732 0.011 
P0DOV2 Interferon-activable protein 204 1.745 0.011 
P62737 Actin, aortic smooth muscle  1.751 0.038 
Q8BH64 EH domain-containing protein 2 1.753 0.049 
Q3ULJ0 







Q9CY64 Biliverdin reductase A  1.779 0.001 
Q6P5F9 Exportin-1  1.780 0.021 
Q99LD9 Translation initiation factor eIF-2B subunit beta  1.787 0.007 
P70372 ELAV-like protein 1 1.796 0.005 
Q8R1B4 
Eukaryotic translation initiation factor 3 subunit 
C  
1.803 0.034 
Q62005 Zona pellucida sperm-binding protein 1 1.844 0.002 
Q9EPL8 Importin-7  1.849 0.017 
Q60715 Prolyl 4-hydroxylase subunit alpha-1  1.852 0.029 
P42567 Epidermal growth factor receptor substrate 15  1.875 0.035 
Q99LJ6 Glutathione peroxidase 7  1.887 0.011 
Q8BWY3 Eukaryotic peptide chain release factor subunit 1  1.926 0.007 
P12815 Programmed cell death protein 6 1.965 0.009 
Q9DCH4 
Eukaryotic translation initiation factor 3 subunit 
F  
1.983 0.021 
Q9WTL7 Acyl-protein thioesterase 2  2.042 0.032 
Q99NB9 Splicing factor 3B subunit 1  2.050 0.033 
Q9JIF7 Coatomer subunit beta 2.055 0.022 
Q07076 Annexin A7  2.074 0.011 
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Q99JX4 
Eukaryotic translation initiation factor 3 subunit 
M  
2.123 0.022 
Q01405 Protein transport protein Sec23A  2.165 0.025 
D3Z7P3 Glutaminase kidney isoform, mitochondrial  2.167 0.015 
B1AZI6 THO complex subunit 2  2.181 0.032 
Q9D7I5 
Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase  
2.190 0.007 
Q8QZY1 




Eukaryotic translation initiation factor 3 subunit 
E  
2.305 0.011 
P31001 Desmin 2.311 0.011 
Q8CH18 
Cell division cycle and apoptosis regulator 
protein 1  
2.317 0.002 
Q80UM3 
N-alpha-acetyltransferase 15, NatA auxiliary 
subunit  
2.406 0.002 
O08638 Myosin-11 2.450 0.009 
Q08091 Calponin-1  2.478 0.015 
O55222 Integrin-linked protein kinase  2.522 0.032 
Q8BML9 Glutamine--tRNA ligase  2.610 0.015 
Q6B966 
NACHT, LRR and PYD domains-containing 
protein 14  
2.673 0.039 
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Supplemental Table 5: Ovarian proteins identified by LC-MS/MS to differ in Atm+/- mice 
after PM relative to WT after PM (log2foldchange ≥ 0.1 and P-value ≤ 0.05).  
UniProt ID Protein names log2(FC) p value 
Q7TMB8 Cytoplasmic FMR1-interacting protein 1 -5.567 <0.0001 
Q9WVB3 Transducin-like enhancer protein 6 -3.649 <0.0001 
Q91XF0 Pyridoxine-5'-phosphate oxidase -3.411 0.008 
Q9Z2M7 Phosphomannomutase 2 -2.974 <0.0001 
Q62059 Versican core protein -2.912 0.006 
Q8BFZ3 Beta-actin-like protein 2 -2.873 0.025 
Q6ZPZ3 Zinc finger CCCH domain-containing protein 4 -2.871 0.002 
O88974 Histone-lysine N-methyltransferase SETDB1 -2.796 0.003 
Q6A068 Cell division cycle 5-like protein -2.745 0.007 
Q8BK64 
Activator of 90 kDa heat shock protein ATPase 
homolog 1 
-2.677 <0.0001 
O35643 AP-1 complex subunit beta-1 -2.671 0.006 
Q9CW03 




116 kDa U5 small nuclear ribonucleoprotein 
component 
-2.456 0.003 
O70493 Sorting nexin-12 -2.444 0.004 
P68372 Tubulin beta-4B chain -2.418 0.002 
P97496 SWI/SNF complex subunit SMARCC1 -2.316 <0.0001 
D3YXK2 Scaffold attachment factor B1 -2.189 0.006 
Q9Z0M5 
Lysosomal acid lipase/cholesteryl ester 
hydrolase 
-2.054 0.011 
Q6PGB6 N-alpha-acetyltransferase 50 -1.987 0.004 
Q64520 Guanylate kinase -1.904 0.001 
Q9CX34 Protein SGT1 homolog -1.881 0.009 
Q3THE2 Myosin regulatory light chain 12B -1.842 0.024 
Q8BIG7 
Catechol O-methyltransferase domain-
containing protein 1 
-1.810 0.014 
Q8BFY9 Transportin-1 -1.782 0.026 
P62331 ADP-ribosylation factor 6 -1.782 0.011 
P62317 Small nuclear ribonucleoprotein Sm D2 -1.739 <0.0001 
Q9CWL8 Beta-catenin-like protein 1 -1.731 0.014 
P13439 Uridine 5'-monophosphate synthase -1.715 0.021 
Q810B6 Rabankyrin-5 -1.707 0.005 
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P35235 











Q8C166 Copine-1 -1.607 0.045 
Q8BHD7 Polypyrimidine tract-binding protein 3 -1.593 0.014 
Q06770 Corticosteroid-binding globulin -1.575 0.038 
Q8CCK0 Core histone macro-H2A.2 -1.550 0.011 
Q9D0I9 Arginine--tRNA ligase, cytoplasmic -1.519 0.014 





Q91VH6 Protein MEMO1 -1.431 0.026 
Q61191 Host cell factor 1 -1.426 0.009 
P97470 
Serine/threonine-protein phosphatase 4 catalytic 
subunit 
-1.425 0.047 
Q9QZB7 Actin-related protein 10 -1.381 0.010 
Q91WG0 Acylcarnitine hydrolase -1.371 <0.0001 
Q60715 Prolyl 4-hydroxylase subunit alpha-1 -1.329 0.032 
Q9Z0H3 
SWI/SNF-related matrix-associated actin-




Arf-GAP with SH3 domain, ANK repeat and 






Q3UL36 Arginine and glutamate-rich protein 1 -1.242 0.014 
Q7TSG5 SH3 domain-containing protein 21 -1.240 0.033 
P22907 Porphobilinogen deaminase -1.238 0.041 
Q9CZ13 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
-1.231 0.046 
Q8CHP5 Partner of Y14 and mago -1.207 0.009 
Q6P8X1 Sorting nexin-6 -1.203 0.047 
P28654 Decorin -1.202 0.015 
Q9CS42 Ribose-phosphate pyrophosphokinase 2 -1.187 <0.0001 
Q8BP92 Reticulocalbin-2 -1.151 0.029 
Q91WV0 Protein Dr1 -1.137 0.005 
Q9QYR9 Acyl-coenzyme A thioesterase 2, mitochondrial -1.129 0.018 
P61087 Ubiquitin-conjugating enzyme E2 K -1.118 0.047 
P20918 Plasminogen -1.117 0.015 
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P59235 Nucleoporin Nup43 -1.101 0.047 
P62737 Actin, aortic smooth muscle -1.080 0.050 
Q8VI75 Importin-4 -1.056 0.009 
P21614 Vitamin D-binding protein -1.052 0.001 
Q62426 Cystatin-B -1.038 0.005 
Q9R0Y5 Adenylate kinase isoenzyme 1 -1.012 0.036 
P12815 Programmed cell death protein 6 -1.008 0.047 
O35841 Apoptosis inhibitor 5 -0.986 0.002 
Q9CQA3 
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial 
-0.973 0.001 
Q99MR8 
Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial 
-0.950 0.002 
Q9JJF0 Nucleosome assembly protein 1-like 5 -0.938 0.032 
Q64133 Amine oxidase [flavin-containing] A -0.925 0.019 
Q9D8S4 Oligoribonuclease, mitochondrial -0.905 0.031 
Q62523 Zyxin -0.901 0.013 
Q8R1I1 Cytochrome b-c1 complex subunit 9 -0.877 0.023 
P01027 Complement C3 -0.872 0.035 
Q9D358 







Q1HFZ0 tRNA (cytosine(34)-C(5))-methyltransferase -0.851 0.004 






Prolow-density lipoprotein receptor-related 
protein 1 
-0.832 0.030 
Q9CT10 Ran-binding protein 3 -0.830 0.006 
P19001 Keratin, type I cytoskeletal 19 -0.815 0.009 
Q64105 Sepiapterin reductase -0.803 0.041 
Q3THS6 S-adenosylmethionine synthase isoform type-2 -0.791 0.046 
P97372 Proteasome activator complex subunit 2 -0.790 0.043 
Q6PE01 
U5 small nuclear ribonucleoprotein 40 kDa 
protein 
-0.789 0.009 
Q8VCM7 Fibrinogen gamma chain -0.779 0.036 
P45377 Aldose reductase-related protein 2 -0.778 0.043 
Q9JKB3 Y-box-binding protein 3 -0.770 0.010 
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P70288 Histone deacetylase 2 -0.748 0.004 
O54890 Integrin beta-3 -0.746 0.024 
Q99L04 
Dehydrogenase/reductase SDR family member 
1 
-0.739 0.039 
Q8CHY7 Tetratricopeptide repeat protein 23 -0.697 0.041 
Q6PDG5 SWI/SNF complex subunit SMARCC2 -0.669 0.042 
Q9CR00 
26S proteasome non-ATPase regulatory subunit 
9 
-0.669 0.009 
Q60598 Src substrate cortactin -0.654 0.021 
P62835 Ras-related protein Rap-1A -0.618 0.036 
P62267 40S ribosomal protein S23 -0.565 0.008 
P47753 F-actin-capping protein subunit alpha-1 -0.565 0.022 
F6ZDS4 Nucleoprotein TPR -0.535 0.038 
Q9ESZ8 General transcription factor II-I -0.526 0.048 
Q62005 Zona pellucida sperm-binding protein 1 -0.526 0.050 
Q9D0J8 Parathymosin -0.524 0.015 
Q8BVY0 Ribosomal L1 domain-containing protein 1 -0.503 0.044 
Q9CXT8 
Mitochondrial-processing peptidase subunit 
beta 
-0.499 0.048 
P62996 Transformer-2 protein homolog beta -0.421 0.026 
Q9DBL1 
Short/branched chain specific acyl-CoA 
dehydrogenase, mitochondrial 
-0.413 0.041 
P49615 Cyclin-dependent-like kinase 5 -0.396 0.015 
Q62432 Mothers against decapentaplegic homolog 2 -0.390 0.043 
Q8BHG1 Nardilysin -0.330 0.006 
P14152 Malate dehydrogenase, cytoplasmic -0.276 0.025 
O55135 Eukaryotic translation initiation factor 6 0.490 0.037 
P02088 Hemoglobin subunit beta-1 0.545 0.011 
Q6ZWY3 40S ribosomal protein S27-like 0.573 0.035 
Q80UM3 
N-alpha-acetyltransferase 15, NatA auxiliary 
subunit 
0.592 0.035 
P10630 Eukaryotic initiation factor 4A-II 0.606 0.034 
Q64213 Splicing factor 1 0.617 0.049 
Q80W21 Glutathione S-transferase Mu 7 0.695 0.016 
Q9CY64 Biliverdin reductase A 0.782 0.010 
O55013 Trafficking protein particle complex subunit 3 0.782 0.017 
P61750 ADP-ribosylation factor 4 0.797 0.047 
P63085 Mitogen-activated protein kinase 1 0.876 0.008 
P55096 ATP-binding cassette sub-family D member 3 0.895 0.035 
Q8K3C3 Protein LZIC 0.933 0.021 




containing protein 2A 
0.954 0.047 
P54775 26S proteasome regulatory subunit 6B 0.969 0.005 
Q6NZC7 SEC23-interacting protein 1.059 0.020 
Q8BMJ2 Leucine--tRNA ligase, cytoplasmic 1.123 0.022 
Q8VCR7 Protein ABHD14B 1.156 0.044 
Q9QXT0 Protein canopy homolog 2 1.183 <0.0001 
Q9D8Y0 EF-hand domain-containing protein D2 1.188 0.042 





Q9EQS3 c-Myc-binding protein 1.200 0.009 
Q9EPL8 Importin-7 1.244 0.017 
P20060 Beta-hexosaminidase subunit beta 1.274 0.021 
Q91YR1 Twinfilin-1 1.283 0.028 
Q3UKJ7 WD40 repeat-containing protein SMU1 1.337 0.037 
Q99PV0 Pre-mRNA-processing-splicing factor 8 1.351 0.005 
P51881 ADP/ATP translocase 2 1.480 0.011 
Q4VA53 




Iron-sulfur cluster assembly enzyme ISCU, 
mitochondrial 
1.509 0.020 
O88447 Kinesin light chain 1 1.552 0.034 
P98078 Disabled homolog 2 1.562 0.001 
Q99KF1 
Transmembrane emp24 domain-containing 
protein 9 
1.604 0.018 
O70310 Glycylpeptide N-tetradecanoyltransferase 1 1.608 0.022 
P15532 Nucleoside diphosphate kinase A 1.673 0.001 
P61759 Prefoldin subunit 3 1.676 0.027 
Q91ZJ5 UTP--glucose-1-phosphate uridylyltransferase 1.698 0.044 
Q9D287 Pre-mRNA-splicing factor SPF27 1.721 0.014 
Q99K51 Plastin-3 1.769 0.025 
Q91YE6 Importin-9 1.832 0.038 
Q9DAW9 Calponin-3 1.856 0.005 
Q9R013 Cathepsin F 1.865 0.001 
P54823 Probable ATP-dependent RNA helicase DDX6 1.894 0.007 
Q9D6J6 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
1.944 0.006 
Q8CHP8 Glycerol-3-phosphate phosphatase 2.002 0.017 
P83917 Chromobox protein homolog 1 2.006 0.003 
P99024 Tubulin beta-5 chain 2.013 0.013 
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O88587 Catechol O-methyltransferase 2.086 0.049 
P17047 Lysosome-associated membrane glycoprotein 2 2.164 0.009 
P03953 Complement factor D 2.395 0.015 
Q62219 
Transforming growth factor beta-1-induced 
transcript 1 protein 
2.404 0.024 
Q02248 Catenin beta-1 2.464 0.019 
Q91ZW3 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A 
member 5 
2.475 0.003 
Q9CQ19 Myosin regulatory light polypeptide 9 2.524 0.008 
Q8R5J9 PRA1 family protein 3 3.095 0.001 
Q3TCH7 Cullin-4A 3.164 0.011 
Q8K124 
Pleckstrin homology domain-containing family 
O member 2 
3.369 <0.0001 
Q8BMF3 NADP-dependent malic enzyme, mitochondrial 3.380 0.003 
Q9CPT4 Myeloid-derived growth factor 4.064 <0.0001 


























Supplemental Figure 1.  Technical control for immunofluorescence staining.  
Ovaries from an adult mouse were immunologically stained using only the secondary 
antibody appropriate for (A) ATM; (B) BRCA1; (C) CASP3; (D) CYCS; (E) CYFIP1; 




























Supplemental Figure 2.  Effects of Atm+/- deficiency on body weight and subsequent 
PM exposure on organ weights. (A) Body weight measured prior to i.p. dosing with 
vehicle-control or PM; (B) Heart; (C) Liver; (D) Spleen; (E) Kidney; (F) Uterus; and (G) 
Ovary weights collected three days post-injection with vehicle-control or PM.  Values 
expressed as mean ± SEM; n = 3 per genotype/treatment.  Significant difference indicated 























Supplemental Figure 3. Effect of Atm deficiency and/or PM exposure on DNA 
damage markers.  Primary antibodies directed against (A) H2AX; and (B) BRCA1 were 
used to determine ovarian localization in WT CT; WT PM; Atm
+/-
 CT; and Atm
+/- 
PM.  
Green staining indicates the protein of interest while cellular DNA is stained in blue; 
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Supplemental Figure 4.  Functional classification and KEGG pathway analysis of 
proteins identified by LC-MS/MS.  Atm+/- mice after PM relative to WT after PM or 
Atm+/- mice after vehicle-control relative to WT after vehicle-control (A) Biological 
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Normal granulosa cell communication and development is critical for cell 
differentiation and oocyte maturation, and the ovarian gap junction protein connexin 43 
(CX43) facilitates cell communication between granulosa cells.  We have discovered that 
gestational diabetes mellitus (GDM) exposure in utero and successive dietary challenge 
decreases healthy follicle populations in the ovary of the female mouse in addition to 
altering the ovarian proteome.  We hypothesized that the abundance of ovarian CX43 
would be decreased as a result from in utero GDM exposure and the added insult of a 
HFHS diet later in life.  A HFHS challenge in the absence of maternal GDM (DLPH) and 
maternal GDM in the absence of a dietary stress (DHPL) did not alter CX43 expression in 
the offspring ovary.  In contrast, a significant (P < 0.01) decrease in CX43 expression in 
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the offspring ovaries due to dietary challenge and exposure to maternal GDM in utero 
(DHPH) was observed.  Additionally, we hypothesized that hyperphagia-induced obesity 
would alter ovarian CX43 abundance to contribute to obesity-induced ovarian dysfunction.   
There was a substantial decrease (P < 0.01) in CX43 abundance in the ovary from the obese 
mouse when compared to lean controls.  Taken together, these findings demonstrate that 
changes in metabolism may impact ovarian CX43 abundance, indicating the importance of 
CX43 in follicular and oocyte health.  
 
Keywords: gap junction, ovary, gestational diabetes, obesity 
 
Introduction 
The female gamete, the oocyte, is surrounded by granulosa cells in a follicular 
structure.  To sustain follicular viability, there must be a source of nutrients and/or 
communication between granulosa cells and also between granulosa cells and the oocyte. 
Gap junctions (GJ) facilitate bidirectional communication between follicular cells (Eppig 
et al., 1996) and are membrane channels that enable the exchange of ions, metabolites, 
nucleotides, and secondary messengers between cells via a contact dependent mechanism 
(Goldberg et al., 2004).  Ovarian GJ function to transfer amino acids, glucose metabolites 
and nucleotides to the growing oocyte (Eppig, 1991) and have a role in regulating meiosis 
in the mature oocyte (Granot and Dekel, 1994, Downs, 1995, Byskov et al., 1997). 
Composed of connexons, a ring of six connexin (CX) proteins embedded within 
the plasma membrane, the GJ docks with another connexon in an adjacent cell, forming an 
intercellular channel, which is subject to functional regulation dependent on protein 
isoform or post-translational modifications (Winterhager and Kidder, 2015, Clarke, 2017).  
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The CX protein family has 20 members in mice and 21 in humans, and localization of 
specific CX can be used to identify GJ in various tissues (Sohl and Willecke, 2003).  There 
are eight identified CX proteins ovarian and their abundance varies in a species-specific 
manner.  In the rodent model, Gjb1/Cx32, Gja4/Cx37, Gja1/Cx43, Gjc1/Cx45, and 
Gja10/Cx62 have been characterized in the ovary (Kidder and Mhawi, 2002).   
GJA1/CX43 is an important GJ protein for communication between granulosa cells 
and is required for proper folliculogenesis (Ackert et al., 2001). Loss of function in the 
Gja1 gene is postnatally lethal due to a severe cardiac defect (Juneja et al., 1999), and 
though the Gja1-/- fetus has some germ cells (Juneja et al., 1999), the absence of Gja1 
arrests folliculogenesis prior to the formation of multilaminar follicles, with negative 
impacts on oocyte growth, resulting in smaller oocyte diameters (Ackert et al., 2001).   
Obesity is a metabolic disorder that predisposes individuals for multiple health 
conditions, and in the overweight or obese female, reproductive complications include poor 
oocyte quality (Metwally et al., 2007), decreased fertility (Brewer and Balen, 2010), 
polycystic ovary syndrome (PCOS) (Dravecka et al., 2003), and gestational diabetes 
mellitus (GDM) (Chu et al., 2007).  Metabolic changes that occur during obesity negatively 
impact ovarian function and increase the insulin-responsive phosphatidylinositol 3-kinase 
(PI3K) pathway (Nteeba et al., 2013), promote inflammation (Nteeba et al., 2014b), reduce 
primordial and primary follicle numbers (Nteeba et al., 2014b), increase basal DNA 
damage and attenuate the DNA damage response (Nteeba et al., 2017, Nteeba et al., 2014a, 
Ganesan et al., 2017, Ganesan et al., 2015, Ganesan et al., 2014), and alter steroid hormone 
biosynthesis (Nteeba et al., 2017).  We and others have demonstrated that Cx43 mRNA 
and/or protein levels decrease during obesity in cardiac tissue in mice (Noyan-Ashraf et 
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al., 2013), uterine tissue in rats (Elmes et al., 2011), and in the ovary after 7,12-
dimethylbenz[a]anthracene (DMBA) exposure (Ganesan and Keating, 2014) as well as 
during obesity at 18 and 24 weeks of age (Ganesan et al., 2015).   
Connexin proteins are also altered in both type 1 and type 2 diabetes.  Decreased 
CX43 abundance is observed in the kidneys (Zhang et al., 2006), retinal pericytes (Li et 
al., 2003), microvascular endothelial cells (Sato et al., 2002), penile corpora (Pointis, 
2006), and epidermis (Wang et al., 2007) of hyperglycemic animal models.  In Type 1 
diabetic mice, CX43 protein level was decreased in cumulus enclosed oocytes (CEOs) from 
antral follicles (Chang et al., 2005).  While pre-gestational obesity and/or insulin resistance 
is a major risk factor for a woman developing gestational diabetes mellitus (GDM), 
interestingly, around a third of GDM cases occur in lean women (Blickstein et al., 2018).  
Offspring from lean GDM dams (Pennington et al., 2017) were challenged during 
adulthood with a high-fat high-sucrose diet and had increased body weight, higher body 
fat percentage and increased adipose insulin sensitivity (Talton et al., 2019). In the female 
offspring, reduced healthy follicle numbers and an altered ovarian proteome were 
demonstrated, suggesting long-term effects on oocyte quality and fertility (Clark et al., 
2019).  Since obesity and Type-1/2 diabetes affects mRNA abundance encoding the Cx43 
gene and CX43 protein abundance in various tissue types, we hypothesized that GDM 
would impact ovarian CX43 abundance and localization both basally and in response to a 
high-fat, high-sucrose diet in adulthood. Additionally, we hypothesized that hyperphagia-
induced obesity would alter ovarian CX43 abundance to contribute to obesity-induced 
ovarian dysfunction.    
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Material and Methods 
Animal procedures and tissue collection 
 In utero GDM model: Ovarian tissue from female mice exposed to GDM in utero 
utilized in this study was obtained as part of a larger study (Clark et al., 2019, Talton et al., 
2019).  Briefly, GDM was induced in female C57B16/J (Jackson Laboratories; n = 14) 
mice by feeding a high-fat, high- sucrose (HFHS) diet one week prior to mating and 
throughout gestation, for a total of 4 weeks (Pennington et al., 2017, Talton et al., 2019).  
Control female C57B16/J mice (n = 20) were fed a chow breeder diet throughout the 
duration of the study.  Female offspring from each litter (control – n = 30; GDM – n = 16) 
were maintained on a chow breeder diet, until 23 weeks of age, at which point 1-2 females 
from each litter were fed a HFHS diet until 31 weeks of age.  Briefly, DLPL were lean dams 
and control diet pups; DLPH were lean dams and HFHS pups; DHPL were HFHS dams and 
control diet pups and DHPH were HFHS dams and HFHS pups.  Ovaries were collected and 
ovaries were fixed in 4% paraformaldehyde and stored in 70% ethanol prior to histological 
processing.   
Adult obese model: Female wild-type normal non-agouti (a/a; n = 6; designated 
lean) and agouti lethal yellow  (KK.Cg-Ay/J mice; n = 6; designated obese) were purchased 
from Jackson Laboratory (Bar Harbor, ME) and maintained in an animal facility at Iowa 
State University under controlled room temperature (21°C-22°C) and lighting (12hr 
light:12hr dark) with ad libitum access to food and water.  At 10 weeks of age, mice were 
euthanized in the pro-estrus phase of the estrous cycle.  Ovaries were fixed in 4% 
paraformaldehyde overnight at 4°C for histological analysis.   
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All animal procedures were approved by the University of Missouri or the Iowa 
State University Institutional Animal Care and Use Committee and handled according to 
National Institutes of Health Guide for Care and Use of Laboratory Animals. 
 
Histology 
After fixation, ovaries were paraffin embedded or passed through a 10%, 
20%/0.1M PBS gradient for 1-3 hours each at room temperature, followed by 30% 
sucrose/0.1M PBS overnight at 4°C and embedded in optimal cutting temperature (OCT) 
compound before being flash frozen on dry ice.  Ovaries from GDM offspring were 
sectioned at 5 µm on a rotary microtome (AO Spencer 820) and ovaries from lean and 
obese mice sectioned at 7 µm on a cryostat (Leica CM1850) and mounted onto glass slides.  
 
Immunofluorescence  
Slides were deparaffinized in Citrisolv and rehydrated in washes of ethanol (100%, 
95%, 75%), followed by one wash in ddH2O.  Heat-mediated antigen retrieval was 
performed using citrate buffer (10 mM citric acid, 0.5% Tween20, pH 6.0) by heating in a 
microwave for 22 min. Tissue sections were encircled with a histology pap pen (Vector 
Laboratories) to keep liquid concentrated on the tissue during processing, followed by the 
application of blocking solution (0.1M PBS/0.4% BSA/0.2% Tween20/2.5% goat serum) 
to the slides for 1 hour at room temperature.  For frozen tissue, slides were warmed briefly 
on a 37°C slide warmer and tissue encircled with a histology pap pen to maintain solutions 
concentrated on the tissue during processing.  Tissue was rehydrated and permeabilized in 
0.1M PBS with 0.1% Tween20 (PBSTw) for 20 min, followed by serum blocking (0.1M 
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PBS/1% BSA/1% DMSO/5% goat serum) for 60 min at room temperature.  Primary 
antibody directed against anti-rabbit CX43 (1:100; ab11370; Abcam) was diluted in fresh 
blocking solution, applied to the tissue sections, and incubated in a humidified box at 4°C 
overnight.  After primary antibody incubation, slides were washed three times in PBSTw 
for 10 min per wash.  Tissue sections were incubated in goat anti-rabbit Alexa Flour 488 
(1:500; A11008; Invitrogen) and incubated at room temperature for 60 min, followed by 
four washes in PBSTw for 10 min per wash.  Slides were air dried, followed by addition 
of Vectashield with DAPI (H1200, Vector Labs) and cured overnight at 4°C.  Negative 
technical controls to confirm specificity were performed using secondary antibodies alone.  
Images were captured on a Zeiss LSM700 confocal microscope equipped with an AxioCam 
MRc5 using a 20x objective.   
 
Quantification of protein abundance 
 For quantification of CX43 immunoreactivity, the total image area threshold 
measures in granulosa cells of antral follicles from the GDM study (n = 4 ovaries per 
treatment; 3 follicles per ovary) and hyperphagia-induced obesity study (n = 6 ovaries per 
treatment; 3 follicles per ovary) were analyzed using ImageJ (Schneider et al., 2012).    
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism 7.0 two-way ANOVA 
function for comparison of more than two treatments, comparing treatment with control or 
unpaired t-tests when two treatments were compared.  Values are expressed as mean ± 
SEM, P < 0.05.   
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Results 
Effects of in utero GDM exposure on ovarian localization of CX43  
CX43 immunoreactivity was observed in the granulosa cells of primary, secondary, 
and antral follicles (Figure 1A-C) from ovaries of female mice that were fed a HFHS for 
8 weeks (DLPH), in the ovaries of female mice that were subjected to GDM during fetal 
development (DHPL), in offspring ovaries that experienced GDM exposure during 
development and received a HFHS in adulthood (DHPH), and the control offspring who 
were not exposed to either treatment (DLPL).  Positive CX43 immunostaining was also 
present in the granulosa lutein cells of the corpus luteum (Figure 1D), though was not 
present in squamous cells surrounding the primordial follicles.   
 
Impact of hyperphagia-induced obesity on ovarian CX43 localization 
Positive CX43 immunofluorescence staining was observed in granulosa cells in 
primary follicles, secondary follicles, antral follicles, and the granulosa lutein cells of the 
corpus luteum in the lean and the obese ovaries (Figure 2B-E).  There was no CX43 
immunostaining detected in the squamous follicular cells of primordial follicles (Figure 
2A).   
 
Impact of in utero GDM exposure on ovarian CX43 protein abundance  
To determine if in utero exposure to GDM and/or dietary stressor later in life had 
an impact on CX43 abundance, fluorescence intensity was measured in the granulosa cells 
of the antral follicles.  In the ovaries of mice exposed to only a HFHS diet in adulthood 
(DLPH) or only GDM in utero (DHPL), there were no differences in CX43 abundance in the 
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granulosa cells of antral follicles relative to controls not exposed to GDM or a dietary 
stressor (Figure 3A-C, 3F).  An additive effect of dietary stress in later life (DHPH) reduced 
(P = 0.002) CX43 intensity in the granulosa cells of the antral follicles from ovaries of the 
offspring exposed to GDM in utero (Figure 3D,F).   
 
Effects of hyperphagia-induced obesity on ovarian CX43 protein abundance 
To determine if hyperphagia-induced obesity affected CX43 abundance, 
fluorescence intensity was measured in the granulosa cells of the antral follicles.  
Hyperphagia-induced obesity resulted in a decrease (P = 0.006) in CX43 immunoreactivity 
in the granulosa cells of the antral follicles with respect to the lean control mice (Figure 
4A-B,D).   
 
Discussion 
Diet-induced obesity (DIO) models effectively mimic the gradual weight gain of 
humans, with the subtle accumulation of fat over a period of time.  Metabolic consequences 
of a high-fat diet (HFD) become apparent after only a few days (Williams et al., 2014).  
CX43 protein is documented to vary in response to DIO: a HFD reduced CX43 abundance 
in atrial myocytes (Meng et al., 2017). In addition, uterine CX43 was reduced in HFD-fed 
relative to control diet-fed rats, and differences are apparent depending on whether the 
animal is experiencing parturition or not (Muir et al., 2016).  In a model of adipocyte-
specific Gja1 knockdown, mice fed a HFD gained weight similarly as the wild-type (WT) 
fed the HFD over an 8 week time period, but demonstrated insulin resistance unlike their 
WT counterparts (Kim et al., 2017), implying some involvement of CX43 in metabolic 
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regulation. Conversely, CX43 protein is increased in the kidney glomerulus during DIO in 
rats (Zhao et al., 2018). Thus, there are tissue-specific differences in the response and 
evidence for an effect of DIO on abundance of the CX43 protein.  
Changes in CX43 that are associated with diabetes include increased protein in 
vascular endothelial cells (VECs) (Dlugosova et al., 2009), smooth muscle cells (SMCs) 
(Alonso et al., 2010), myocytes (Howarth et al., 2008), sinoatrial node (Howarth et al., 
2007), bladder detrusor muscle (Suadicani et al., 2009), and in the dermis after injury (Qiu 
et al., 2003, Wang et al., 2007).  Conversely, CX43 levels are decreased in the SMCs of 
post-glomerular arterioles and mesangial cells in the diabetic kidney (Takenaka et al., 2011, 
Dronavalli, 2008), retinal pericytes and microvascular endothelial cells of the retina (Li et 
al., 2003, Fernandes et al., 2004), penile corpora (Pointis, 2006), and epidermis during 
wound healing (Kamibayashi et al., 1993).   
The continuous rise of obesity in the global population has detrimental effects on 
the reproductive health of women and young girls including primary ovarian insufficiency 
(Shrestha et al., 2011), polycystic ovary syndrome (PCOS) (Dravecka et al., 2003), poor 
oocyte quality (Metwally et al., 2007), and decreased fecundity (Brewer and Balen, 2010). 
Ovarian folliculogenesis is regulated by a series of extrinsic and intrinsic signaling 
pathways, with definite roles for intraovarian gap junctions in oocyte development and 
maturation (Kidder and Mhawi, 2002).  CX43 is one of the major ovarian gap junction 
proteins, and is essential for folliculogenesis, with Cx43-null ovaries having arrested 
follicle maturation and reduced oocyte growth (Ackert et al., 2001, Gittens et al., 2005).  
Additionally, in chimeric ovary studies that paired wild-type (WT) oocytes with Cx43 
deficient somatic cells and Cx43 deficient oocytes with WT granulosa cells, fertilization 
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could be achieved in Cx43 null oocytes supported by WT granulosa cells. In ovaries 
containing the Cx43-/- granulosa cells and WT oocytes, however, follicles halted at 
preantral stages and had smaller oocytes (Gittens et al., 2005, Gittens and Kidder, 2005).  
These functional studies provide strong support for the importance of CX43-mediated 
GJIC between granulosa cells in promoting follicular maturation. In the ovary of a Type 1 
diabetic mouse model, CX43 protein level is decreased in cumulus enclosed oocytes 
(CEOs) derived from antral follicles (Chang et al., 2005). In this study, increased CX43 
abundance was observed in granulosa cells of follicles as they mature, consistent with the 
requirements of intercellular communication for follicle growth and development as it 
prepares for ovulation (Eppig, 1991, Eppig et al., 1996).   
Gap junction proteins are subject to hormonal regulation in the ovary and their 
abundance is dynamic throughout the estrous cycle. Estradiol (E2) increases Gja1 mRNA 
and stimulates GJ formation, while an inhibitory effect occurs with progesterone (P4) (Lye 
et al., 1993, Karasinski et al., 2010).  Follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) also impact GJs, with FSH increasing Gja1 mRNA and protein expression 
as follicle size enlarges (Valdimarsson et al., 1993, Beyer et al., 1989, Okuma et al., 1996, 
Fang et al., 2015) and LH suppressing Gja1 mRNA and protein abundance (El-Hayek and 
Clarke, 2015, Granot and Dekel, 1994, Granot and Dekel, 1998, Khan-Dawood et al., 
1998).   
Considering impacts of obesity and/or diabetes on CX43 protein abundance, we 
sought to define whether this was also the case in the ovary.  To investigate this posit, two 
different models of obesity were employed. The first is the ovaries from offspring who 
experienced GDM in utero in the absence of maternal obesity (Talton et al., 2019) and who 
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also were challenged with a high fat high sugar (HFHS) diet in adulthood. The second 
model used ovaries from adult mice who experienced hyperphagia-induced obesity.  
Our group has recently described the impacts of lean in utero GDM on the offspring 
ovary as well as a dietary stressor later in life, which include reduced numbers of pre-antral 
follicles and an altered ovarian proteome (Clark et al., 2019). This model allowed us to 
investigate the underlying effects of maternal GDM without additive effects of maternal 
obesity on oocyte quality or development.  Exposure to metabolic events such as diabetes 
during pregnancy predispose both the mother (Bellamy et al., 2009, Kim, 2014) and 
offspring (Vohr and Boney, 2008) to type 2 diabetes later in life, furthered by obesity 
(Nehring et al., 2013) and hypoglycemia (Gasim, 2012) in the offspring.  Offspring that 
were exposed to our model of GDM in utero and later on challenged with the HFHS diet 
had increased body weight, higher body fat percentage, and increased adipose insulin 
sensitivity (Talton et al., 2019).  We discovered that neither a HFHS diet nor GDM 
exposure alone affected CX43 protein abundance in antral follicles relative to the WT 
control. Interestingly, however, the two-hit stress of in utero GDM coupled with HFHS 
diet consumption in adulthood considerably reduced antral follicle CX43 protein 
abundance.  The mice were aged 31 weeks and we have previously determined that aging 
contributes to a decline in CX43 protein abundance (Ganesan et al., 2015), however, these 
were compared to age-matched control females.  Additionally, we had previously 
determined that GDM exposure and/or dietary stress does not result in increased apoptosis 
within the follicle (Clark et al., 2019), so the reduced levels of CX43 in the antral follicles 
are not attributable to a reduction in antral follicle number or viability.  Additional 
experiments utilizing this same model at earlier timepoints would be beneficial in further 
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deciphering effects of GDM in sensitizing the offspring ovary to metabolic stressors later 
in life, resulting in potential negative impacts on fertility through a breakdown on GJ 
proteins and GJIC in the absence of advanced age.   
The GDM model was designed to elucidate the effects of diabetes in the absence of 
obesity, and we also utilized a model in which the confounding effects of differing diets 
was absent. The lethal yellow mouse has a mutation which results in hypothalamic agouti 
overexpression, leading to hyperphagia due to altered alpha-melanocyte stimulating 
hormone and cocaine- and amphetamine regulated (Lu et al., 1994).  We have previously 
determined that progressive obesity using this model as well as aging in lean and obese 
mice reduces both Cx43 mRNA and protein levels (Ganesan et al., 2015) but have not 
examined the effects of obesity on CX43 at a time point of prime reproductive status.  We 
have determined that, as early as 10 weeks, CX43 protein levels are markedly decreased 
due to obesity without any additive effects from dietary content.  Similar to ovaries subject 
to GDM in utero, we observed no difference in numbers of cells marked for apoptosis 
(Clark et al, under review), indicating that reduced CX43 expression in the hyperphagia-
induced obese model is not simply due to increased amounts of granulosa cell death.   
 
Conclusions 
These findings demonstrate the impact of obesity and altered metabolic 
programming on ovarian CX43 abundance. While it remains to be determined how this 
observation may impact fertility, decreased levels of CX43 protein in ovaries exposed to 
the metabolic changes that occur during obesity or GDM exposure in utero may indicate 
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an early target for improving ovarian function and underscore the importance of CX43 for 
follicular and oocyte health.   
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Figures and Figure Legends 
  
Figure 1: Localization of CX43 in the 31-week-old ovary.  (A) primary; (B) secondary; 
(C) antral follicles; and (D) corpus luteum.  Green staining indicates CX43 while cellular 
DNA is stained in blue.  Scale bar = 50 µm 
 
Figure 1: Localization of CX43 in the 31-week-old ovary.  Immunofluorescence staining 
to detect CX43 location and abundance was performed. Positive staining in (A) primary; 
(B) secondary; (C) antral follicles; and (D) corpus luteum are presented.  Green staining 
indicates CX43 while cellular DNA is stained in blue. Arrows indicate CX43 positive 


























Figure 2: Localization of CX43 in the 10-week-old ovary.  The localization and 
abundance of CX43 in (A) primordial; (B) primary; (C) secondary; (D) antral follicles; and 
(E) corpus luteum was determined using immunofluorescence staining.  Green staining 
indicates CX43 while cellular DNA is stained in blue.  Arrows indicate CX43 positive 



























Figure 3: Effect of GDM and/or dietary stress on ovarian CX43. The abundance and 
location of CX43 protein in (A) DLPL; (B) DHPL; (C) DLPH; (D) DHPH mice was 
investigated using immunofluorescence staining. (E) Secondary antibody only control 
panel. Green staining indicates CX43 while cellular DNA is stained in blue. Arrows 
indicate CX43 positive staining. Asterix indicates oocyte. (F) The bars represent relative 



























Figure 4: Effect of hyperphagia-induced obesity on ovarian CX43. Using ovaries 
from (A) Lean or (B) Obese mice, immunofluorescence staining was utilized to 
determine CX43 protein localization and abundance. Panel C  illustrates the ovary in 
which only the secondary antibody was used in the staining procedure.  Green staining 
indicates CX43 while cellular DNA is stained in blue. Arrows indicate CX43 positive 
staining. Asterix indicates oocyte. (D) The bars represent relative total fluorescence 














CHAPTER 6. GENERAL CONCLUSIONS 
Dissertation Summary 
 The studies conducted in this dissertation demonstrate the impacts of stressors such 
as obesity, in utero exposure to gestational diabetes, and chemotherapeutic drug 
administration on the ovarian proteome as well as on the ovarian DNA damage response.  
This work is relevant to the field of women’s reproductive health and medicine, lending 
more insight into the dynamics of the molecular mechanisms that govern ovarian 
physiology and providing potentially novel targets to aid in planning or procedures that can 
help lessen the effects of harmful events to the germline and/or maternal health.   
 In chapter 2, we investigated the impacts of in utero gestational diabetes exposure 
on the ovaries from the adult offspring, some of which were subsequently challenged with 
a high-fat, high-sucrose diet later in life.  Previous work by our group  has determined that 
the metabolic alterations that occur during obesity such as hyperinsulinemia and 
hyperleptinemia have negative impacts on ovarian function [1-7], therefore, we 
hypothesized that the metabolic changes that occur during GDM in the absence of obesity 
would compromise ovarian function in the offspring both basally and in response to an 
environmental stressor later in life.  The goal of this project was to determine what, if any, 
alterations occurred in the ovary, such as impacts on folliculogenesis, DNA damage, 
apoptosis, and changes in the ovarian proteome.  Our results demonstrated that the two-hit 
stress model of GDM exposure in utero and later exposure to a HFHS diet in adulthood 
reduced follicle numbers relative to the age-matched control mice.  The ovarian proteome 
was altered in all of the treatment groups from this study, though most significantly in the 
ovaries from offspring exposed to GDM in utero regardless of dietary challenge.  
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Interestingly, these metabolic alterations did not evoke a substantial DNA damage or 
apoptotic response in the ovary.  The findings from this study illustrate that in utero 
exposure to GDM sensitizes the offspring ovary to an environmental stressor later in life, 
highlighting potential long-term effects to the health of the offspring in the presence of a 
metabolic event during development, potentially contributing to fertility issues and oocyte 
quality and laying the foundation for the developmental origin of ovarian disorder.   
 In chapter 3, we furthered our investigation of the impacts of a metabolic state on 
the ovary, focusing more on the DNA damage response during obesity.  Utilizing a model 
of hyperphagia-induced obesity, we hypothesized that the DNA damage response would 
be altered during obesity.  Our results discovered elevated levels of ATM in the oocytes 
from the obese mouse and increased amounts of γH2AX-positive cells in the ovary, 
indicating a low-level DNA response.  Though other markers of the DNA damage response 
such as cleaved-caspase 3, BRCA1, and phospho-specific markers of BRCA1 and ATM 
were not increased globally, there were responses observed that were specific to follicle 
size.   Additionally, the proteins CNPY2 and DAZAP1 that were identified in the proteomic 
study from offspring exposed to GDM in utero and a HFHS diet were not altered in our 
10-week-old obese model.  The data from this study illustrates that obesity elicits a 
universal DNA damage response from the ovary as well as a follicle stage-specific 
response.  This provides rationale for the consideration of utilizing markers of the DNA 
damage response in diagnosis of ovarian health as well as the diagnosis and prevention of 
obesity-related reproductive disorders.     
 Based upon the findings described in chapter 4, we sought to further elucidate the 
molecular aspects of ATM-mediated DNA damage repair initiation.  Previous work by our 
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group had determined that after chemical exposure, the DNA damage response was active 
within 24 hours of exposure [8-11], and that inhibition of the key transducer ATM resulted 
in the retention of follicles after chemical exposure, potentially contributing to germline 
DNA damage [11].  From this, we hypothesized that the DNA damage response is blunted 
in Atm-deficient mice, and that unhealthy follicles that would normally be triggered for 
repair and/or apoptosis remain, resulting in impaired fertility and increased amounts of 
retained DNA damage.  The results determined that Atm deficiency results in fewer 
follicles basally, but no substantial follicle loss is observed between PM-exposed Atm+/- 
mice and Atm+/- controls, indicative of irregular activity in the DNA repair pathway.  
Moreover, the altered abundance of ovarian proteins during Atm deficiency highlights the 
critical interactions relative to DNA damage repair and the maintenance of genomic 
stability.  These findings demonstrate the role of ATM in ovarian DNA repair and perhaps 
follicular atresia, indicating the importance of the pathway in response to a genotoxic 
stress.   
 Finally, in chapter 5, we examined the impacts of metabolic disorder on abundance 
of a gap junction protein, connexin-43 (CX43) in the ovary.  Our previous finding that in 
utero GDM exposure and subsequent dietary challenge reduces healthy follicle numbers in 
the ovary [12] led to the hypothesis that abundance of CX43 would be decreased in this 
two-hit stress model.  Additionally, using our model of hyperphagia-induced obesity, we 
hypothesized that CX43 abundance would decrease thus contributing to obesity-induced 
ovarian dysfunction.  In both models, a decrease in CX43 abundance was observed in the 
antral follicles of the treatment ovaries relative to their respective controls.  Together, these 
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findings demonstrate that changes in central metabolism impact CX43 abundance in the 
ovary with implications in follicular and oocyte health.   
 Albeit this work provides novel and interesting information on female reproductive 
function and health, it does meet with some limitations, most importantly that this research 
was performed in a rodent model and translation to other species, including humans, may 
not be coextensive.  In the second chapter, we observed a decline in follicle numbers in our 
two-hit stress model, but age of the animals is a possible confounding factor to the study.  
Additionally, mice were not euthanized at the same stage of the estrous cycle as the ovaries 
were collected as a secondary and not the primary endpoint of interest.  For this reason, we 
omitted antral follicle counts as we acknowledge that variation in the estrous cycle could 
have impacted this data.  In chapter 3, four of the ten mice in the obese group were removed 
from the study since they were experiencing persistent diestrus, thus, reducing our overall 
number of observations in these experiments.  Tandem mass spectroscopy liquid 
chromatography was utilized in this dissertation to establish novel proteomic impacts of 
the various exposures on the ovary. While a valuable tool in gleaning greater amounts of 
information from limited tissue source, there are considerations to be made including the 
fact that the protein was isolated from the entire ovary and post-translational protein 
modifications are not identified. For future proteomic studies it would be beneficial to 
isolate particular structures such as granulosa cell or theca cell layers, oocytes, whole 
follicles, and corpus lutea to determine protein dynamics localized to these tissue/cell types 





 With the continuous rise in obesity, strategies to preserve and improve ovarian 
function during altered metabolic states are urgent.  Continued investigation into 
established mechanisms, the identification and pursuit of novel targets in less characterized 
pathways and bridging the gap between the two will be the key to diminishing adverse 
reproductive outcomes.  The work done by our group and others has established that 
obesity has several negative impacts on fertility including alterations in folliculogenesis [1, 
13], the phosphatidylinositol 3-kinase (PI3K) pathway [2, 4], steroid hormone biosynthesis 
[1], increases amounts of inflammation [1, 3], DNA damage [5-7], and enhances 
susceptibility to genotoxic exposures [7, 14].  One of the studies included in this 
dissertation investigated the effects of an in utero metabolic exposure [12], but as more and 
more women become obese or overweight at younger ages, more pre-gestational exposures 
to obesity are occurring.  An area for further consideration is investigating offspring 
reproductive effects throughout the lifespan, from development in utero, prepubertal 
stages, adolescence, adulthood, and advanced years.  Of other interest would be 
investigating the transformation from obesity to weight loss and the plasticity of these 
effects that are observed during obesity.   
 Mutations in genes within the DDR pathway such as Atm [15] and Brca1 [16] cause 
individual to have increased tumor susceptibility, therefore increasing their chances of 
being exposed to some form of anti-neoplastic therapy.  While there have been great 
advances in cancer treatments, improving cancer survival rates, women who undergo 
various forms of cancer treatments have irreversible consequences on fertility from off-
target effects from the harsh, yet life-saving drugs.  The group especially impacted are pre-
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menopausal women and girls and those who are heterozygous carriers of the Atm mutation.  
As a further insult to the reproductive health of women carrying these mutations, they may 
be subject to accelerated ovarian aging or begin with a smaller follicle reserve when 
compared to unaffected women [17].  Additionally, pregnancy outcomes are not well 
documented after pre-gestational chemotherapy treatment, with insight arising mostly from 
clinical data which presents several limitations such retrospective questionnaires, data 
pulled from various clinics, and varying chemotherapeutic agents [18].  Further 
investigations into fertility outcomes post-chemotherapy and the role of the DNA damage 
response could lead to planning or procedures that can help to lessen the effects of DNA 
damage on the germline.     
Conclusion 
 Collectively, the research in this dissertation illustrates the importance of ovarian 
health and physiology, and the dynamic processes behind it in order to maintain a healthy 
reproductive status.  Metabolic events, direct or indirect chemical exposures, and 
chemotherapy are sources of negative or ovotoxic effects on the ovary, thus identifying the 
mechanisms which cause follicle loss can lead to the development of preventative therapies 
which are less invasive than the current standards of gamete preservation.  In addition to 
positive fertility outcomes, the perpetuation of female health also relies on proper ovarian 
signaling and function, preventing the onset of other disorders related to the cessation or 
dysfunction of ovarian activity.  Identification of the potential mechanisms behind 
follicular atresia and the relationship with oocyte quality remain valuable to the field of 
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Primary cell culture is a valuable tool to utilize in parallel with in vivo studies in order to 
maximize our understanding of the mechanisms surrounding neurogenesis and central 
nervous system (CNS) regeneration and plasticity.  The zebrafish is an important model 
for biomedical research and primary neural cells are readily obtainable from their 
 234
embryonic stages via tissue dissociation.  Further, transgenic reporter lines with cell type-
specific expression allows for observation of distinct cell populations within the dissociated 
tissue. 
New Method 
Here, we define an efficient method for ex vivo quantification and characterization of 
neuronal and glial tissue dissociated from embryonic zebrafish. 
Results 
Zebrafish brain dissociated cells have been documented to survive in culture for at least 9 
days in vitro (div).  Anti-HuC/D and anti-Acetylated Tubulin antibodies were used to 
identify neurons in culture; at 3 div approximately 48% of cells were HuC/D positive and 
85% expressed serotonin, suggesting our protocol can efficiently isolate neurons from 
whole embryonic zebrafish brains. Live time-lapse imaging was also carried out to analyze 
cell migration in vitro.  
Comparison with Existing Methods 
Primary cultures of zebrafish neural cells typically have low rates of survivability in vitro.  
We have developed a culture system that has long term cell viability, enabling direct 
analysis of cell-cell and cell-extracellular matrix interactions.   
Conclusions 
These results demonstrate a practical method for isolating, dissociating and culturing of 
embryonic zebrafish neural tissue. This approach could further be utilized to better 
understand zebrafish regeneration in vitro.  
 




The use of zebrafish, Danio rerio, has emerged as a powerful tool in several aspects 
of developmental biology and biomedical research, frequently utilized as an in vivo model 
for several etiologies due to their optical clarity and external embryonic development [1]. 
The zebrafish boasts a fully sequenced genome, which makes it favorable to use for gene 
editing technologies such as TALEN or CRIPSR/Cas9 [2].  Likewise, the availability of 
cell and tissue specific fluorescent reporter lines allows for direct observations in the 
developing organism [3]. 
During embryonic development, neurogenesis begins in the zebrafish soon after 
gastrulation, defined by rapid proliferation and differentiation of neural progenitor cells, 
driving the formation of distinct brain and retinal structures as early as 2 days post 
fertilization (dpf) [4, 5]. Complementary to the dynamic shaping of the early nervous 
system, regeneration of mature neural tissue has been observed in the adult zebrafish.  
Functional and anatomical recovery of the CNS after brain or spinal cord injury occurs 
after initiation of axon regeneration and neurogenesis from putative stem cells [6], existing 
mature neurons [7], and radial glial cells [8].  These investigations have been crucial to our 
understanding of the cellular and molecular processes of neurogenesis and may potentially 
lead to the application of these findings in treating CNS disease or injury.   
In addition to in vivo models, in vitro models have also been productive in gaining 
insights on the mechanisms of neuron specification and the active analysis of neural 
migration, though these studies have been primarily conducted in cells isolated from 
mammalian models [9-11]. In vitro methods utilizing neural tissue from both larval and 
adult zebrafish have been previously described and are becoming more prevalent, though 
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methods commonly result in a heterogeneous population of cells isolated from whole 
zebrafish embryos, known as primary cells  [12-15].  Some methods have successfully 
isolated more specific groups of cells such as the spinal cord [16-18], brainstem [19], adult 
zebrafish brain [20, 21], and embryonic zebrafish brain [17].  Additionally, primary neuron 
cultures from specific cell types have been generated by fluorescence-activated cell sorting 
(FACS) and magnetic-activated cell sorting (MACS) [22-25]. The benefit of a primary 
culture system is that it allows direct observation of cell-type specific processes, which can 
easily be subject to molecular manipulation [21, 26, 27], chemical toxicity screening [28, 
29], and/or live imaging [24, 30].  Further, zebrafish brain-derived cells can provide insight 
into mechanisms specific to lower vertebrates and help provide a better understanding of 
regeneration and plasticity that may be applicable to human medicine. 
Here, we report an efficient method to isolate and dissociate zebrafish neural tissue 
adapted from a previous method of neural progenitor isolation from fetal mouse intestine 
[31]. Current protocols have demonstrated little quantitative assessment of zebrafish neural 
tissue derived cells. We sought to characterize the various cell types in culture using 
immunocytochemistry experiments. Zebrafish brain-derived cells were cultured for up to 
9 days in vitro (div) with characterization of cells at 3 and 6 div.  Our results produced a 
clean and efficient method for utilizing zebrafish as a source for primary neural culture.  
Further, we performed time-lapse imaging to better understand the dynamic nature of the 






Fish stocks and husbandry 
Embryos were obtained from the wild-type zebrafish line NHGRI (Zebrafish 
International Resource Center - ZIRC) and from zebrafish lines Tg(elavl3:GFP) [32] 
(provided by Dr. Robert Cornell, University of Iowa) and Tg(gfap:GFP)mi2001 [33]. Adult 
fish used for the generation of embryos were raised at 28.5°C in a light/dark cycle 
according to standard zebrafish husbandry protocols [34].  All experiments were performed 
within U.S. laws, guidelines, and policies for laboratory animals and were approved by the 
Institutional Animal Care and Use Committee (IACUC) and Institutional Biosafety 
Committee at Iowa State University. 
 
Embryo collection and gnotobiotic techniques  
Fertilized embryos were collected after natural spawning.  At 24 hours post 
fertilization (hpf), developing embryos were incubated in 100 units/mL penicillin, 100 
µg/mL streptomycin, and 0.25 µg/mL Amphotericin B Anti-biotic/Anti-mycotic solution 
(Sigma Aldrich, St. Louis, MO) in sterile embryo media (0.63g marine salt/liter) for 2-6 
hours at 29.6°C.  Embryos were rinsed in fresh sterile embryo media, washed in 0.005% 
sodium hypochlorite for 2 minutes, a subsequent rinse of sterile embryo media, then 
washed in 0.01% polyvinylpyrrolidone-iodine for 2 minutes.  After disinfection, the 
embryos were rinsed two times in sterile embryo media and raised in an incubator at 29.6°C 
until 48-hpf (modified from [35]). At 48-hpf, surviving embryos were selected, rinsed in 
0.005% sodium hypochlorite and placed in fresh sterile embryo media before being 
processed for cell culture. 
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Embryo extract preparation  
Embryo extract was prepared as detailed in Kinikoglu et al., 2013.  Briefly, 200 3-
dpf wild-type embryos were rinsed with 0.5% sodium hypochlorite in sterile embryo 
medium followed by three subsequent washes in calcium-magnesium-free PBS. Embryos 
were transferred to a 1.5 mL microcentrifuge tube and excess PBS was removed, leaving 
only enough PBS to cover the embryos in the tube. Embryos were then homogenized on 
ice using a pestle, followed by addition of 1 mL L-15 basal media, and centrifugation at 
900 rpm at 4°C for 6 minutes. The supernatant was removed and filtered through a 0.22 
µm sterile filter and stored at -20°C.  Prepared embryo extract can be utilized for several 
rounds of culture.    
 
Dissection and dissociation  
Embryos were staged to long pec stage (48-hpf) and where required, selected for 
GFP expression [34].  Embryos still in the chorion at the time of processing were manually 
removed from the chorions using fine forceps.  For dissection, embryos were anesthetized 
in 0.01% MS222 (tricaine methanesulfonate, Sigma Aldrich) in Hank’s Balanced Salt 
Solution (HBSS; Sigma Aldrich).  Removal of the whole brain was done by first separating 
the head from the remaining embryo at the anterior portion of the spinal cord and then 
applying gentle pressure immediately anterior of the optic tectum. The whole brain was 
released from the cut posterior portion of the head.  Tissue was collected in HBSS on ice 
with a maximum of 20 brains per tube, then spun down at 1500 rpm for 5 minutes at 4°C 
and remaining HBSS removed.  For dissociation, Accumax™ (Innovative Cell 
Technologies, Inc, San Diego, CA) was added at a volume of 200 µL, followed by a 7-
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minute incubation in a 37°C water bath.  To stop the dissociation reaction, 700 µL of 
zebrafish culture media was added to the tube and mixed by gentle pipetting.  The sample 
was then spun again at 1500 rpm for 5 minutes at 4°C and the cell-free supernatant 
discarded.  The remaining pellet was resuspended in 100 µL of fresh culture media and 
placed on ice until plating.  
 
Substrate preparation and cell culture 
Entactin-Collagen IV-Laminin (ECL; Millipore, Burlington, MA) was diluted in L-
15 basal media to a final concentration of 10 µg/mL and vortexed. Using a 12-channel 
micropipette, 100 µL of ECL solution was added into each well of a 96-well plate (Greiner 
Bio-One, Kremsmünster, Austria). The plate was sealed using Parafilm and stored 
overnight at 4°C.  
For propidium iodide experiments, 12 mm glass coverslips were cleaned with RBS-
35 detergent (1:50 in deionized (DI) water; Thermo Fisher Scientific, Waltham, MA) and 
boiled for 15 minutes. Coverslips were rinsed in DI water and sterilized under ultraviolet 
light for 1 hour. Coverslips were coated with ECL diluted in L-15 basal media (10 µg/mL) 
overnight at 4°C. 
After dissociation, a Trypan blue (Sigma Aldrich) viable cell count was performed 
using a hemocytometer. The zebrafish brain-derived neural cells were plated at 6,000 
cells/well in 96 well plates. Zebrafish complete media was composed of L-15 (Sigma 
Aldrich), supplemented with 2.5 mM L-alanyl-L-glutamine (GlutaMAX; Thermo Fisher 
Scientific), 15 ng/mL epidermal growth factor (human recombinant EGF; Thermo Fisher 
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Scientific), 10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA) and 
5% zebrafish embryo extract.  
Cells were maintained in ambient temperature in a sterile environment. For time-
lapse studies, media from wells was removed, the wells rinsed with sterile HBSS and fresh 
media was added prior to placing the 96 well plate into the ImageXpress Micro XLS. For 
immunocytochemistry experiments to characterize cells, media was changed every other 
day and cells were cultured for 3, 6 or 9 div.  
 
Immunocytochemistry  
After 3 or 6 days, the cells were rinsed twice with 0.1 M phosphate buffer followed 
by fixation with 4% paraformaldehyde (PFA; Thermo Fisher Scientific) in 0.1 M phosphate 
buffer for 20 minutes.  After fixation, samples were rinsed (3 x 5 minutes) using phosphate 
buffered saline (PBS) and incubated for 90 minutes in a blocking buffer: 0.2% Tween20, 
2.5% normal donkey serum (NDS; Jackson ImmunoResearch, West Grove, PA), 2.5% 
normal goat serum (NGS; Jackson ImmunoResearch), and 0.4% bovine serum albumin 
(BSA; Sigma-Aldrich) in PBS.  Primary antibodies (Supplemental Table 1) were diluted 
in blocking buffer and incubated overnight at 4°C.  Samples were rinsed (4 x 8 minutes) in 
PBS, followed by incubation in secondary antibody (Table 1) and 4',6-diamidino-2-
phenylindole (1:50, DAPI; Invitrogen, Carlsbad, CA) nuclear stain diluted in blocking 
buffer and incubated for 90 minutes at room temperature.  After secondary antibody 
incubation, wells were rinsed with PBS (4 x 8 minutes). Plates were sealed with Parafilm 




 Zebrafish larvae (2, 5, or 8-dpf) were anesthetized in 0.01% MS222 and fixed in 
4% PFA in 0.1 M phosphate buffer for 4-6 hours at 4°C, then subsequently washed in PBS.  
For cryoprotection, fixed larvae were incubated in 5% sucrose/PBS solution for 1-3 hours 
at room temperature followed by 30% sucrose/PBS solution at 4°C overnight.  Tissue was 
then placed in OCT (Fisher Healthcare, Houston, Texas) at room temperature before being 
flash frozen using dry ice.  Sections were cut at 10 μm on a cryostat (Leica CM1850, 
Wetzlar, Germany), left to dry overnight on a slide warmer at 37°C, and processed directly.  
For antibody staining, tissue was rehydrated and permeabilized for 15 minutes in PBS with 
0.1% Tween 20 (PBSTw) and blocked as described above.  Sections were encircled with a 
histology pap pen to maintain antibody concentration over tissue.  Primary antibodies 
(Table 1) were added in fresh blocking buffer and incubated in a humidified box at 4°C 
overnight.  Slides were washed (3 x 10 minutes) in PBSTw, incubated in secondary 
antibody (Table 1) for 60 minutes at room temperature, followed by washes (4 x 10 
minutes) in PBSTw.  Slides were allowed to air dry, mounted using Vectashield Antifade 
Mounting Medium with DAPI (Vector Labs, Burlingame, CA), and left to cure overnight 
at 4°C.  Images were taken on a LSM700 (Zeiss, Oberkochen, Germany) confocal 
microscope equipped with an AxioCam MRc5 using a 20x objective.  For quantification 
of HuC/D (n = 8), 5-HT (n = 8), TH (n = 8), ChAT (n = 8), and GFAP (n = 8) 
immunoreactivity, the percentage of the total image area threshold (transverse section of 




Propidium iodide staining 
Propidium Iodide (PI; Thermo Fisher Scientific) staining was used to detect dead 
cells in cultures at 3, 6 and 9 div. For these experiments, cells were cultured on ECL coated 
12 mm glass coverslips. The stock solution of PI was diluted to 1.5 µM in zebrafish culture 
medium. For PI staining at each time-point, culture media was replaced with the PI solution 
and incubated for 20 minutes at room temperature. As a reagent control, one sample per 
time-point was incubated in 70% ethanol for 8 minutes to cause cell death before adding 
PI solution. After incubation, samples were rinsed with 0.1 M phosphate buffer, fixed with 
4% PFA in 0.1 M phosphate buffer for 20 minutes at room temperature and rinsed with 
PBS. To stain cell nuclei, samples were incubated with DAPI (1:50) diluted in blocking 
solution for 30 minutes at room temperature. Samples were rinsed with PBS and mounted 
on microscope slides with DAPI Fluoromount-G mounting media for imaging. 
 
Cell quantification and imaging 
After immunocytochemistry, cells were imaged on the ImageXpress Micro high 
content screening system (HCS; Molecular Devices, San Jose, CA). Each 96-well plate 
was loaded into the ImageXpress Micro and allowed to equilibrate for 45 min at 25°C. 
Imaging was performed using a 20x objective. From one well, 49 microscopic fields were 
imaged. For imaging, four wavelengths were selected: Cy3 for primary antibodies 
(550 nm), GFP for endogenous transgene expression (395 nm), DAPI for nuclei (358 nm) 
and phase contrast. For quantification, all sites were analyzed quickly and without bias 
using a multiwavelength cell scoring module in the MetaXpress 4.0 software (Molecular 
Devices). The percentage of positively stained cells was calculated by dividing the number 
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of cells immunoreactive for each antibody by the total number of DAPI-stained nuclei per 




For time-lapse imaging, Tg(elavl3:GFP) and Tg(gfap:GFP)mi2001 transgenic fish 
lines were dissociated and plated into an ECL coated 96-well plate as described above. 
After 24 hours in vitro, media from all wells was removed using a multi-channel pipette 
and rinsed with sterile HBSS. Fresh media was added to all wells and the plate was placed 
into the environmental chamber of the HCS system set to 25°C and the plate allowed to 
equilibrate for 1 hour prior to imaging. For time-lapse imaging, the 20x objective was used. 
Four wells per zebrafish line (Tg(elavl3:GFP) and Tg(gfap:GFP)mi2001) were selected for 
imaging and four sites from each well were imaged. A total of 16 sites were imaged from 
each zebrafish line. Two wavelengths (phase contrast and GFP fluorescence) were selected 
for time-lapse imaging. Once the focus was established, images were captured every 5 
minutes for 24 hours from all sites. Time-lapse imaging analysis for cell migration/cell 
tracking is described below. 
 
Cell migration 
Cells from each zebrafish transgenic line (Tg(elavl3:GFP) and Tg(gfap:GFP)mi2001) 
were selected for analysis. Cells were tracked using MetaXpress software using the “Track 
objects” feature. For each cell tracked, the distance traveled, and the migration rate were 
collected. Cells tracked were single cells that remained within the imaging field for 24 
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hours. The selected cells’ movements were tracked on a frame by frame basis using the 
cell tracker tool in the MetaXpress software. The output raw data was logged into a 
Microsoft Excel file. To better understand how migration may be different among cells, 
tracked cells were further classified based on cell morphology: spindle, flat or round). The 
data for average velocity of migration and total migration distance were compared between 
different cell morphologies using a one-way ANOVA or an ordinary t-test.  
 
Results 
Culture of zebrafish-brain derived cells 
 Zebrafish offer several advantages compared to mammals to study development. 
The zebrafish embryo is transparent and develops ex vivo, allowing for in vivo imaging and 
monitoring of neurodevelopment. Although in vivo approaches to study development have 
been well documented, little research has been directed to developing in vitro systems 
using zebrafish. Current protocols to dissociate cells from neural tissue have shown 
variable cell viability and quantitative analyses of cells [17, 24, 37, 38]. In an attempt to 
utilize current protocols, we made efforts to adapt those protocols with different variations 
but had little success (Supplemental Table 2). Therefore, the purpose of this study was to 
develop a new method to isolate and dissociate zebrafish neural tissue for primary culture 
that can be cultured for a longer period of time than current protocols.  As a result of our 
experiments, we identified AccumaxTM as the best enzymatic component for dissociation 
that also yielded the highest cell survival and viability.  Further, our group optimized the 
AccumaxTM incubation time in order to obtain clean cultures with viable cells 
(Supplemental Figure 1). Cells incubated in Accumax TM for less than 7 minutes had many 
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detached cells by 2 div and those incubated for more than 7 minutes exhibited a fibroblast-
like morphology. On the other hand, cells dissociated using an incubation time of 7 minutes 
had many cells attached at 2 div as well as a neuronal morphology with small processes 
emanating from the cell body. 
To generate primary neural tissue, whole brains from embryonic Tg(elavl3:GFP), 
which expresses GFP in neurons and can be easily identified in culture, and wild-type 
zebrafish were isolated and dissociated using the protocol described above (summarized in 
Figure 1). The cells were cultured as a monolayer on ECL-coated 96 well plates. As shown 
in Figure 1, the cells displayed a variety of morphologies such as round with short and 
long processes, spindle-shaped and flat fibroblast-like. During the time of plating, single 
cells were present for up to 6 div and cultures were observed up to 9 div. (Figure 1 (B).  
 
Cell viability 
Propidium iodide (PI) staining was used to evaluate cell survival from the 
dissociated zebrafish neural tissue at 3, 6 and 9 div (Figure 2). This assay uses a red-
fluorescent nuclear and chromosome counterstain that is only permeable to dead cells. The 
dissociated neural cells were seeded onto ECL coated glass coverslips. As a positive 
reagent control, two different coverslips at each time-point were exposed to 70% ethanol 
to intentionally kill cells. At 3, 6 and 9 div, there was an average of 311± 16, 214 ± 25 and 
160 ± 16 DAPI positive cells present in culture, respectively. At 3 div, approximately 27% 
PI-labeled cells were detected following the ethanol incubation as illustrated in Figure 2 
(A1,B1,C1). The percentage of PI-labeled dead cells at 3 div (3.1%) was negligible with 
only a few cells labeled with PI compared to a parallel coverslip that was ethanol treated 
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(Figure 2 (A1-A4, B1-B4)). At 9 div 28.2% of the cells in the primary cultures were PI-
stained. (Figure 2 (C1-C4)). These results indicate that our culture conditions provide 
survivability of dissociated zebrafish brains for up to 9 div.  
 
Characterization of dissociated neural tissue 
Embryonic wild-type and Tg(elavl3:GFP) zebrafish brains were isolated and 
dissociated in order to obtain a primary culture of neuronal cells. A total of 40 brains were 
dissected and dissociated for each replicate. An image-based high content screening (HCS) 
system using MetaXpress software coupled with immunocytochemistry using a panel of 
cell type specific antibodies was used to characterize the differentiation of the dissociated 
neural tissue. This technology enables screening a panel of cell-specific antibodies at 
multiple time-points. Compared to conventional imaging methods, using an HCS system 
is rapid and allows for non-bias characterization.  For this study, adult fish from 5 different 
tanks represented 5 experimental replicates. From each replicate, 40 brains were 
dissociated and plated into 32 wells of a 96 well plate. Three replicates were plated in a 
single 96 well plate while the remaining 2 replicates were plated in a second plate. In each 
well, 49 microscopic imaging fields were taken using three fluorescent filter sets: Cy3, 
GFP and DAPI and transmitted light for a total of 196 images per well. For 
characterization, four wells were used per cell-specific antibody, leading to 784 imaging 
fields analyzed per replicate, for a total of 3,920 sites analyzed between all 5 replicates per 
antibody. 
 Cells were plated into an ECL coated 96 well-plate and characterized using 
immunostaining for various neuronal and glial cell specific antibody markers. First to 
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detect neurons in culture, two pan-neuronal antibodies were used: HuC/D, an early marker 
for neurons [39] and Acetylated Tubulin, an axonal marker which demarcates axonal tracts 
in the zebrafish brain [40]. These two neuronal antibodies were used together to label the 
nucleus and processes of the neuron (referred to as HuC/D-Acetylated Tubulin in this 
study). At 3 div, approximately 47% of cells were immunopositive for HuC/D-Acetylated 
Tubulin. In Figure 3 (A1), long processes are seen labeled with Acetylated Tubulin at 3 
div (Figure 3 (A1)) and at 6 div (Figure 3 (B1)). Quantification revealed there was no 
significant difference for HuC/D-Acetylated Tubulin expression between 3 and 6 div 
cultures (47.6% ± 8.8 and 27.3% ± 4.3, respectively). Although there is a slight decrease 
in the number of cells labeled with HuC/D-Acetylated Tubulin at 6 div, this protocol 
allowed for longer zebrafish neuron survival in vitro.   
To detect serotonergic neurons within cultures, we found 85% expressed 5‐
hydroxytryptamine (5‐HT) (Figure 4), a neurotransmitter important in development and 
neurogenesis in zebrafish [41] as well as mammals [42] however this was significantly 
decreased by 6 div (48% ± 5).  No detectable immunolabeling was found for tyrosine 
hydroxylase (TH) and choline acetyltransferase (ChAT) (data not shown).   
To determine if this dissociation and culturing protocol promoted the survival of 
other neural tissue cell types, we investigated the presence of glial cells, which are 
abundant in the CNS of zebrafish. Glial fibrillary acidic protein (Gfap) identifies glial cells 
within the zebrafish brain including radial glia and astrocytes [43]. The percentage of cells 
immunostained with Gfap at 3 div (26% ± 1.8) were comparable to those at 6 div (30.1% 
± 2.2) indicating no loss of Gfap immunopositive cells in our cultures (Figure 5 (A1 and 
B1)).  
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These results indicate our method of dissociating embryonic zebrafish neural tissue 
is efficient in maintaining a viable population of glial cells. Frozen-sectioned zebrafish 
brain tissue at comparable time-points were immunolabeled as positive controls for the 
antibodies (Supplemental Figure 2(A).  The neuronal subtypes 5-HT, ChAT, and TH, as 
well as pan-neuronal marker HuC/D and the glia marker Gfap were detected in our 
sections, though ChAT and TH positive cells were substantially lower than HuC/D, 5-HT, 
and Gfap, similar to the results from the neural tissue culture (Supplemental Figure 2(B).   
Thus far, using our method to dissociate zebrafish neural tissue we have created a 
primary culture containing neurons and glial cells.  Our cultures survive up to 9 div as 
detected with the propidium iodide assay, with approximately 85% of cells expressing 5-
HT at 3 div and neurons present as detected by HuC/D-Acetylated tubulin immunostaining 
for up to 6 div.  Due to the low number of cells at 9 div immunocytochemistry experiments 
were not conducted, however using propidium iodide assays we were able to demonstrate 
the survival of cells up to 9 div.  
 
Migration of cells in vitro 
To investigate the behavior of neuronal and glial cells in vitro, embryonic brain 
tissue from two transgenic zebrafish lines (Tg(elavl3:GFP) marking the neuronal 
populations and Tg(gfap:GFP)mi2001 marking the glia populations were dissociated using 
the protocol described above. The behaviors of the dissociated cells were monitored using 
time-lapse digital microscopy with transmitted and fluorescence illumination of the HCS 
system. Multiple sites were time-lapsed imaged and used to calculate the distance travelled 
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for Tg(elavl3:GFP) (Supplemental video 1) and Tg(gfap:GFP)mi2001  (Supplemental video 
2) cell types as well as their migration rates.  
The average velocity of cell migration and total distance travelled by cells was 
obtained using MetaXpress software for both cell types. First, cells were classified based 
on morphology (flat, spindle or round). Distance travelled and migration rates were 
calculated for cells dissociated from Tg(elavl3:GFP) or Tg(gfap:GFP)mi2001 zebrafish 
larval brains. From cells dissociated from Tg(elavl3:GFP) neural tissue, the GFP 
expressing round cells (17.5 ± 1.18 µm/h) and GFP-expressing spindle shaped cells (12.04 
± 1.07 µm/h) had higher migration rates compared to flat cells (6.65 ± 0.67 µm/h) (Figure 
6A). Additionally, the average total migration of round cells (279.28 ± 22.72 µm) during 
the 24-hour imaging period was higher than flat cells (117.91 ± 11.47 µm) (Figure 6B). 
These results are captured in supplementary video 1 as round cells migrate long distances 
towards other cells, rather than being isolated. Further, round cells are migrating towards 
flatter cells and often change behavior; once adhered to flatter cells, the round cells do not 
migrate as fast and the distance travelled is lower. Interestingly, cell behavior was distinct 
among different morphologies which may be associated to neuronal subtypes present in 
culture.  
From cells dissociated using Tg(gfap:GFP)mi2001 neural tissue, we observed both 
GFP-expressing round and spindle shaped cells but no flat cells in culture.  GFP-expressing 
round and spindle shaped cells migrated similar distances (336.4 ± 77.87 µm and 328.3 ± 
52.89 µm, respectively) and with similar average migration rates (13.78 ± 3.17 µm/h and 
13.45 ± 2.15 µm/h, respectively) over a period of 24 hours. Overall, GFP positive Gfap 
cells, regardless of cell morphology, migrated relatively larger distances (331.8 ± 43.39 
 250
µm) compared to GFP positive Elavl3 cells (114.2 ± 41.07 µm), demonstrating that overall, 
glial cells travelled longer distances than neurons in vitro.  
 
Discussion 
Primary cell culture is used as a tool to understand cell biology under defined 
conditions as an alternate to in vivo systems. However, zebrafish primary cultures receive 
little attention due to the fact that zebrafish serve as a great in vivo system to study genetics, 
development, regeneration and more. Unlike in vivo systems, in vitro systems offer several 
advantages, such as studying cell behavior in controlled environments and provide a better 
understanding of cellular mechanisms and interactions.  Zebrafish primary culture can be 
used to investigate developmental and regenerative processes by studying cell-cell and cell-
extracellular matrix (ECM) interactions, as well as for drug screening and toxicity 
bioassays. Currently, several protocols exist to isolate neural cells from larval and adult 
zebrafish tissue [12, 15-18, 24, 25, 38, 44, 45].  Only a portion of these protocols show cell 
survival past 7 div [19, 21, 22].  However, these protocols have not described conditions 
that permit survival of cells long-term and lack quantitative analysis of the dissociated 
cells. The current study examines a new method for isolation and dissociation of embryonic 
zebrafish brains with quantitative characterization of the primary culture and cultures that 
survive for up to 9 div. Immunohistochemistry conducted alongside immunocytochemistry 
experiments validate that our antibodies are properly immunostaining neuronal subtypes 
including ChAT and TH although they were not present in vitro.  
Our protocol resulted in successful dissociation and culture of embryonic zebrafish 
neural tissue for up to 9 days in vitro.  For optimal growth conditions, epidermal growth 
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factor (EGF) was necessary to promote survival of cells. Initial experiments did not include 
EGF and cells were not viable for longer than 3 div with very small processes. Although 
the process of enzymatic dissociation may affect the growth of neurons previously 
developed in the brain, the addition of EGF promoted cell growth and survival in vitro for 
up to 9 div.  The inclusion of zebrafish embryo extract also promoted viability and growth 
in the culture; when omitted from culture we observed slower growth and less cell 
attachment.  Furthermore, incubation times of Accumax™ were optimized to achieve 
adequate cell dissociation with extensive cell survival. We found that incubating cells for 
longer than 7 minutes resulting in considerably less cell attachment and survival after 1 div 
and incubation times less than 7 minutes resulting in substantially large clusters of 
undissociated tissue.  Further, additional trituration performed halfway during the 
dissociation time increased the yield of individual cells, but at the cost of total viable cell 
yield.  Given this, additional mechanical dissociation can be utilized in our method to 
segregate a greater number of individual cells if cell density is not such an important 
consideration for an experimental endpoint such as in this study.  The amount of dissected 
tissue per tube was also a factor in cell viability. The cells with decreased surface area at 
the bottom or center of the collection tube experienced a hypoxic-like effect, ultimately 
effecting the likelihood of cell survival after plating.  Overall cell viability and attachment 
probability could be estimated after plating by observing cells under phase contrast. Round, 
phase bright cells had higher attachment probably compared to darker cells along with 
debris in wells, which may indicate dead cells. 
Embryonic zebrafish brain cultures contain neuronal and glial cells, with a majority 
of neurons co-expressing pan-neuronal marker HuC/D and serotonin (5-HT), indicating a 
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serotonergic phenotype.  The 5-HT neurotransmitter has various roles in the CNS, 
stemming from the raphe nuclei and contributing to the proliferation, migration, 
differentiation of neuroblasts, synapse formation, and regulating neurite outgrowth [46-
50]. Around 85% of cells in our culture system were 5-HT positive at 3 div, coinciding 
with a timeline of rapid 5-HT innervation  observed in the larval zebrafish at 5-dpf [51] 
(brain tissue from 2 dpf + 3 div would be equivalent to 5-dpf). Interestingly, this decreases 
after 6 div to 48%, exhibiting a possible decrease in this developmental time point as 
observed in vivo [51].  Further, radial glial cells have been shown to proliferate and give 
rise to 5-HT neurons in the paraventricular organ located in the diencephalon in the adult 
zebrafish [41].  This is a possible explanation as to why we detected less HuC/D positive 
cells than 5-HT possible cells, though this remains to be investigated at the larval stage in 
zebrafish.      
Surprisingly, immunoreactivity was not detected when using antibodies directed 
against other neuronal subtypes ChAT and TH, though the subtypes were observed in 
whole tissue sections. This could be as a result of the dissociation process, which could 
alter the endogenous signaling in dissociated tissue.  Additionally, at the initial dissociation 
timepoint of ~48 hpf, secondary neurogenesis has commenced in the embryonic zebrafish 
brain [27].  From this timepoint on, the distribution of proliferative cells, newly determined 
neurons, and advanced post-mitotic neurons is dynamic, with tighter spatio-temporal 
restriction on the distinct populations as the brain develops [52].  The substantial 
differences in immunoreactivity we observed in our culture and our tissue sections of the 
neuronal subtypes versus the predominate labeling of serotonergic cells is possibly a result 
of the progressive rates of maturation in our culture post-dissociation.  We also observed 
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Gfap-positive cells in 25% of cells after 3 div, with a slight increase to around 30% of cells 
after 6 div.  In the developing brain, Gfap positive radial glia have been shown to be 
progenitors for astrocytes and neurons in mammals suggesting that radial glia were present 
in culture [53].   
Cell culture systems allow researchers to study cell behavior in a controlled 
environment while being able to vary conditions, such as substrates for cell attachment and 
exogenous growth factors for regulating in vitro differentiation. In our experiments, cells 
were cultured on an ECL substrate, however cell migration can differ on other substrates, 
including Poly-L-ornithine, Poly-L-lysine or fibronectin; neural stem/progenitor cells 
(NSPCs) cultured on these substrates exhibited varying levels of differentiation and 
proliferation [54, 55]. Endogenous NSPCs grow within specialized areas of the brain, 
known as niches. Cells secrete an ECM within this niche and is an important contributor 
to essential cell functions including mitosis, cell migration, cell signaling and apoptosis 
[56, 57]. Because the ECM is a vital component, our current study can be expanded using 
other substrates to provide insight on cell functions and better understand cell behavior in 
vitro.  
Using our protocol, cells were successfully dissociated from zebrafish neural tissue 
and used for time-lapse microscopy. Round shaped cells had a strong tendency to adhere 
to flatter cells, which may be indicative of radial glial cells in culture. In the CNS, radial 
glial cells support neuronal migration during development and guide axons to their correct 
targets [58, 59]. Our results support our analysis of cell migration because Gfap-positive 
cells migrated longer distances than Elavl3-positive neurons. Time-lapse microscopy can 
be used to monitor cell division, apoptosis as well as be used to study cell-cell interactions. 
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Therefore, our protocol is sufficient in producing a clean and viable culture that can be 
used for real time imaging experiments. 
Overall, our method for dissociation of embryonic zebrafish brains is efficient to 
generate a heterogenous primary culture of neurons and glia.  It requires basic 
microdissection skills, standard lab equipment, and minimal reagents.  Further, our study 
examined the population in detail by conducting immunocytochemistry for neuronal 
subtypes as well as glial cells.  Our culture method could be used to compliment studies 
using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting 
(MACS) for more targeted cell type observations.  Whether paired with in vivo models or 
utilized exclusively, zebrafish in vitro methods can provide further insight into the 
molecular mechanisms between cell-cell interactions and in a variety of applications 
including developmental biology and regeneration.   
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Figures and Figure Legends 
 
Figure 1. Primary neural cell culture from embryonic zebrafish.  (A) Schematic 
illustration depicting (1) Embryos collection and disinfection, (2) dissection of neural 
tissue from 48-hpf staged embryos, (3) enzymatic dissociation at 37ºC for 7 minutes using 
AccumaxTM, (4) cell resuspension in complete media (5) and plating cells in 96 well plates 
maintained at ambient temperatures.  Following culture period, (6) plates were used for 
high content imaging. Cells were (7a) time-lapsed for 24 hours or (7b) characterized using 
immunocytochemistry, (8) followed by data analysis performed using the MetaXpress 
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Figure 1. (continued) software. (B) Phase contrast images of zebrafish-brain derived cells 
at initial isolation (1 div) through 9 div. At 1 div, small clusters of cells along with cells 
with short and long processes, spindle-shape and large flatter cells are seen. In later days, 
a greater proportion of cells displayed a flattened morphology and cells clustered together 





















Figure 2. Propidium iodide cell viability assay at 3, 6 and 9 div of dissociated zebrafish 
neural tissue. (A1,B1,C1) As a control for the PI reagent, samples were subjected to 70% 
ethanol incubation (10 minutes) to intentionally cause cell death at 3, 6 and 9 div. Dead 
cells were stained with PI (red) and cell nuclei stained with DAPI (blue), with pink cells 
indicating dead cells. (A1-A4) 3 div cells, (B1-B4) 6 div cells, and (C1-C4) 9 div cells. Scale 
bar = 50 μm. (D) Quantitative analysis for number of dead cells at various time-points. 
Error bar represent standard error of the mean. n= 3 independent experiments, 5 imaging 
fields per replicate. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; PI; 




Figure 3. Dissociated zebrafish neural tissue immunolabeled with neuronal markers 
anti-HuC/D-Acetylated Tubulin at 3 and 6 div. Fluorescence images of zebrafish brain-
derived cells illustrating immunoreactivity for HuC/D-Acetylated Tubulin at 3 div (A1-A3) 
and 6 div (B1-B3): HuC/D-Acetylated Tubulin:FITC (green) (to identify neuronal nuclei 
and processes, respectively) with DAPI staining (blue). Scale bar = 50 μm. Abbreviations: 
DAPI, 4',6-diamidino-2-phenylindole. (C): Quantitative analysis of zebrafish brain-
derived cells immunoreactive for HuC/D-Acetylated Tubulin. Error bars represent standard 
error of the mean. n = 5 independent experiments, 196 imaging fields per experiment.  No 










Figure 4. Co-labeling with neuronal markers, anti-5-HT, anti-HuC/D and anti-
Acetylated Tubulin antibodies at 3 and 6 div of dissociated zebrafish neural tissue. 
Fluorescence images of zebrafish brain-derived cells illustrating immunoreactivity for 5-
HT and HuC/D-Acetylated Tubulin at 3 div (A1-A3) and 6 div (B1-B3): 5-HT:Cy3 (red) 
and HuC/D-Acetylated Tubulin:FITC (green) with DAPI staining (blue). Scale bar = 50 
μm (25 µm for insets). Abbreviations: DAPI, 4',6-diamidino-2-phenylindole. (C): 
Quantitative analysis of zebrafish brain-derived cells immunoreactive for 5-HT at 3 div 
and 6 div. Error bars represent standard error of the mean. n = 5 independent experiments, 









Figure 5. Co-labeling with an anti-Gfap antibody to identify glial cells and anti-
HuC/D and anti-Acetylated Tubulin antibodies to identify neurons at 3 and 6 div of 
dissociated zebrafish neural tissue. Fluorescence images of zebrafish brain-derived cells 
illustrating immunoreactivity for Gfap and HuC/D-Acetylated Tubulin at 3 div (A1-A3) and 
6 div (B1-B3): Gfap:Cy3 (red) and HuC/D-Acetylated Tubulin:FITC (green) with DAPI 
staining (blue). Scale bar = 50 μm (25 µm for insets). Abbreviations: DAPI, 4',6-diamidino-
2-phenylindole. (C): Quantitative analysis of zebrafish brain-derived cells immunoreactive 
for Gfap at 3 div and 6 div. Error bars represent standard error of the mean. *Significantly 






Figure 6: Zebrafish dissociated neural cells tracked with image acquisition and 
analysis software. (A) Average distance travelled and (B) average migration rates 
(expressed as µm/hr) for GFP positive Tg(elavl3:GFP) dissociated cells based on 
morphology.  (C) Average distance travelled and (D) average migration rates for GFP 
positive Tg(gfap:GFP)mi2001 dissociated cells based on morphology. Each bar represents 
the average of 7-9 imaged cells from 2 time-lapse videos over 24 hours. Error bars represent 







Supplemental Figures and Legends 















Primary Antibody Host  Dilution  Supplier  Code 
HuC/D Mouse 1:250 Thermo Fisher  A21271 
Acetylated Tubulin Mouse 1:500 Sigma Aldrich T6793 
Gfap Rabbit 1:250 Sigma Aldrich SAB2702475 
Serotonin (5-HT) Rabbit 1:100  Sigma Aldrich S5545 
Tyrosine Hydroxylase Rabbit 1:100 Chemicon AB152 
ChAT Rabbit 1:100 Sigma Aldrich AB1582 
Secondary Antibody Host  Dilution  Supplier  Code 
Mouse IgG 488 Goat  1:500 Thermo Fisher A11029 
Mouse IgG 568 Goat 1:500 Thermo Fisher A11004 
Rabbit IgG 568 Goat  1:500 Thermo Fisher A11011 
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Supplemental Table 2: Enzymatic trials determining the effectiveness of specific 
enzymes to dissociate neural tissue from embryonic zebrafish for neuronal cultures.  
Temperature, volume, and incubation times varied between experiments and affected the 
overall cell survival and attachment rates, with AccumaxTM  demonstrating the optimum 






























(Chen et. al, 2013) 










solution (Anderson et. 
al, 2001) 
 
















No survival/attachment at 24 hours 
in vitro 
 
Papain 15, 30 
minutes 
37° No survival/attachment at 24 hours 
in vitro 
 
AccumaxTM 5, 7, 10 
minutes 
37° Survival and attachment up to 9 DIV 
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Supplemental Figure 1: Zebrafish brain derived cells after 1 and 2 div using different 
AccumaxTM incubation times. Zebrafish neural tissue dissociated using AccumaxTM 
for (A1-A2) 5 minutes, (B1-B2) 7 minutes or (C1-C2) 10 minutes. Cells incubated for 5 or 
10 minutes after 1 div had many detached cells compared to those incubated for 7 minutes. 
Cells incubated for 7 minutes at 2 div displayed neuronal morphologies compared to other 





Supplemental Figure 2.  Positive control for immunofluorescence staining.  (A) 
Primary antibodies directed against HuC/D, 5-HT, ChAT, TH, and Gfap were used to 
determine localization in the larval zebrafish brain at 2 dpf, 5 dpf, and 8 dpf, respective to 
the time points studied in vitro.  (B) Quantification of total area immunofluorescence for 




Supplemental Video 1: Time-lapse microscopy of cells dissociated from neural tissue 
dissected from Tg(elavl3:GFP) zebrafish. Images were captured every 5 minutes over 18 
hours. GFP-expressing cells indicate neurons. Videos were used to analyzed cell migration 
and cell velocity using MetaXpress software. Scale bar = 50 µm. 
 
Supplemental Video 2: Time-lapse microscopy of cells dissociated from neural tissue 
dissected from Tg(gfap:GFP)mi2001 zebrafish. GFP-expressing cells indicate glial cells. 
Images were captured every 5 minutes over 18 hours. Videos were used to analyzed cell 
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